MedUniver.com - Все по медицине
  МедУнивер - MedUniver.com Поиск по сайту и его разделы Видео по медицине  
  Поиск и разделы Видео уроки  
Рекомендуем:
Обшая онкология:
Онкология
Общие вопросы онкологии
Детская онкология
Генетика рака - опухолей
Химиотерапия опухолей
Частная онкология:
Опухоли кожи
Опухоли головы и шеи
Опухоли легких и средостения
Опухоли молочной железы
Опухоли органов ЖКТ
Опухоли мочеполовой системы
Онкогинекология
Саркомы костей и мягких тканей
Опухоли крови:
Острые лейкозы
Хронические лейкозы
Макроглобулинемии
Миелодиспластические синдромы (МДС)
Книги по онкологии
Видео по онкологии
Лимфомы
Форум
 

Авторы трудов (статей) использованные при подготовке материалов по раку молочной железы

Сокращения использованные в статьях:

  1. АДФ — аденозиндифосфат
  2. АИХ — аменорея, индуцированная химиотерапией
  3. ГнРГ — гонадотропин-рилизинг гормон
  4. ГР — гомологичная рекомбинация
  5. ДИ — доверительный интервал
  6. ДНК — дезоксирибонуклеиновая кислота
  7. ИА — ингибиторы ароматазы
  8. ИМТ — индекс массы тела
  9. иРМЖ — ипсилатеральный рак молочной железы кРМЖ — контралатеральный рак молочной железы
  10. КСЯ — контролируемая стимуляция яичников мРНК — матричная рибонуклеиновая кислота МРР — местно-регионарный рецидив
  11. МРТ — магнитно-резонансная томография
  12. ОР — относительный риск
  13. ОСО — органосохраняющая операция
  14. ПК — протоковая карцинома
  15. ПМЛТ — постмастэктомическая лучевая терапия
  16. ПНЯ — преждевременная недостаточность яичников пПО — полный патоморфологический ответ
  17. ПФЯ — подавление функций яичников РМЖ — рак молочной железы
  18. РНК — рибонуклеиновая кислота
  19. тнРМЖ — тройной негативный рак молочной железы
  20. УЗИ — ультразвуковое исследование ЭТ — эндокринная терапия
  21. ADM (от англ, acellular dermal matrix) — бесклеточная кожная матрица
  22. DRFI (от англ, distant recurrence-free interval) — выживаемость без отдаленных рецидивов
  23. EORTC (от англ. European Organization for Research and Treatment of Cancer) — Европейская организация по исследованию и лечению рака
  24. ER (от англ, estrogen receptor) — рецептор эстрогена
  25. ESMO (от англ. European Society for Medical Oncology) — Европейское общество медицинской онкологии
  26. HER (от англ, human epidermal growth factor receptor) — рецептор эпидермального фактора роста
  27. IBCSG (от англ. International Breast Cancer Study Group)
  28. Международная группа по изучению рака молочной железы
  29. LD (от лат. latissimus dorsi) — широчайшая мышца спины
  30. NCCN (от англ. National Comprehensive Cancer Network) — Национальная комплексная онкологическая сеть
  31. РАМ50 (от англ, prediction analysis of the microarrays) — количественный анализ 50 генов с помощью полимеразной цепной реакции в режиме реального времени
  32. PARP (от англ. poly-(ADP-ribose) polymerases) — поли-(АДФ-рибоза)-полимераза
  33. PgR (от англ, progesterone receptor) — рецептор прогестерона
  34. PI3K (от англ, phosphoinositide 3-kinase) — фосфоинозитид-3-киназа
  35. ROR-PT (от англ, risk of recurrence score) — балл риска рецидива
  36. SEER (от англ. Surveillance, Epidemiology, and End Results) — анализ течения, распространенности и исходов злокачественных новообразований

В ходе подготовки статей по раку молочной железы для пользователей сайта МедУнивер использованы труды следующих авторов:

  1. Scott Н. «Me: why те»? One patient story // Cancer and Emotion: a Practical Guide to Psycho-oncology / ed. J. Barraclough. Chichester : John Wiley and Sons, 1994. P. xiii.
  2. Travado L., Reis J. What do they think about their illness? Breast cancer patients’ conceptions about their illness and recovery // Psychooncology. 2000. Vol. 9, N 5. P 386.
  3. Travado L., Reis J.C. Breast cancer meanings: a cognitive-developmental study // Psychooncology. 2013. Vol. 22, N 9. P. 2016-2023. DOI: https://doi.org/10.1002/ pon.3246
  4. Paluch-Shimon S., Pagani O., Partridge A.H., Abulkhair O., Cardoso MJ., Dent R.A. et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) // Breast. 2017. Vol. 35. P. 203-217. DOI: https://doi.org/10.1016/j.breast.2017.07.017 URL: http://www.thebreastonline. com/article/S0960-9776( 17)30548-9/pdf
  5. Rowland J.H., Mariotto A., Elena J.W. Epidemiology of cancer survivorship: past, current and future // Handbook of Cancer Survivorship / eds M. Feuerstein, L. Nekhlyudov. Philadelphia : Springer-Verlag, 2018.
  6. Howard-Anderson J., Ganz P.A., Bower J.E. et al. Quality of life, fertility concerns and behavioral health outcomes in younger breast cancer survivors: a systematic review //J. Natl Cancer Inst. 2012. Vol. 104. P. 386-405.
  7. Ahmad S., Fergus K., McCarthy M. Psychosocial issues experienced by young women with breast cancer: the minority group with the majority of need // Curr. Opin. Support Palliat. Care. 2015. Vol. 9, N 3. P. 271-278.
  8. Stanton A.L., Wiley J.E, Krull J.L. et al. Depressive episodes, symptoms, and trajectories in women recently diagnosed with breast cancer // Breast Cancer Res. Treat. 2015. Vol. 154. P. 105-115.
  9. Loscalzo M., BrintzenhofeSzoc K. Brief crisis counseling // Psycho-Oncology / ed. J. Holland. New York : Oxford University Press, 1998. P. 662-675.
  10. Adler N.E., Page A.E.K. Cancer care for the whole patient: meeting psychosocial health needs. Washington, DC : The National Academies Press, 2008.
  11. Grassi L., Travado L. The role of psychosocial oncology in cancer care // Responding to the Challenge of Cancer in Europe / eds M.P Coleman, D. Alexe, T. Albreht, M. McKee. Ljubljana : Institute of Public Health of the Republic of Slovenia, 2008. P. 209—229.
  12. Monteiro-Grillo L, Marques-Vidal P, Jorge M. Psychosocial effect of mastectomy versus conservative surgery in patients with early breast cancer // Clin. Transl. Oncol. 2005. Vol. 7, N 11. P. 499-503.
  13. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007 //J. Exp. Clin. Cancer Res. 2008. Vol. 27. P. 32.
  14. Al-Ghazal S.K., Fallowfield L., Blarney R.W Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction // Eur. J. Cancer. 2000. Vol. 36. P. 1938-1943.
  15. Cigler T, Isseroff D., Fiederlein B. et al. Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients receiving adjuvant docetaxel and cyclophosphamide chemotherapy // Clin. Breast Cancer. 2015. Vol. 15, N 5. P. 332-334.
  16. Ahles T.A., Correa D.D. Neuropsychological impact of cancer and cancer treatments // Psycho-Oncology / eds J. Holland, W. Breitbart, P. Jacobsen, M. Lederberg, M. Loscalzo, R. McCorkle. New York : Oxford University Press, 2010. P. 251-257.
  17. Goedendorp M.M., Jacobsen P.B., Andrykowski M.A. Fatigue screening in breast cancer patients: identifying likely cases of cancer-related fatigue // Psychooncology. 2016. Vol. 25, N 3. P. 275-281. DOI: https://doi.org/10.1002/pon.3907
  18. Yue H.J., Dimsdale J.E. Sleep and cancer // Psycho-Oncology / eds J. Holland, W. Breitbart, P. Jacobsen, M. Lederberg, M. Loscalzo, R. McCorkle. New York : Oxford University Press, 2010. P. 259-269.
  19. Fleishman S.B., Chadha J.S. Weight and appetite loss in cancer // PsychoOncology / eds J. Holland, W. Breitbart, P. Jacobsen, M. Lederberg, M. Loscalzo, R. McCorkle. New York : Oxford University Press, 2010. P. 270-274.
  20. Roth A.J., Carter J., Nelson C.J. Sexuality after cancer // Psycho-Oncology / eds J. Holland, W. Breitbart, P. Jacobsen, M. Lederberg, M. Loscalzo, R. McCorkle. New York : Oxford University Press, 2010. P. 245-250.
  21. Grassi L., Travado L., Gil F, Sabato S., Rossi E.; The SEPOS Group. Psychosocial morbidity and its correlates in cancer patients of the Mediterranean area: findings from the southern European psycho-oncology study (SEPOS) //J. Affect. Disord. 2004. Vol. 83. P. 243-248.
  22. Travado L., Grassi L., Gil E, Martins C., Ventura C., Bairradas J.; The SEPOS Group. Do spirituality and faith make a difference? Report from the southern European psycho-oncology study (SEPOS) // Palliat. Support Care. 2010. Vol. 8. P. 405-413.
  23. Epstein R.M., Street R.L. Jr. Patient-centered communication in cancer care: promoting healing and reducing suffering. Bethesda: MD : National Cancer Institute, 2007. NIH Publication No. 07-6225.
  24. Yang H.C., Thornton L.M., Shapiro C.L. et al. Surviving recurrence: psychological and quality-of-life recovery // Cancer. 2008. Vol. 112. P. 1178-1187.
  25. Mayer M., Grober S. Silent voices: women with metastatic breast cancer share their needs and preferences for information, support and practical services // Living Beyond Breast Cancer. 2006. URL: http://www. advancedbc.org/content/ silent-voices (date of access January 24, 2018)
  26. Grabsch B., Clarke D.M., Love A., McKenzie D.P., Snyder R.D., Bloch S. et al. Psychological morbidity and quality of life in women with advanced breast cancer: a cross-sectional survey // Palliat. Support Care. 2006. Vol. 4. P. 47-56.
  27. Lo C. et al. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer //J. Clin. Oncol. 2010. Vol. 28. P. 3084-3089.
  28. Baucom D.H., Porter L.S., Kirby J.S., Gremore T.M., Keefe FJ. Psychosocial Issues confronting young women with breast cancer // Breast Dis. 2005-2006. Vol. 23. P. 103-113.
  29. Bellizzi K.M., Smith A.W., Reeve B.B. et al. Posttraumatic growth and health-related quality of life in a racially diverse cohort of breast cancer survivors // J. Health Psychol. 2010. Vol. 15. P. 615-626.
  30. Bradley C.J., Neumark D., Luo Z. Employment and cancer: findings from a longitudinal study of breast and prostate cancer survivors // Cancer Invest. 2007. Vol. 25. P. 47-54.
  31. Weaver K.E., Forsythe L.P, FReeve B.B. et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey // Cancer Epidemiol. Biomarkers Prev. 2012. Vol. 21. P. 2108-2117.
  32. Schairer C., Brown L.M., Chen B.E. et al. Suicide after breast cancer: an international population-based study of 723,810 women //J. Natl Cancer Inst. 2006. Vol. 98, N 19. P. 1416-1419.
  33. Andersen B.L., Rowland J.H., Somerfield M.R. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guidelines adaptation //J. Oncol. Pract. 2015. Vol. 11, N 2. P. 133-134.
  34. Andersen B.L., DeRubeis RJ., Berman B.S. et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guidelines adaptation // J. Clin. Oncol. 2014. Vol. 20, N 32. P. 1605-1619.
  35. Brandao T, Schulz M.S., Matos P.M. Psychological adjustment after breast cancer: a systematic review of longitudinal studies // Psychooncology. 2017. Vol. 26, N 7. P. 917-926.
  36. Burgess C., Cornelius V, Love S., Graham J., Richards M., Ramirez A. Depression and anxiety in women with early breast cancer: five year observational cohort study // Br. Med. J. 2005. Vol. 330, N 7493. P 702-705.
  37. Janz N.K., Mujahid M., Lantz P.M., Fagerlin A., Salem B., Morrow M. et al. Population-based study of the relationship of treatment and sociodemographics on quality of life for early stage breast cancer // Qual. Life Res. 2005. Vol. 14, N 6. P. 1467-1479.
  38. Miller K.L., Rowland J.H., Massie M.J. Psychosocial adaptation during and after breast cancer // Diseases of the Breast. 5th ed. / eds J.R. Harris, M.E. Lippman, M. Morrow, C.K. Osborne. Philadelphia : Wolters Kluwer, 2014. P. 1138-1154.
  39. National Comprehensive Cancer Network. Clinical practice guidelines in oncology™. Distress management. Version 1.2018. URL: http://www.nccn.org/ professionals/physician_gls / defau 11 .asp
  40. Stanton A. Positive consequences of the experience of cancer: perceptions of growth and meaning // Psycho-Oncology / eds J. Holland, W. Breitbart, P. Jacobsen, M. Lederberg, M. Loscalzo, R. McCorkle. New York : Oxford University Press, 2010. P. 547-550.
  41. Spijker A., Trijsburg R.W., Duivenvoorden D.J. Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980 // Psychosom. Med. 1997. Vol. 59. P. 280-293.
  42. Zabora J., BrintzenhofeSzoc K., Curbow B., Hooker C„ Piantadosi S. The prevalence of psychological distress by cancer site // Psychooncology. 2001. Vol. 10. P. 19-28.
  43. Carlson L.E. et al. High levels of untreated distress and fatigue in cancer patients // Br. J. Cancer. 2004. Vol. 90. P. 2297-2304.
  44. Carlson L.E., Waller A., Mitchell A.J. Screening for distress and unmet needs in patients with cancer: review and recommendations //J. Clin. Oncol. 2012. Vol. 30. P. 1160-1177.
  45. Ruddy K., Gelber S., Tamimi R., Mayer E., Schapira L., Come S. et al. Prevalence and predictors of distress in young women with newly diagnosed early stage breast cancer // Cancer Res. 2009. Vol. 69, N 24. Suppl. Abstr. 1067.
  46. Mosher C.E., DuHamel K.N. An examination of distress, sleep, and fatigue in metastatic breast cancer patients // Psychooncology. 2012. Vol. 21, N 1. P. 100-107. DO: https://doi.org/10.1002/pon.1873
  47. Mitchell A.J. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies // Lancet Oncol. 2011. Vol. 12, N 2. P. 160-174.
  48. Li M., Hales S., Rodin G. Adjustment disorders // Psycho-Oncology. 2nd ed. / eds J.C. Holland et al. New York : Oxford University Press, 2010.
  49. Fann J. Major depression after breast cancer: a review of epidemiology and treatment // Gen. Hosp. Psychiatry. 2008. Vol. 30, N 2. P. 112-126.
  50. Mehnert A., Koch U. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors // J. Psychosom. Res. 2008. Vol. 64, N 4. P. 383-391.
  51. Reich M., Lesur A., Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature // Breast Cancer Res. Treat. 2008. Vol. 110. P. 9-17.
  52. Akechi T, Okuyama T, Imoto S., Yamawaki S., Uchitomi Y. Biomedical and psychosocial determinants of psychiatric morbidity among postoperative ambulatory breast cancer patients // Breast Cancer Res. Treat. 2001. Vol. 65. P. 195-202.
  53. Hopwood P, Sumo G., Mills J., Haviland J., Bliss J.M. The course of anxiety and depression over 5 years of follow-up and risk factors in women with early breast cancer: results from UK Standardization of Radiotherapy Trials (START) // Breast. 2010. Vol. 19, N 2. P. 84-91.
  54. Travado L., Ventura C., Martins C. Breast cancer patients’ psychosocial profile: a study with a Portuguese population // Psychooncology. 2006. Vol. 15, N S2. P 1023.
  55. Jassim G.A., Whitford D.L., Grey I.M. Psychological interventions for women with non-metastatic breast cancer // Cochrane Database Syst. Rev. 2015. Vol. 5. CD008729. DOI: https://doi.org/10.1002/14651858.CD008729
  56. Longman A.J., Braden C.J., Mishel M.H. Side-effects burden, psychological adjustment, and life quality in women with breast cancer: pattern of association over time // Oncol. Nurs. Forum. 1999. Vol. 26, N 5. P. 909-915.
  57. Okamura M., Yamawaki S., Akechi T, Tanigychi K., Uchitomi Y. Psychiatric disorders following first breast cancer recurrence: prevalence, associated factors and relationship to quality of life // Jpn J. Clin. Oncol. 2005. Vol. 35, N 6. P. 302-309.
  58. Miller K., Massie MJ. Depressive disorders // Psycho-Oncology / eds J. Holland, W. Breitbart, P. Jacobsen, M. Lederberg, M. Loscalzo, R. McCorkle. New York : Oxford University Press, 2010. P. 311-318.
  59. Li M., Fitzgeral P, Rodin G. Evidence-based treatment of depression in patients with cancer //J. Clin. Oncol. 2012. Vol. 30, N 11. P. 1187-96.
  60. Levin T.T, Alici Y. Anxiety disorders // Psycho-Oncology / eds J. Holland, W. Breitbart, P. Jacobsen, M. Lederberg, M. Loscalzo, R. McCorkle. New York : Oxford University Press, 2010. P. 324-331.
  61. Doka KJ. Counseling individuals with life-threatening illness. New York : Springer Publishing Company, 2009.
  62. Traeger L., Greer J. A., Fernandez-Robles C., Temel J.S., Pirl W.F. Evidence-based treatment of anxiety in patients with cancer //J. Clin. Oncol. 2012. Vol. 30. P. 1197-1205.
  63. Gil F, Grassi L., Travado L., Tomamichele M., Gonzalez J.R.; The SEPOS Group. Use of distress and depression thermometers to measure psychosocial morbidity among southern European cancer patients // Support. Care Cancer. 2005. Vol. 13. P. 600-606.
  64. BrintzenhofeSzoc К.М., Kevin Т.Т., Li Y, Kissane D.W., Zabora J.R. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type // Psychosomatics. 2009. Vol. 50. P. 383-391.
  65. Parker P.A., Baile W.F., de Moor C., Cohen L. Psychosocial and demographic predictors of quality of life in a large sample of cancer patients // Psychooncology. 2003. Vol. 12, N2. P. 183-193.
  66. Colleoni M., Mandala M., Peruzzotti G., Robertson C., Bredart A., Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs // Lancet. 2000. Vol. 356, N 9238. P. 1326-1327.
  67. DiMatteo M.R., Lepper H.S., Croghan T.W. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence //Arch. Intern. Med. 2000. Vol. 160. P. 2101-2107.
  68. Walker L.G., Heys S.D., Walker M.B., Ogston K., Miller I.D., Hutcheon A.W. et al. Psychological factors can predict the response to primary chemotherapy in patients with locally advanced breast cancer // Eur. ). Cancer. 1999. Vol. 35, N 13. P. 1783-1788.
  69. Watson M., Homewood J., Haviland J., Bliss J.M. Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort // Eur. J. Cancer. 2005. Vol. 41, N 12. P. 1710-1714.
  70. Prieto J.M., AtalaJ., Blanch J. et al. Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation // J. Clin. Oncol. 2005. Vol. 23, N25. P. 6063-6071.
  71. Katon W, Lin E.H., Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness // Gen. Hosp. Psychiatry. 2007. Vol. 29. P. 147-155.
  72. Prieto J.M., Blanch J., Atala J., Carreras E., Rovira M., Cirera E. et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation // J. Clin. Oncol. 2002. Vol. 20, N 7. P. 1907-1917.
  73. Henriksson M.M., Isometsa E.T., Hietanen P.S., Aro H.M., Lonnqvist J.K. Mental disorders in cancer suicides //J. Affect. Disord. 1995. Vol. 36. P. 11-20.
  74. Lazarus R.S., Folkman S. Stress, appraisal and coping. New York : Springer, 1984.
  75. Lazarus R.S. Stress and emotion: a new synthesis. London : Free Association Books, 1999.
  76. Antoni M.H. Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer // Brain Behav. Immun. 2013. Vol. 30. P. S88-S98. DOI: https://doi.Org/10.1016/j.bbi.2012.05.009
  77. Faller H., Schuler M., Richard M. et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis //J. Clin. Oncol. 2013. Vol. 31, N 6. P 782-793.
  78. Stanton A.L., Rowland J.H., Ganz P.A. Life after diagnosis and treatment of cancer in adulthood: contributions from psychosocial oncology research // Am. Psychol. 2015. Vol. 70, N2. P. 159-174.
  79. Matthews H., Grunfeld E.A., Turner A. The efficacy of interventions to improve psychosocial outcomes following surgical treatment for breast cancer: a systematic review and meta-analysis // Psychooncology. 2017. Vol. 26, N 5. P. 593-607.
  80. Gudenkauf L.M., Ehlers S.L. Psychosocial interventions in breast cancer survivorship care // Breast. 2017. Vol. 38. P. 1-6. DOI: https://doi.org/10.1016/ j.breast.2017.11.005
  81. Zimmerman T, Heinrichs N., Baucom D.H. «Does one size fit all»? Moderators in psychosocial interventions for breast cancer patients: a meta-analysis // Ann. Behav. Med. 2007. Vol. 34. P. 225-239.
  82. Osborn R.L., Demoncada A.C., Feuerstein M. Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: meta-analyses // Int. J. Psychiatry Med. 2006. Vol. 36. P. 1334.
  83. Rehse B., Pukrop R. Effects of psychosocial interventions on quality of life in adult cancer patients: meta-analysis of 37 published controlled outcome studies // Patient Educ. Couns. 2003. Vol. 50. P. 225-239.
  84. Zainal N.Z., Booth S., Huppert EA. The efficacy of mindfulness-based stress reduction on mental health of breast cancer patients: a meta-analysis // Psychooncology. 2013. Vol. 22. P. 1457-1465. DOI: https://doi.org/10.1002/ pon.3171
  85. Smedslund G., Ringdal G.I. Meta-analysis of the effects of psychosocial interventions on survival time in cancer patients // J. Psychosom. Res. 2004. Vol. 57. P. 123-135.
  86. Barrera I., Spiegel D. Review of psychotherapeutic interventions on depression in cancer patients and their impact on disease progression // Int. Rev. Psychiatry. 2014. Vol. 26, N 1. P. 31-43.
  87. Andersen B.E., Yan H.C., Farrar W.B. et al. Psychologic intervention improves survival for breast cancer patients. A randomized clinical trial // Cancer. 2008. Vol. ИЗ. P. 3450-3458.
  88. Stagl J.M., Lechner S.C., Carver C.S. et al. A randomized controlled trial of cognitive-behavioral stress management in breast cancer: survival and recurrence at 11-year follow-up // Breast Cancer Res. Treat. 2015. Vol. 154. P. 319-328. DOI: https://doi.org/10.1007/sl0549-015-3626-6
  89. Carlson L.E., Bultz B.D. Efficacy and medical cost offset of psychosocial interventions in cancer care: making the case for economic analyses // Psychooncology. 2004. Vol. 13, N 12. P. 837-849.
  90. The Scientific Evidence of Cost-Effectiveness of Psychological Interventions in Health Care, prepared by the Portuguese College of Psychologists in 2011. OPP, 2011.
  91. Bultz B.D., Johansen C. Screening for distress, the 6th vital sign: where are we, and where are we going? // Psychooncology. 2011. Vol. 20. P. 569-571.
  92. Jacobsen P.B., Wagner L.I. A new quality standard: the integration of psychosocial care into routine cancer care //J. Clin. Oncol. 2012. Vol. 30, N 11. P. 1154-1159.
  93. Bultz B.D., Travado L., Jacobsen P.B., Turner J., Borras J.M., Ullrich A.W. 2014 President’s plenary international psycho-oncology society: moving toward cancer care for the whole patient // Psychooncology. 2014. Vol. 24. P. 1587-1593. DOI: https://doi.org/10.1002/pon.3844
  94. Travado L., Breitbart W., Grassi L. et al. 2015 President’s plenary international psycho-oncology society: psychosocial care as a human rights issue - challenges and opportunities // Psychooncology. 2017. Vol. 26. P. 563-569. DOI: https:// doi.org/10.1002/pon.4209
  95. Dunn J., Bultz B.D., Watson M. Emerging international directions for psychosocial care // Psycho-Oncology Textbook. 3rd ed. / eds J.C. Holland, W.S. Breitbart, PB. Jacobsen, MJ. Loscalzo, R. McCorkle, P.N. Butow. New York : Oxford University Press, 2015. P. 739-744.
  96. National Breast Cancer Centre and National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Camperdown, NSW : National Breast Cancer Centre. 2003. URL: http://canceraustralia. gov.au/sites/default/files/publications/pca-1 -clinical-practiceguidelines-for-psychosocial-care-of-adults-withcancer_504af02682bdf.pdf (date of access December 10, 2017)
  97. Travado L., Dalmas M. Psychosocial oncology care // European Guide for Quality National Cancer Control Programmes / eds T. Albreht, J.M. Martin-Moreno, M. Jelenc, L. Gorgojo, M. Harris. Ljubljana, Slovenia : National Institute of Public Health, 2015. P. 35-39.
  98. Albreht T, Borr.s J.M., Dalmas M. et al. Survivorship and rehabilitation: policy recommendations for quality improvement in cancer survivorship and rehabilitation in EU Member States // European Guide on Quality Improvement in Comprehensive Cancer Control / eds T. Albreht, R. Kiasuwa, M. Vanden Bulcke. Ljubljana, Slovenia : National Institute of Public Health; Brussels : Scientific Institute of Public Health, 2017. URL: https://cancercontrol.eu/ archived/uploads/images/Guide/pdf/CanCon_Guide_FINAL_Web.pdf
  99. Baken D.M., Woolley C. Validation of the distress thermometer, impact thermometer and combinations of these in screening for distress // Psychooncology. 2011. Vol. 20. P. 609-614.
  100. Mitchell A.J. Short screening tools for cancer-related distress: a review and diagnostic validity meta-analysis //J. Natl Compr. Cancer Netw. 2010. Vol. 8. P. 487-494.
  101. Bultz B.D., Travado L., Jacobsen P.B., Turner J., Borras J.M., Ullrich A.W 2014 President’s plenary international psycho-oncology society: moving toward cancer care for the whole patient // Psychooncology. 2015. Vol. 24. P. 1587-1593. DOI: https://doi.org/10.1002/pon.3844
  102. Travado L., Reis J.C., Watson M., Borr.s J. Psychosocial oncology care resources in Europe: a study under the European Partnership for Action Against Cancer (EPAAC) // Psychooncology. 2017. Vol. 26. P. 523-530. DOI: https://doi. org/10.1002/pon.4044
  103. Grassi L., Fujisawa D., Odyio P, Asuzu C., Ashley L., Bultz B. et al. Disparities in psychosocial cancer care: a report from the International Federation of PsychoOncology Societies // Psychooncology. 2016. Vol. 25, N 10. P. 1127-1136. DOI: https://doi.org/10.1002/pon.4228
  104. Neamfiu L., Deandrea S., Pylkk.nen L. et al. Psycho-oncological support for breast cancer patients: a brief overview of breast cancer services certification schemes and national health policies in Europe // Breast. 2016. Vol. 29. P. 178-180. DOI: https://doi.Org/10.1016/j.breast.2016.07.002
  105. Gilbert Е., Ussher J.M., Perz J. Sexuality after breast cancer: a review // Maturitas. 2010. Vol.' 66. P. 398-407.
  106. Lee S.J., Schover L.R., Partridge A.H. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients //J. Clin. Oncol. 2006. Vol. 24. P. 2917-2931.
  107. Loren A., Mangu P.B., Beck L.N. et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update // J. Clin. Oncol. 2013. Vol. 31. P. 2500-2510.
  108. Goldfarb S.B., Kramer A.S., Oppong B.A. et al. Fertility preservation for the young breast cancer patient // Ann. Surg. Oncol. 2016. Vol. 23. P. 1530-1536.
  109. Carter J., Lacchetti C., Andersen B.L. et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guidelines // J. Clin. Oncol. 2017. Vol. 11. P. 492. DOI: https://doi.org/10.1200/JCO.2017.75.8995
  110. Holt-Lumstad J., Smith T.B., Layton J.B. Social relationships and mortality risk: a meta-analytic review // PLoS Med. 2010. Vol. 7. Article ID el000316.
  111. Weihs K.L., Enright T.M., Simmens S.J. Close relationships and emotional processing predict decreased mortality in women with breast cancer: preliminary evidence // Psychosom. Med. 2008. Vol. 70. P. 117-124.
  112. Kroenke C.H., Quesenberry C., Kwan M.L. et al. Social networks, social support, and burden in relationships, and mortality after breast cancer diagnosis in the Life After Breast Cancer Epidemiology (LACE) study // Breast Cancer Res. Treat. 2013. Vol. 137. P. 261-271.
  113. Northouse L., Williams A.L., Given B., McCorkle R. Psychosocial care for family caregivers of patients with cancer // J. Clin. Oncol. 2012. Vol. 30, N 11. P. 1227-1234. DOI: https://doi.org/10.1200/JCO.2011.39.5798
  114. Van Ryn M., Sanders S., Kahn D. et al. Objective burden, resources, and other stressors among informal cancer caregivers: a hidden quality issue? // Psychooncology. 2011. Vol. 20, N 1. P. 44-52.
  115. Cancer Caregiving in the U.S.: An Intense, Episodic and Challenging Care Experience. Report prepared by the National Alliance for Caregiving, in collaboration with the National Cancer Institute and the Cancer Support Community. June 2016. URL: http://www.caregiving.org/wp-content/ uploads/2016/06/CancerCaregivingReport_FINALJ une-17-2016.pdf
  116. de Moor J.H.S., Dowling E.C., Ekwueme D.U. et al. Employment implications of informal cancer caregiving //J. Cancer Surviv. 2017. Vol. 11, N 1. P. 48-57.
  117. Weaver K.E., Rowland J.H., Alfano C.M., NcNeel T.S. Parental cancer and the family: a population based estimate of the number of US cancer survivors residing with their minor children // Cancer. 2010. Vol. 116, N 18. P. 4395-4401.
  118. Girgis A., Lambert S., Johnson C., Waller A., Currow D. Physical, psychosocial, relationship, and economic burden of care for people with cancer: a review // J. Oncol. Pract. 2013. Vol. 9, N 4. P. 197-202.
  119. Litzelman K.L, Green P.A., Yabroff K.R. Cancer and quality of life in spousal dyads: spillover in couples with and without cancer-related health problems // Support. Care Cancer. 2016. Vol. 24, N 2. P. 763-771.
  120. Frambes D., Given В., Lehto R., Sikorskii A., Wyatt G. Informal caregivers of cancer patients: review of interventions, care activities, and outcomes // West. J. Nurs Res. 2018. Vol. 40, N 7. P. 1069-1097. DOI: https://doi. org/10.1177/0193945917699364
  121. Badr H., Krebs P. A systematic review and meta-analysis of psychosocial interventions for couples coping with cancer // Psychooncology. 2013. Vol. 22, N8. P. 1688-1704.
  122. Dorros S.M., Segrin C., Badger T.A. Cancer survivor’ and partners’ key concerns and quality of life // Psychol. Health. 2017. Vol. 32, N 11. P. 1407-1427.
  123. Weaver K.E., Rowland J.H., Alfano C.M., McNeel T.S. Parental cancer and the family: a population-based estimate of the number of US cancer survivors residing with their minor children // Cancer. 2010. Vol. 116, N 18. P. 4395-4401.
  124. Shah B.K., Armaly J., Swieter E. Impact of parental cancer on children // Anticancer Res. 2017. Vol. 37. P. 4025-4028.
  125. Osborn T. The psychosocial impact of parental cancer on children and adolescents: a systematic review // Psychooncology. 2007. Vol. 16, N 2. P. 101-126.
  126. Purc-Stephenson R., Lyseng A. How are the kids holding up? A systematic review and meta- analysis on the psychosocial impact of maternal breast cancer on children // Cancer Treat. Rev. 2016. Vol. 49. P. 45-56.
  127. Huizinga G.A., Visser A., Zelders-Steyn Y.E., Teule J.A., Reijneveld S.A. et al. Psychological impact of having a parent with cancer // Eur. J. Cancer. 2011. Vol. 47, suppl. 3. P. S239-S246.
  128. Morris J.N., Martini A., Preen D. The well-being of children impacted by a parent with cancer: an integrated review // Support. Care Cancer. 2016. Vol. 24, N 7. P. 3235-3251.
  129. Brown R.T, Fuemmeler B., Anderson D., Jamieson S., Simonian S., Hall R.K. et al. Adjustment of children and their mothers with breast cancer // J. Pediatr. Psychol. 2007. Vol. 32, N 3. P. 297-308.
  130. Wellisch D.K., Ormseth S.R., Hartoonian N., Owen J.E. A retrospective study predicting psychological vulnerability in adult daughters of breast cancer patients // Fam. Syst. Health. 2012. Vol. 30, N 3. P. 253-264.
  131. Inhestern L., Bergelt C. When a mother has cancer: strains and resources of affected families from the mother’s and father’s perspective - a qualitative study // BMC Womens Health. 2018. Vol. 18, N 1. P. 72. DOI: https:// doi. org/10.1186/sl2905-018-0562-8
  132. Coscarelli A. When a parent has cancer: taking care of the children. URL: http://www.simmsmanncenter.ucla.edu/index.php/resources/articles-from-the-director-when-a-parenthas-cancer-taking-care-of-the-children/ (date of access December 17, 2018)
  133. Harpham W. When a parent has cancer: a guide to caring for your children. New York : Harper Collins Publishers, 1997.
  134. Heiney S.P., Hermann J.F. Cancer in our family: helping children cope with a parent’s illness. 2nd ed. Atlanta, GA : American Cancer Society, 2013.
  135. Ellis SJ., Wakefield C.E., Antill G., Bums M., Patterson P. Supporting children facing a parent’s cancer diagnosis: a systematic review of children’s psychosocial needs and existing interventions // Eur. J. Cancer Care. 2016. Vol. 26. Article ID e12432.
  136. Visser A., Huizinga G.A., Van der graaf W.T., Hoekstra HJ., Hoekstra-weebers J.E. The impact of parental cancer on children and the family: a review of the literature // Cancer Treat. Rev. 2004. Vol. 30, N 8. P. 683- 694.
  137. Shea S.E., Moore C.W. Parenting with a life-limiting illness // Child Adolesc Psychiatr. Clin. N. Am. 2018. Vol. 27, N 4. P. 567-578.
  138. Arrospide A., Forne С., Rue М., Тога N., Mar J., Bare М. An assessment of existing models for individualized breast cancer risk estimation in a screening program in Spain // BMC Cancer. 2013. Vol. 13. P. 587. DOI: https://doi.org/10.1186/1471-2407-13-587
  139. Anothaisintawee T, Teerawattananon Y, Wiratkapun C., Kasamesup V, Thakkinstian A. Risk prediction models of breast cancer: a systematic review of model performances // Breast Cancer Res. Treat. 2012. Vol. 133, N 1. P. 1-10.
  140. Decarli A., Calza S., Masala G., Specchia C., Palli D., Gail M.H. Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort // J. Natl Cancer Inst. 2006. Vol. 98, N 23. P. 1686-1693.
  141. Gail M.H., Brinton L.A., Byar D.P, Corle D.K., Green S.B., Schairer C. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually //J. Natl Cancer Inst. 1989. Vol. 81, N24. P. 1879-1886.
  142. Costantino J.P, Gail M.H., Pee D., Anderson S., Redmond C.K., Benichou J. et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence //J. Natl Cancer Inst. 1999. Vol. 91, N 18. P. 1541-1548.
  143. Chen J., Pee D., Ayyagari R., Graubard B., Schairer C., Byrne C. et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density // J. Natl Cancer Inst. 2006. Vol. 98, N 17. P. 1215-1226.
  144. Barlow W.E., White Е., Bal lard-Barbash R., Vacek P.M., Titus-Ernstoff L., Carney Р.А. et al. Prospective breast cancer risk prediction model for women undergoing screening mammography //J. Natl Cancer Inst. 2006. Vol. 98, N 17. P. 1204-1214.
  145. Antoniou A.C., Cunningham A.P., Peto J., Evans D.G., Lalloo E, Narod S.A. et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions // Br. J. Cancer. 2008. Vol. 98, N 8. P. 1457 1466.
  146. Lee A.J., Cunningham A.P., Kuchenbaecker K.B., Mavaddat N., Easton D.F., Antoniou A.C. et al. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface // Br. J. Cancer. 2014. Vol. 110, N 2. P. 535-545.
  147. Antoniou A.C., Pharoah P.P., Smith P, Easton D.F. The BOADICEA model of genetic susceptibility to breast and ovarian cancer // Br. J. Cancer. 2004. Vol. 91, N8. P. 1580-1590.
  148. Fischer C., Kuchenbacker K., Engel C., Zachariae S., Rhiem K., Meindl A. et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium // J. Med. Genet. 2013. Vol. 50, N 6. P. 360-367.
  149. Berry D.A., Iversen E.S. Jr, Gudbjartsson D.F., Hiller E.H., Garber J.E., Pesh-kin B.N. et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/ BRCA2, and prevalence of other breast cancer susceptibility genes // J. Clin. Oncol. 2002. Vol. 20, N 11. P. 2701-2712.
  150. Tyrer J., Duffy S.W., Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors // Stat. Med. 2004. Vol. 23, N 7. P. 1111-1130.
  151. Claus E.B., Risch N., Thompson W.D. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction // Cancer. 1994. Vol. 73, N 3. P. 643-651.
  152. ITurnbull C., Rahman N. Genetic predisposition to breast cancer: past, present, and future // Annu. Rev. Genomics Hum. Genet. 2008. Vol. 9. P. 321-345.
  153. Paluch-Shimon S., Cardoso E, Sessa C., Balmana J., Cardoso M.J., Gilbert F. et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening // Ann. Oncol. 2016. Vol. 27, suppl. 5. P. vl03-vll0.
  154. Gonzalez-Angulo A.M., Timms K.M., Liu S„ Chen H„ Litton J.K., Potter J. et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer // Clin. Cancer Res. 2011. Vol. 17, N 5. P. 1082-1089.
  155. Hartman A.R., Kaldate R.R., Sailer L.M., Painter L., Grier C.E., Endsley R.R. et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer // Cancer. 2012. Vol. 118, N 11. P. 2787-2795.
  156. Grindedal E.M., Heramb C., Karsrud L, Ariansen S.L., Maehle L., Undlien D.E. et al. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers // BMC Cancer. 2017. Vol. 17, N 1. P. 438. DOI: https://doi.org/10.1186/sl2885-017-3422-2.
  157. Couch FJ., Hart S.N., Sharma P., Toland A.E., Wang X., Miron P. et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer // J. Clin. Oncol. 2015. Vol. 33, N 4. P. 304-311.
  158. LaDuca H., Stuenkel A.J., Dolinsky J.S., Keiles S., Tandy S., Pesaran T. et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients // Genet. Med. 2014. Vol. 16, N 11. P. 830-837.
  159. The NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian V2.2019. National Comprehensive Cancer Network.
  160. National Collaborating Centre for Cancer (UK). 2013.
  161. Warner E., Plewes D.B., Hill K.A., Causer P.A., Zubovits J.T., Jong R.A. et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination //JAMA. 2004. Vol. 292, N 11. P. 1317-1325.
  162. Kriege M., Brekelmans C.T., Boetes C., Besnard P.E., Zonderland H.M., Obdeijn I.M. et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition //N. Engl. J. Med. 2004. Vol. 351, N 5. P. 427-437.
  163. Horsman D., Wilson B.J., Avard D., Meschino W.S., Kim Sing C., Plante M. et al. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation // J. Obstet. Gynaecol. Can. 2007. Vol. 29, N 1. P. 45-60.
  164. Chiarelli A.M., Prummel M.V, Muradali D., Majpruz V, Horgan M., Carroll J.C. et al. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the Ontario High Risk Breast Screening Program //J. Clin. Oncol. 2014. Vol. 32, N 21. P. 2224-2230.
  165. Daly B., Olopade O.I. A perfect storm: how tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change // CA Cancer J. Clin. 2015. Vol. 65, N 3. P. 221-238.
  166. DeSantis C.E., Lin C.C., Mariotto A.B., Siegel R.L., Stein K.D., Kramer J.L. et al. Cancer treatment and survivorship statistics, 2014 // CA Cancer J. Clin. 2014. Vol. 64, N4. P. 252-271.
  167. DeSantis C., Siegel R., Bandi P, Jemal A. Breast cancer statistics, 2011 // CA Cancer J. Clin. 2011. Vol. 61, N 6. P. 409-418.
  168. Chlebowski R.T., Chen Z., Anderson G.L., Rohan T, Aragaki A., Lane D. et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome //J. Natl Cancer Inst. 2005. Vol. 97, N 6. P. 439-448.
  169. Cunningham J.E., Montero A.J., Garrett-Mayer E., Berkel H.J., Ely B. Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status // Cancer Causes Control. 2010. Vol. 21, N3.P. 399-409.
  170. Kurian A.W, Fish K., Shema S.J., Clarke C.A. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups // Breast Cancer Res. 2010. Vol. 12, N6. P. R99.
  171. Howlader N., Altekruse S.F., Li C.I., Chen V.W., Clarke C.A., Ries L.A. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status //J. Natl Cancer Inst. 2014. Vol. 106, N 5. Article ID dju055. DIO: https:// doi.org/10.1093/jnci/dju055
  172. Clarke C.A., West D.W., Edwards B.K., Figgs L.W., Kerner J., Schwartz A.G. Existing data on breast cancer in African-American women: what we know and what we need to know // Cancer. 2003. Vol. 97, N 1. Suppl. P. 211-221.
  173. Surveillance, Epidemiology, and End Results program. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) stat fact sheets: breast cancer.
  174. Hunt B.R., Whitman S., Hurlbert M.S. Increasing Black:White disparities in breast cancer mortality in the 50 largest cities in the United States // Cancer Epidemiol. 2014. Vol. 38, N 2. P. 118-123.
  175. Iqbal J., Ginsburg O., Rochon P.A., Sun P, Narod S.A. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States //JAMA. 2015. Vol. 313, N 2. P. 165-173.
  176. Brennan M. Breast cancer in ethnic minority groups in developed nations: case studies of the United Kingdom and Australia // Maturitas. 2017. Vol. 99. P 16-19.
  177. Carey L.A., Perou C.M., Livasy C.A., Dressier L.G., Cowan D., Conway K. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study // JAMA. 2006. Vol. 295, N 21. P. 2492-2502.
  178. O’Brien K.M., Cole S.R., Tse C.K., Perou C.M., Carey L.A., Foulkes WD. et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study // Clin. Cancer Res. 2010. Vol. 16, N 24. P. 6100-6110.
  179. Palmer J.R., Viscidi E., Troester M.A., Hong C.C., Schedin P, Bethea T.N. et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium //J. Natl Cancer Inst. 2014. Vol. 106, N 10. Article ID dju237. DOI: https://doi.org/10.1093/jnci/dju237
  180. McCormack V.A., dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis // Cancer Epidemiol. Biomarkers Prev. 2006. Vol. 15, N 6. P. 1159-1169.
  181. Cil T„ Fishell E., Hanna W, Sun P, Rawlinson E., Narod S.A. et al. Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery // Cancer. 2009. Vol. 115, N 24. P. 5780-5787.
  182. Eriksson L., Czene K., Rosenberg L., Humphreys K., Hall P. Possible influence of mammographic density on local and locoregional recurrence of breast cancer // Breast Cancer Res. 2013. Vol. 15, N 4. P. R56.
  183. Park C.C., Rembert J., Chew K., Moore D., Kerlikowske K. High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer // Int. J. Radial. Oncol. Biol. Phys. 2009. Vol. 73, N 1. P. 75-79.
  184. Porter G.J., Evans A.J., Cornford E.J., Burrell H.C., James J.J., Lee A.H. et al. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival // AJR Am. J. Roentgenol. 2007. Vol. 188, N 3. P. 676-683.
  185. Gierach G.L., Ichikawa L., Kerlikowske K., Brinton L.A., Farhat G.N., Vacek P.M. et al. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium //J. Natl Cancer Inst. 2012. Vol. 104, N 16. P. 1218-1227.
  186. Chiu S.Y., Duffy S., Yen A.M., Tabar L., Smith R.A., Chen H.H. Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening // Cancer Epidemiol Biomarkers Prev. 2010. Vol. 19, N 5. P. 1219-1228.
  187. Boyd N.F., Guo H., Martin LJ., Sun L., Stone J., Fishell E. et al. Mammographic density and the risk and detection of breast cancer // N. Engl. J. Med. 2007. Vol. 356, N 3. P. 227-236.
  188. Boyd N.F., Huszti E., Melnichouk O., Martin L.J., Hislop G., Chiarelli A. et al. Mammographic features associated with interval breast cancers in screening programs // Breast Cancer Res. 2014. Vol. 16, N 4. P. 417. DOI: https://doi. org/10.1186/sl3058-014-0417-7
  189. Yan S., Wang Y, Aghaei E, Qiu Y, Zheng B. Applying a new bilateral mammographic density segmentation method to improve accuracy of breast cancer risk prediction // Int. J. Comput. Assist. Radiol. Surg. 2017. Vol. 12, N 10. P. 1819-1828.
  190. MelnikowJ., Fenton JJ., Whitlock E.P., Miglioretti D.L., Weyrich M.S., Thompson J.H. et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. preventive services task force // Ann. Intern. Med. 2016. Vol. 164, N 4 P. 268-278.
  191. Greendale G.A., Reboussin B.A., Slone S., Wasilauskas C., Pike M.C., Ursin G. Postmenopausal hormone therapy and change in mammographic density //J. Natl Cancer Inst. 2003. Vol. 95, N 1. P. 30-37.
  192. Lee E., Ingles S.A., Van Den Berg D., Wang W, Lavallee C., Huang M.H. et al. Progestogen levels, progesterone receptor gene polymorphisms, and mammographic density changes: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study // Menopause. 2012. Vol. 19, N 3. P. 302-310.
  193. Singletary K.W., Gapstur S.M. Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms //JAMA. 2001. Vol. 286, N 17. P. 2143-2151.
  194. Harvey J.A., Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk // Radiology. 2004. Vol. 230, N 1. P. 29-41.
  195. Heine J.J., Malhotra P. Mammographic tissue, breast cancer risk, serial image analysis, and digital mammography. Part 1. Tissue and related risk factors // Acad. Radiol. 2002. Vol. 9, N 3. P. 298-316.
  196. Heine J.J., Malhotra P. Mammographic tissue, breast cancer risk, serial image analysis, and digital mammography. Part 2. Serial breast tissue change and related temporal influences // Acad. Radiol. 2002. Vol. 9, N 3. P. 317-335.
  197. Sellers T.A., Vachon C.M., Pankratz V.S., Janney C.A., Fredericksen Z., Brandt K.R. et al. Association of childhood and adolescent anthropometric factors, physical activity, and diet with adult mammographic breast density // Am. J. Epidemiol. 2007. Vol. 166, N 4. P. 456-464.
  198. Vachon C.M., Kushi L.H., Cerhan J.R., Kuni C.C., Sellers TA. Association of diet and mammographic breast density in the Minnesota breast cancer family cohort // Cancer Epidemiol. Biomarkers Prev. 2000. Vol. 9, N 2. P. 151-160.
  199. Dall G.V., Britt K.L. Estrogen effects on the mammary gland in early and late life and breast cancer risk // Front. Oncol. 2017. Vol. 7. P. 110.
  200. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies // Lancet Oncol. 2012. Vol. 13, N11. P. 1141-1151.
  201. Sisti J.S., Bernstein J.L., Lynch C.F., Reiner A.S., Mellemkjaer L., Brooks J.D. et al. Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study // Springerplus. 2015. Vol. 30, N 4. P. 825. DOI: https://doi.org/10.1186/s40064-015-1642-y
  202. Anderson K.N., Schwab R.B., Martinez M.E. Reproductive risk factors and breast cancer subtypes: a review of the literature // Breast Cancer Res. Treat. 2014. Vol. 144, N 1. P. 1-10.
  203. Chen L., Li C.I., Tang M.T, Porter P, Hill D.A., Wiggins C.L. et al. Reproductive factors and risk of luminal, HER2-overexpressing, and triple- negative breast cancer among multiethnic women // Cancer Epidemiol. Biomarkers Prev. 2016. Vol. 25, N9. P. 1297-1304.
  204. Gaudet M.M., Press M.F., Haile R.W., Lynch C.F, Glaser S.L., Schildkraut J. et al. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger // Breast Cancer Res. Treat. 2011. Vol. 130, N 2. P. 587-597.
  205. Lambe M., Hsieh C.C., Chan H.W., Ekbom A., Trichopoulos D., Adami H.O. Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden // Breast Cancer Res. Treat. 1996. Vol. 38, N 3. P. 305-311.
  206. Rao C.V Protective effects of human chorionic gonadotropin against breast cancer: how can we use this information to prevent/treat the disease? // Reprod. Sci. 2017. Vol. 24, N8. P. 1102-1110.
  207. Andrieu N., Goldgar D.E., Easton D.F., Rookus M., Brohet R., Antoniou A.C. et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS) //J. Natl Cancer Inst. 2006. Vol. 98, N 8. P. 535-544.
  208. Newcomb P.A., Storer B.E., Longnecker M.P, Mittendorf R., Greenberg E.R., Clapp R.W. et al. Lactation and a reduced risk of premenopausal breast cancer // N. Engl. J. Med. 1994. Vol. 330, N 2. P. 81-87.
  209. Lambertini M., Santoro L., Del Mastro L., Nguyen B., Livraghi L., Ugolini D. et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies // Cancer Treat. Rev. 2016. Vol. 49. P. 65-76.
  210. Jernstrom H., Lubinski J., Lynch H.T, Ghadirian P, Neuhausen S., Isaacs C. et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers //J. Natl Cancer Inst. 2004. Vol. 96, N 14. P 1094-1098.
  211. Downing N.S., Shah N.D., Neiman J.H., Aminawung J.A., Krumholz H.M., Ross J.S. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals // Trials. 2016. Vol. 17. P 199. DOI: https://doi.org/10.1186/sl3063-016-1322-4
  212. Shinde S.S., Forman M.R., Kuerer H.M., Yan K., Peintinger E, Hunt K.K. et al. Higher parity and shorter breastfeeding duration: association with triplenegative phenotype of breast cancer // Cancer. 2010. Vol. 116, N 21. P. 4933-4943.
  213. Soroush A., Farshchian N., Komasi S., Izadi N., Amirifard N., Shahmohammadi A. The role of oral contraceptive pills on increased risk of breast cancer in Iranian populations: a meta-analysis //J. Cancer Prev. 2016. Vol. 21, N 4. P. 294-301.
  214. Charlton B.M., Rich-Edwards J.W., Colditz G.A., Missmer S.A., Rosner B.A., Hankinson S.E. et al. Oral contraceptive use and mortality after 36 years of followup in the Nurses’ Health Study: prospective cohort study // BMJ. 2014. Vol. 349. Article ID g6356.
  215. Li L., Zhong Y, Zhang H., Yu H., Huang Y, Li Z. et al. Association between oral contraceptive use as a risk factor and triple-negative breast cancer: a systematic review and meta-analysis // Mol. Clin. Oncol. 2017. Vol. 7, N 1. P. 76-80.
  216. Althuis M.D., Brogan D.R., Coates R.J., Baling J.R„ Gammon M.D., Malone K.E. et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women // Br. J. Cancer. 2003. Vol. 88, N 1. P. 50-57.
  217. Marchbanks P.A., McDonald J.A., Wilson H.G., Folger S.G., Mandel M.G., Da-ling J.R. et al. Oral contraceptives and the risk of breast cancer // N. Engl. J. Med. 2002.Vol. 346, N 26. P. 2025-2032.
  218. Lu Y, Ma H., Malone K.E., Norman S.A., Sullivan-Halley J., Strom B.L. et al. Oral contraceptive use and survival in women with invasive breast cancer // Cancer Epidemiol. Biomarkers Prev. 201 1. Vol. 20, N 7. P. 1391-1397.
  219. Cuzick J., Powles T, Veronesi U., Forbes J., Edwards R., Ashley S. et al. Overview of the main outcomes in breast-cancer prevention trials // Lancet. 2003. Vol. 361, N 9354. P. 296-300.
  220. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study //J. Natl Cancer Inst. 2005. Vol. 97, N 22. P. 1652-1662.
  221. Cuzick J., Forbes J., Edwards R., Baum M., Cawthorn S., Coates A. et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial // Lancet. 2002. Vol. 360, N 9336. P. 817-824.
  222. Powles T.J., Ashley S., Tidy A., Smith I.E., Dowsett M. Twenty-year followup of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial //J. Natl Cancer Inst. 2007. Vol. 99, N 4. P. 283-290.
  223. Veronesi U., Maisonneuve P, Rotmensz N., Bonanni B., Boyle P, Viale G. et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy // J. Natl Cancer Inst. 2007. Vol. 99, N 9. P. 727-737.
  224. Nelson H.D., Smith M.E., Griffin J.C., Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force // Ann. Intern. Med. 2013. Vol. 158, N 8. P 604-614.
  225. Visvanathan K., Lippman S.M., Hurley P, Temin S.; American Society of Clinical Oncology Clinical Practice Guideline. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction // Gynecol. Oncol. 2009. Vol. 115, N 1. P. 132-134.
  226. Winer E.P Optimizing endocrine therapy for breast cancer //J. Clin. Oncol. 2005. Vol. 23, N8. P. 1609-1610.
  227. Pagani О., Regan М.М., Walley В.A., Fleming G.F., Colleoni М., Lang I. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer // N. Engl. J. Med. 2014. Vol. 371, N 2. P. 107-118.
  228. Saha P, Regan M.M., Pagani O., Francis P.A., Walley B.A., Ribi K. et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials //J. Clin. Oncol. 2017. Vol. 35, N 27. P 3113-3122. DOI: https:// doi.org/10.1200/JCG.2016.72.0946
  229. Hartmann L.C., Sellers T.A., Schaid D.J., Frank T.S., Soderberg C.L., Sitta D.L. et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers // J. Natl Cancer Inst. 2001. Vol. 93, N 21. P. 1633-1637.
  230. Rebbeck T.R., Friebel T, Lynch H.T., Neuhausen S.L., van’t Veer L., Garber J.E. et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group //J. Clin. Oncol. 2004. Vol. 22, N6. P. 1055-1062.
  231. Heemskerk-Gerritsen B.A., Brekelmans C.T, Menke-Pluymers M.B., van Geel A.N., Tilanus-Linthorst M.M., Bartels C.C. et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: longterm experiences at the Rotterdam Family Cancer Clinic // Ann. Surg. Oncol. 2007. Vol. 14, N 12. P. 3335-3344.
  232. Evans D.G., Baildam A.D., Anderson E., Brain A., Shenton A., Vasen H.F. et al. Risk reducing mastectomy: outcomes in 10 European centres //J. Med. Genet. 2009.Vol. 46, N 4. P. 254-258.
  233. Chung A.P., Sacchini V Nipple-sparing mastectomy: where are we now? // Surg. Oncol. 2008. Vol. 17, N 4. P. 261-266.
  234. Morrow M., Mehrara B. Prophylactic mastectomy and the timing of breast reconstruction // Br. J. Surg. 2009. Vol. 96, N 1. P. 1-2.
  235. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers //J. Natl Cancer Inst. 2009. Vol. 101, N 2. P. 80-87.
  236. Marchetti C., De Felice E, Palaia L, Perniola G„ Musella A., Musio D. et al. Riskreducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all-cause mortality in BRCA 1 and BRCA 2 mutation carriers // BMC Womens Health. 2014. Vol. 14. P. 150. DOI: https://doi.org/10.1186/ sl2905-014-0150-5
  237. Erickson B.K., Conner M.G., Landen C.N. Jr. The role of the fallopian tube in the origin of ovarian cancer // Am. J. Obstet. Gynecol. 2013. Vol. 209, N 5. P. 409-414.
  238. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths // CA Cancer J. Clin. 2011. Vol. 61, N 4. P. 212-236.
  239. Hirth J.M., Laz TH., Rahman M., Berenson A.B. Racial/ethnic differences affecting adherence to cancer screening guidelines among women // J. Womens Health (Larchmt.). 2016. Vol. 25, N 4. P. 371-380.
  240. Belkic K., Cohen M„ Wilczek B., Andersson S., Berman A.H., Marquez M. et al. Imaging surveillance programs for women at high breast cancer risk in Europe: аге women from ethnic minority groups adequately included? (Review) // Int. J. Oncol. 2015. Vol. 47, N 3. P. 817-839.
  241. Bigby J., Holmes M.D. Disparities across the breast cancer continuum // Cancer Causes Control. 2005. Vol. 16, N 1. P. 35-44.
  242. Reeder-Hayes K.E., Wheeler S.B., Mayer D.K. Health disparities across the breast cancer continuum // Semin. Oncol. Nurs. 2015. Vol. 31, N 2. P. 170-177.
  243. Yedjou C.G., Tchounwou P.B., Payton M., Miele L., Fonseca D.D., Lowe L. et al. Assessing the racial and ethnic disparities in breast cancer mortality in the United States // Int. J. Environ. Res. Public Health. 2017. Vol. 14, N 5. P. E486. DOI: https://doi.org/10.3390/ijerphl4050486
  244. Gorin S.S., Heck J.E., Cheng B., Smith SJ. Delays in breast cancer diagnosis and treatment by racial/ethnic group // Arch. Intern. Med. 2006. Vol. 166, N 20. P. 2244-2252.
  245. Gwyn K., Bondy M.L., Cohen D.S., Lund M.J., Liff J.M., Flagg E.W. et al. Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma // Cancer. 2004. Vol. 100, N8. P. 1595-1604.
  246. Parsons H.M., Lathrop K.I., Schmidt S., Mazo-Canola M., Trevino-Jones J., Speck H. et al. Breast cancer treatment delays in a majority minority community: is there a difference? //J. Oncol. Pract. 2015. Vol. 11, N 2. P. el44-el53.
  247. Kidd A.D., Colbert A.M., Jatoi I. Mammography: review of the controversy, health disparities, and impact on young African American women // Clin. J. Oncol. Nurs. 2015. Vol. 19, N 3. P. E52-E58.
  248. Guibout C., Adjadj E., Rubino C., Shamsaldin A., Grimaud E., Hawkins M. et al. Malignant breast tumors after radiotherapy for a first cancer during childhood // J. Clin. Oncol. 2005. Vol. 23, N 1. P. 197-204.
  249. Kenney L.B., Yasui Y, Inskip P.D., Hammond S., Neglia J.P, Mertens A.C. et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study // Ann. Intern. Med. 2004. Vol. 141, N 8. P. 590-597.
  250. Bluhm E.C., Ronckers C., Hayashi R.J., Neglia J.P., Mertens A.C., Stovall M. et al. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study // Blood. 2008. Vol. Ill, N8. P. 4014-4021.
  251. Hancock S.L., Tucker M.A., Hoppe R.T. Breast cancer after treatment of Hodgkin’s disease //J. Natl Cancer Inst. 1993. Vol. 85, N 1. P. 25-31.
  252. Swerdlow A.J., Barber J.A., Hudson G.V, Cunningham D., Gupta R.K., Hancock B.W. et al. Risk of second malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment // J. Clin. Oncol. 2000. Vol. 18, N 3. P. 498-509.
  253. Bhatia S., Yasui Y, Robison L.L., Birch J.M., Bogue M.K., Diller L. et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group //J. Clin. Oncol. 2003.Vol. 21, N 23. P. 4386-4394.
  254. Marcus P.M., Newman B., Millikan R.C., Moorman P.G., Baird D.D., Qaqish B. The associations of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk (United States) // Cancer Causes Control. 2000. Vol. 11, N 3. P. 271-278.
  255. Preston D.L., Kitahara C.M., Freedman D.M., Sigurdson A.J., Simon S.L., Little M.P et al. Breast cancer risk and protracted low-to-moderate dose occupational radiation exposure in the US Radiologic Technologists Cohort, 1983-2008 // Br. J. Cancer. 2016. Vol. 115, N 9. P. 1105-1112.
  256. Rajaraman P, Doody M.M., Yu C.L., Preston D.L., Miller J.S., Sigurdson A.J. et al. Cancer risks in U.S. radiologic technologists working with fluoroscopically guided interventional procedures, 1994-2008 // AJR Am. J. Roentgenol. 2016. Vol. 206, N5. P. 1101-1108.
  257. Pijpe A., Andrieu N., Easton D.F., Kesminiene A., Cardis E., Nogues C. et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK) // BMJ. 2012. Vol. 345. Article ID e5660.
  258. Berrington de Gonzalez A., Berg C.D., Visvanathan K„ Robson M. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers // J. Natl Cancer Inst. 2009. Vol. 101, N 3. P. 205-209.
  259. McDonald J.A., Goyal A., Terry M.B. Alcohol intake and breast cancer risk: weighing the overall evidence // Curr. Breast Cancer Rep. 2013. Vol. 5. P. 3. DOI: https://doi.org/10.1007/sl2609-013-0114-z
  260. Seitz H.K., Pelucchi C., Bagnardi V, La Vecchia C. Epidemiology and pathophysiology of alcohol and breast cancer: update 2012 // Alcohol Alcohol. 2012. Vol. 47, N 3. P. 204-212.
  261. Oyesanmi O., Snyder D., Sullivan N., Reston J., Treadwell J., Schoelles K.M. Alcohol consumption and cancer risk: understanding possible causal mechanisms for breast and colorectal cancers // Evid. Rep. Technol. Assess. (Full Rep.). 2010. Vol. 197. P. 1-151.
  262. Boyd N.F., Martin LJ., Yaffe M.J., Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects // Breast Cancer Res. 2011. Vol. 13, N6. P. 223.
  263. Conroy S.M., Koga K., Woolcott C.G., Dahl T, Byrne C„ Nagata C. et al. Higher alcohol intake may modify the association between mammographic density and breast cancer: an analysis of three case-control studies // Cancer Epidemiol. 2012. Vol. 36, N 5. P. 458-460.
  264. Hamajima N., Hirose K., Tajima K., Rohan T, Calle E.E., Heath C.W. Jr et al. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease // Br. J. Cancer. 2002. Vol. 87, N 11. P. 1234-1245.
  265. Chen W.Y, Rosner B., Hankinson S.E., Colditz G.A., Willett W.C. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk // JAMA. 2011. Vol. 306, N 17. P. 1884-1890.
  266. Jayasekara H., Maclnnis R.J., Hodge A.M., Room R., Milne R.L., Hopper J.L. et al. Is breast cancer risk associated with alcohol intake before first full-term pregnancy? // Cancer Causes Control. 2016. Vol. 27, N 9. P. 1167-1174.
  267. Colditz G.A., Bohlke К., Berkey C.S. Breast cancer risk accumulation starts early: prevention must also // Breast Cancer Res. Treat. 2014. Vol. 145, N 3. P. 567 -579.
  268. Liu Y, Colditz G.A., Rosner B., Berkey C.S., Collins L.C., Schnitt S.J. et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk // J. Natl Cancer Inst. 2013. Vol. 105, N 20. P. 1571-1578.
  269. Band PR., Le N.D., Fang R., Deschamps M. Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer // Lancet. 2002. Vol. 360, N 9339. P. 1044-1049.
  270. Gaudet M.M., Gapstur S.M., Sun J., Diver W.R., Hannan L.M., Thun M.J. Active smoking and breast cancer risk: original cohort data and meta-analysis // J. Natl Cancer Inst. 2013. Vol. 105, N 8. P. 515-525.
  271. Bjerkaas E., Parajuli R., Weiderpass E., Engeland A., Maskarinec G., Selmer R. et al. Smoking duration before first childbirth: an emerging risk factor for breast cancer? Results from 302,865 Norwegian women // Cancer Causes Control. 2013. Vol. 24, N7. P. 1347-1356.
  272. Johnson K,C. Accumulating evidence on passive and active smoking and breast cancer risk // Int. J. Cancer. 2005. Vol. 117, N 4. P. 619-628.
  273. Luo J., Margolis K.L., Wactawski-Wende J., Horn K., Messina C., Stefanick M.L. et al. Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study // BMJ. 2011. Vol. 342. Article ID d 1016.
  274. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults // N. Engl. J. Med’ 2003. Vol. 348, N 17. P. 1625-1638.
  275. Ligibel J.A., Alfano C.M., Courneya K.S., Demark-Wahnefried W., Burger R.A., Chlebowski R.T et al. American Society of Clinical Oncology position statement on obesity and cancer //J. Clin. Oncol. 2014. Vol. 32, N 31. P. 3568-3574.
  276. Renehan A.G., Zwahlen M., Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology //Nat. Rev. Cancer. 2015. Vol. 15, N 8. P. 484-498.
  277. Arnold M., Pandeya N., Byrnes G., Renehan A.G., Stevens G.A., Ezzati M. et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study // Lancet Oncol. 2015. Vol. 16, N 1. P. 36-46.
  278. National Cancer Institute. NC: Fact sheet: Obesity and cancer risk. URL: http:// www.cancer.gov/cancertopics/causes-prevention/risk/obesity/obesity-fact-sheet
  279. Protani M., Coory M., Martin J.H. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis // Breast Cancer Res. Treat. 2010. Vol. 123, N 3. P. 627-635.
  280. Engin A. Obesity-associated breast cancer: analysis of risk factors // Adv. Exp. Med. Biol. 2017. Vol. 960. P. 571-606.
  281. Schmidt S., Monk J.M., Robinson L.E., Mourtzakis M. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: potential effects of exercise // Obes. Rev. 2015. Vol. 16, N 6. P. 473-487.
  282. Bhaskaran K., Douglas L, Forbes H., dos-Santos-Silva L, Leon D.A., Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults // Lancet. 2014. Vol. 384, N 9945. P. 755-765.
  283. Dowsett М„ Folkerd Е. Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis // Breast Cancer Res. Treat. 2015. Vol. 149, N 1. P. 1-4.
  284. Freisling H., Arnold M., Soerjomataram I., O’Doherty M.G., Ordonez-Mena J.M., Bamia C. et al. Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe // Br. J. Cancer. 2017. Vol. 116, N 11. P. 1486-1497.
  285. Vaysse C., Lomo J., Garred O., Fjeldheim E, Lofteroed T, Schlichting E. et al. Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer // NPJ Breast Cancer. 2017. Vol. 3. P. 19. DOI: https://doi.org/10.1038/s41523-017-0015-9
  286. Horn-Ross P.L., Canchola A.J., Bernstein L., Neuhausen S.L., Nelson D.O., Reynolds P. Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort // Breast Cancer Res. 2016. Vol. 18, N 1. P. 132. DOI: https://doi.org/10.1186/sl3058-016-0790-5
  287. Al Jarroudi O., AbdaN., Seddik Y, Brahmi S.A., Overweight A.S. Is it a prognostic factor in women with triple-negative breast cancer? // Asian Рас. J. Cancer Prev. 2017. Vol. 18, N 6. P. 1519-1523.
  288. Farvid M.S., Eliassen A.H., Cho E., Liao X., Chen W.Y., Willett W.C. Dietary fiber intake in young adults and breast cancer risk // Pediatrics. 2016. Vol. 137, N 3. Article ID e20151226.
  289. Cho E., Spiegelman D., Hunter D.J., Chen W.Y., Colditz G.A., Willett W.C. Premenopausal dietary carbohydrate, glycemic index, glycemic load, and fiber in relation to risk of breast cancer // Cancer Epidemiol. Biomarkers Prev. 2003. Vol. 12, N 11. Pt 1. P. 1153-1158.
  290. Gandini S., Merzenich H., Robertson C., Boyle P. Meta-analysis of studies on breast cancer risk and diet: the role of fruit and vegetable consumption and the intake of associated micronutrients // Eur. J. Cancer. 2000. Vol. 36, N 5. P. 636-646.
  291. Bradbury K.E., Appleby P.N., Key TJ. Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC) // Am. J. Clin. Nutr. 2014. Vol. 100, suppl. 1. P. 394S-398S.
  292. Emaus M.J., Peeters P.H., Bakker M.F., Overvad K., Tjonneland A., Olsen A. et al. Vegetable and fruit consumption and the risk of hormone receptor-N defined breast cancer in the EPIC cohort // Am. J. Clin. Nutr. 2016. Vol. 103, N 1. P. 168-177.
  293. Jung S., Spiegelman D., Baglietto L., Bernstein L., Boggs D.A., van den Brandt P.A. et al. Fruit and vegetable intake and risk of breast cancer by hormone receptor status //J. Natl Cancer Inst. 2013. Vol. 105, N 3. P. 219-236.
  294. Farvid M.S., Cho E., Chen WY, Eliassen A.H., Willett W.C. Adolescent meat intake and breast cancer risk // Int. J. Cancer. 2015. Vol. 136, N 8. P. 1909-1920.
  295. Chen M„ Rao Y, Zheng Y, Wei S., Li Y, Guo T. et al. Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies // PLoS One. 2014. Vol. 9, N 2. Article ID e89288.
  296. Yao S., Kwan M.L., Ergas I.J., Roh J.M., Cheng T.D., Hong C.C. et al. Association of serum level of vitamin D at diagnosis with breast cancer survival: a case-cohort analysis in the pathways study //JAMA Oncol. 2017. Vol. 3, N 3. P. 351-357.
  297. Friedenreich C.M., Neilson H.K., Lynch B.M. State of the epidemiological evidence on physical activity and cancer prevention // Eur. J. Cancer. 2010. Vol. 46, N 14. P. 2593-2604.
  298. Lee I.M. Physical activity and cancer prevention - data from epidemiologic studies // Med. Sci. Sports Exerc. 2003. Vol. 35, N 11. P. 1823-1827.
  299. Monninkhof E.M., Elias S.G., Vlems F.A., van der Tweel L, Schuit A.J., Voskuil D.W. et al. Physical activity and breast cancer: a systematic review // Epidemiology. 2007. Vol. 18, N 1. P. 137-157.
  300. Schmid S.M., Hallschmid M., Schultes B. The metabolic burden of sleep loss // Lancet Diabetes Endocrinol. 2015. Vol. 3, N 1. P. 52-62.
  301. Erren T.C., Morfeld P, Stork J., Knauth P, von Mulmann M.J., Breitstadt R. et al. Shift work, chronodisruption and cancer? The IARC 2007 challenge for research and prevention and 10 theses from the Cologne Colloquium 2008 // Scand. J. Work Environ. Health. 2009. Vol. 35, N 1. P. 74-79.
  302. Haus E.L., Smolensky M.H. Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation // Sleep Med. Rev. 2013. Vol. 17, N 4. P. 273-284.
  303. Stevens R.G., Brainard G.C., Blask D.E., Lockley S.W., Motta M.E. Breast cancer and circadian disruption from electric lighting in the modern world // CA Cancer J. Clin. 2014. Vol. 64, N 3. P. 207-218.
  304. Blask D.E. Melatonin, sleep disturbance and cancer risk // Sleep Med Rev. 2009. Vol. 13, N 4. P. 257-264.
  305. Kakizaki M., Kuriyama S., Sone T, Ohmori-Matsuda K., Hozawa A., Nakaya N. et al. Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study // Br. J. Cancer. 2008. Vol. 99, N 9. P. 1502-1505.
  306. Grandes G., Sanchez A., Cortada J.M., Balague L., Calderon C., Arrazola A. et al. Is integration of healthy lifestyle promotion into primary care feasible? Discussion and consensus sessions between clinicians and researchers // BMC Health Serv. Res. 2008. Vol. 8. P. 213. DOI: https://doi.org/10.1186/1472-6963-8-213
  307. Jamal A., Dube S.R., Malarcher A.M., Shaw L., Engstrom M.C.; Centers for Disease Control and Prevention (CDC). Tobacco use screening and counseling during physician office visits among adults - National Ambulatory Medical Care Survey and National Health Interview Survey, United States, 2005-2009 // MMWR Suppl. 2012. Vol. 61, N 2. P. 38-45.
  308. Sherson E.A., Yakes Jimenez E., Katalanos N. A review of the use of the 5 As model for weight loss counselling: differences between physician practice and patient demand // Fam. Pract. 2014. Vol. 31, N 4. P. 389-398.
  309. Paluch-Shimon S., Pagani О., Partridge А.Н., Abulkhair О., Cardoso M.-J., Dent R.A. et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) // Breast. 2017. Vol. 35. P. 203-217.
  310. Lambertini M., Goldrat O., Clatot E, Demeestere I., Awada A. Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art // Curr. Opin. Oncol. 2017. Vol. 29, N 4. P. 243-252.
  311. Ruddy K.J., Gelber S.I., Tamimi R.M., Ginsburg E.S., Schapira L., Come S.E. et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer //J. Clin. Oncol. 2014. Vol. 32, N 11. P. 1151-1156.
  312. Loren A.W., Mangu P.B., Beck L.N., Brennan L., Magdalinski A.J., Partridge A.H. et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update //J. Clin. Oncol. 2013. Vol. 31, N 19. P. 2500-2510.
  313. Peccatori F.A., Azim H.A. Jr, Orecchia R„ Hoekstra H.J., Pavlidis N., Kesic V. et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2013. Vol. 24, suppl. 6. P. vil60-vi70.
  314. Lambertini M., Anserini P, Levaggi A., Poggio E, Del Mastro L. Fertility counseling of young breast cancer patients // J. Thorac. Dis. 2013. Vol. 5, suppl. 1 p. S68-S80.
  315. Woodruff T.K., Smith K., Gradishar W. Oncologists’ role in patient fertility care: a call to action //JAMA Oncol. 2016. Vol. 2, N 2. P. 171-172.
  316. Quinn G.P., Vadaparampil S.T., Gwede C.K., Reinecke J.D., Mason T.M., Silva C. Developing a referral system for fertility preservation among patients with newly diagnosed cancer //J. Natl Compr. Cancer Netw. 2011. Vol. 9, N 11. P. 1219-1225.
  317. Kelvin J.F., Reinecke J. Institutional approaches to implementing fertility preservation for cancer patients // Adv. Exp. Med. Biol. 2012. Vol. 732. P. 165-173.
  318. Reinecke J.D., Kelvin J.F., Arvey S.R., Quinn G.P., Levine J., Beck L.N. et al. Implementing a systematic approach to meeting patients’ cancer and fertility needs: a review of the fertile Hope centers of excellence program //J. Oncol. Pract. 2012. Vol. 8, N 5. P. 303-308.
  319. Partridge A.H., Ruddy KJ., Kennedy J., Winer E.P. Model program to improve care for a unique cancer population: young women with breast cancer //J. Oncol. Pract. 2012. Vol. 8, N 5. P. elO5-ellO.
  320. Clayman M.L., Harper M.M., Quinn G.P., Reinecke J., Shah S. Oncofertility resources at NCI-designated comprehensive cancer centers // J. Natl Compr. Cancer Netw. 2013. Vol. 11, N 12. P. 1504-1509.
  321. Kelvin J.F., Thom B., Benedict C., Carter J., Corcoran S., Dickler M.N. et al. Cancer and fertility program improves patient satisfaction with information received //J. Clin. Oncol. 2016. Vol. 34, N 15. P. 1780-1786.
  322. Biglia N., Torrisi R., D’Alonzo M., Codacci Pisanelli G., Rota S., Peccatori F.A. Attitudes on fertility issues in breast cancer patients: an Italian survey // Gynecol. Endocrinol. 2015. Vol. 31, N 6. P. 458-464.
  323. Lambertini M., Di Maio M., Pagani O., Curigliano G., Poggio E, Del Mastro L. et al. The BCY3/BCC 2017 survey on physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients // Breast. 2018. Vol. 42. P. 41-49.
  324. Stensheim H., Cvancarova M., Moller B., Fossa S.D. Pregnancy after adolescent and adult cancer: a population-based matched cohort study // Int. J. Cancer. 2011. Vol. 129, N5. P. 1225-1236.
  325. Lee S.J., Schover L.R., Partridge A.H., Patrizio P, Wallace W.H., Hagerty K. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients //J. Clin. Oncol. 2006. Vol. 24, N 18. P. 2917-2931.
  326. Reh A., Oktem O., Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers // Fertil. Steril. 2008. Vol. 90, N 5. P. 1635-1639.
  327. Lambertini M., Ceppi M., Cognetti E, Cavazzini G., De Laurentiis M., De Placi-do S. et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies // Eur. J. Cancer. 2017. Vol. 71. P. 34-42.
  328. Ganz P.A., Land S.R., Geyer C.E. Jr, Cecchini R.S., Costantino J.P„ Pajon E.R. et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial //J. Clin. Oncol. 2011. Vol. 29, N 9. P. 1110-1116.
  329. Bedoschi G., Navarro P.A., Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact // Future Oncol. 2016. Vol. 12, N 20. P. 2333-2344.
  330. Codacci-Pisanelli G., Del Pup L., Del Grande M., Peccatori F.A. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients // Crit. Rev. Oncol. Hematol. 2017. Vol. 113. P. 90-96.
  331. Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion // Fertil. Steril. 2013. Vol. 100, N 5. P. 1214-1223.
  332. European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE); Calhaz-Jorge C., de Geyter C., Kupka M.S., de Mouzon J., Erb K. et al. Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE // Hum. Reprod. 2016. Vol. 31, N 8. P. 1638-1652.
  333. Meirow D„ Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data //J. Natl Cancer Inst. Monogr. 2005. Vol. 34. P. 21-25.
  334. Lambertini M., Pescio M.C., Viglietti G., Goldrat O., Del Mastro L., Anserini P. et al. Met hods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients // Expert Rev Qual. Life Cancer Care. 2017. Vol. 2, N 1. P. 47-59.
  335. Oktay K., Hourvitz A., Sahin G., Oktem O., Safro B., Cil A. et al. Letrozole reduces estrogen and gonadotropinexposure in women with breast cancer undergoing ovarian stimulation before chemotherapy // J. Clin. Endocrinol. Metab. 2006. Vol. 91, N 10. P. 3885-3890.
  336. Azim A.A., Costantini-Ferrando M., Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study //J. Clin. Oncol. 2008. Vol. 26, N 16. P. 2630-2635.
  337. Oktay K., Buyuk E., Davis O., Yermakova I., Veeck L., Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen // Hum. Reprod. 2003. Vol. 18, N 1. P. 90-95.
  338. Meirow D., Raanani H., Maman E., Paluch-Shimon S., Shapira M., Cohen Y. et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies // Fertil. Steril. 2014. Vol. 102, N 2. P. 488-495.e3.
  339. Oktay K., Turan V, Bedoschi G., Pacheco F.S., Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer //J. Clin. Oncol. 2015. Vol. 33, N 22. P. 2424-2429.
  340. Revelli A., Porcu E., Levi Setti P.E., Delle Piane L., Merlo D.F., Anserini P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? // Gynecol. Endocrinol. 2013. Vol. 29, N 11 P. 993-996.
  341. Pereira N., Hancock K., Cordeiro C.N., Lekovich J.P., Schattman G.L., Rosenwaks Z. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes // Gynecol. Endocrinol. 2016. Vol. 32, N 10. P. 823-826.
  342. Kim J., Turan V, Oktay K. Long-term safety of Letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer // J. Clin. Endocrinol. Metab. 2016. Vol. 101, N 4. P. 1364-1371.
  343. Balkenende Е.М.Е., Dahhan Т, Linn S.С., Jager N.G.L., Beijnen J.H., Goddijn M. A prospective case series of women with estrogen receptor positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen // Hum. Reprod. 2013. Vol. 28, N 4. P. 953-959.
  344. Cakmak H., Katz A., Cedars M.I., Rosen M.P. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation // Fertil. Steril. 2013. Vol. 100, N 6. P. 1673-1680.
  345. Kuang Y, Chen Q., Hong Q., Lyu Q., Ai A., Fu Y. et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol) // Reprod. Biomed. Online. 2014. Vol. 29, N 6. P. 684-691.
  346. Shalom-Paz E., Almog B., Shehata E, Huang J., Holzer H., Chian R.-C. et al. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification // Reprod. Biomed. Online. 2010. Vol. 21, N 4. P. 566-571.
  347. Chian R.-C., Uzelac P.S., Nargund G. In vitro maturation of human immature oocytes for fertility preservation // Fertil. Steril. 2013. Vol. 99, N 5. P. 1173-1181.
  348. Walls M.L., Hunter T, Ryan J.P., Keelan J.A., Nathan E., Hart R.J. In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes // Hum. Reprod. 2015. Vol. 30, N 1. P. 88-96.
  349. Rosendahl M., Greve T, Andersen C.Y The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature // J. Assist. Reprod. Genet. 2013. Vol. 30, N 1. P. 11-24.
  350. Lambertini M., Del Mastro L., Pescio M.C., Andersen C.Y., Azim H.A., Peccato-ri F.A. et al. Cancer and fertility preservation: international recommendations from an expert meeting // BMC Med. 2016. Vol. 14, N 1. P. 1.
  351. Kim S.S., Lee W.S., Chung M.K., Lee H.C., Lee H.H., Hill D. Long-term ovarian function and fertility after heterotopic autotransplantation of cryobanked human ovarian tissue: 8-year experience in cancer patients // Fertil. Steril. 2009. Vol. 91, N 6. P. 2349-2354.
  352. Andersen C.Y, Silber S.J., Bergholdt S.H., Berghold S.H., Jorgensen J.S., Ernst E. Long-term duration of function of ovarian tissue transplants: case reports // Reprod. Biomed. Online. 2012. Vol. 25, N 2. P. 128-132.
  353. Donnez J., Dolmans M.-M., Pellicer A., Diaz-Garcia C., Ernst E., Mackion K.T. et al. Fertility preservation for age-related fertility decline // Lancet. 2015. Vol. 385, N 9967. P. 506-507.
  354. Andersen C.Y. Success and challenges in fertility preservation after ovarian tissue grafting // Lancet. 2015. Vol. 385, N 9981. P. 1947-1948.
  355. Van der Ven H., Liebenthron J., Beckmann M., Toth B., Korell M., Krussel J. et al. Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates // Hum. Reprod. 2016. Vol. 31, N 9. P. 2031-2041.
  356. Jensen A.K., Mackion K.T, Fedder J., Ernst E., Humaidan P, Andersen C.Y. 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children //J. Assist. Reprod. Genet. 2017. Vol. 34, N 3. P. 325-336.
  357. Lambertini М„ Ginsburg E.S., Partridge А.Н. Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy // Curr. Opin. Obstet. Gynecol. 2015. Vol. 27, N 1. P. 98-107.
  358. Turner N.H., Partridge A., Sanna G., Di Leo A., Biganzoli L. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain // Ann. Oncol. 2013. Vol. 24, N 9. P. 2224-2235.
  359. Del Mastro L., Lambertini M. Temporary ovarian suppression with gonadotropinreleasing hormone agonist during chemotherapy for fertility preservation: toward the end of the debate? // Oncologist. 2015. Vol. 20, N 11. P. 1233-1235.
  360. Lambertini M., Peccatori F.A., Moore H.C.F., Del Mastro L. Reply to the letter to the editor «Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients»? By Rodriguez-Wallberg et al. // Ann. Oncol. 2016. Vol. 27, N 3. P. 548-549.
  361. Lambertini M., Falcone T, Unger J.M., Phillips K.-A., Del Mastro L., Moore H.C.F. Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer // J. Clin. Oncol. 2017. Vol. 35, N 7. P. 804-805.
  362. Lambertini M., Poggio E, Vaglica M., Blondeaux E., Del Mastro L. News on the medical treatment of young women with early-stage HER2-negative breast cancer // Expert Opin. Pharmacother. 2016. Vol. 17, N 12. P. 1643-1655.
  363. Lambertini M., Boni L., Michelotti A., Gamucci T, Scotto T, Gori S. et al. Ovarian suppression with Triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial //JAMA. 2015. Vol. 314, N 24. P. 2632-2640.
  364. Leonard R.C.F., Adamson D.J.A., Bertelli G., Mansi J., Yellowlees A., Dunlop J. et al. GnRU agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic group OPTION trial // Ann Oncol. 2017. Vol. 28, N8. P. 1811-1816.
  365. Moore H.C.F., Unger J.M., Phillips K.-A., Boyle E, Hitre E., Moseley A. et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230 //J. Natl Cancer Inst. 2019. Vol. Ill, N 2. P. 210-213.
  366. Lambertini M„ Ceppi M., Poggio E, Peccatori F.A., Azim H.A., Ugolini D. et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies // Ann. Oncol. 2015. Vol. 26, N 12. P. 2408-2419.
  367. Lambertini M., Cinquini M., Moschetti L, Peccatori F.A., Anserini P, Valenzano Menada M. et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology // Eur. J. Cancer. 2017. Vol. 71. P. 25-33.
  368. Oktay K., Harvey B.E., Partridge A.H., Quinn G.P., Reinecke J., Taylor H.S. et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update //J. Clin. Oncol. 2018. Vol. 36, N 19. P. 1994-2001.
  369. Letourneau J.M., Smith J.F., Ebbel Е.Е., Craig A., Katz P.P., Cedars M.I. et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer // Cancer. 2012. Vol. 118, N 18. P. 4579-4588.
  370. Moore H.C.F., Unger J.M., Phillips K.-A., Boyle E, Hitre E., Porter D. et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy // N. Engl. J. Med. 2015. Vol. 372, N 10. P. 923-932.
  371. Hartman E.K., Eslick G.D. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis // Breast Cancer Res. Treat. 2016. Vol. 160, N 2. P. 347-360.
  372. Azim H.A. Jr, Kroman N., Paesmans M., Gelber S., Rotmensz N., Ameye L. et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study // J. Clin. Oncol. 2013. Vol. 31, N 1. P. 73-79.
  373. Lambertini M., Kroman N., Ameye L., Cordoba O., Pinto A., Benedetti G. et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status //J. Natl Cancer Inst. 2018. Vol. 110, N 4. P. 426-429.
  374. Pagani O., Ruggeri M., Manunta S., Saunders C., Peccatori E, Cardoso F. et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? // Breast. 2015. Vol. 24, N 3. P. 201-207.
  375. Luke B., Brown M.B., Missmer S.A., Spector L.G., Leach R.E., Williams M. et al. Assisted reproductive technology use and outcomes among women with a history of cancer// Hum. Reprod. 2016. Vol. 31, N 1. P. 183-189.
  376. Lambertini M., Anserini P., Fontana V, Poggio E, lacono G., Abate A. et al. The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients // BMC Cancer. 2017. Vol. 17, N 1. P. 346.
  377. Lambertini M., Fontana V, Massarotti C., Poggio E, Dellepiane C., lacono G. et al. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: results of the pilot phase of the PREgnancy and FERtility (PREFER) study // Breast. 2018. Vol. 41. P. 51-56.
  378. Cohen L., Hamer J., Helwig C., Fergus K., Kiss A., Mandel R. et al. Formal evaluation of PYNK: breast cancer program for young women-the patient perspective // Curr. Oncol. 2016. Vol. 23, N 2. P el02-el08.
  379. Villarreal-Garza C., Platas A., Martinez-Cannon B.A., Bargallo-Rocha E., Aguilar-Gonzalez C.N., Ortega-Leonard V. et al. Information needs and internet use of breast cancer survivors in Mexico // Breast J. 2017. Vol. 23, N 3. P. 373-375.
  380. Lambertini M., Goldrat O., Toss A., Azim H.A., Peccatori F.A., Ignatiadis M. et al. Fertility and pregnancy issues in BRCA-mutated breast cancer patients // Cancer Treat Rev. 2017. Vol. 59. P. 61-70.
  381. Peccatori F.A., Mangili G., Bergamini A., Filippi E, Martinelli E, Ferrari F. et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? // Hum. Reprod. 2018. Vol. 33, N 2. P. 181-187.
  382. Nichols Н.В., Schoemaker M.J., Wright L.B., McGowan C., Brook M.N., McClain K.M. et al. The premenopausal breast cancer collaboration: a pooling project of studies participating in the National Cancer Institute Cohort Consortium // Cancer Epidemiol Biomarkers Prev. 2017. Vol. 26, N 9. P. 1360-1369.
  383. Bloom J.R., Stewart S.L., Chang S., Banks P.J. Then and now: quality of life of young breast cancer survivors // Psychooncology. 2004. Vol. 13, N 3. P. 147—160.
  384. Howlader N.. Noone A.M., Krapcho M., Miller D., Bishop K., Altekruse S.F. et al. SEER Cancer statistics review, 1975-2013. Bethesda, MD : National Cancer Institute, 2016.
  385. Anders C.K., Fan C., Parker J.S., Carey L.A., Blackwell K.L., Klauber-DeMore N. et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? //J. Clin. Oncol. 2011. Vol. 29, N 1. P. el8-e20.
  386. Shannon C., Smith I.E. Breast cancer in adolescents and young women // Eur. J. Cancer. 2003. Vol. 39, N 18. P. 2632-2642.
  387. Anderson W.F., Chatterjee N., Ershler W.B., Brawley O.W. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database // Breast Cancer Res. Treat. 2002. Vol. 76, N 1. P. 27-36.
  388. Thewes B., Butow P, Girgis A., Pendlebury S. The psychosocial needs of breast cancer survivors; a qualitative study of the shared and unique needs of younger versus older survivors // Psychooncology. 2004. Vol. 13, N 3. P. 177-189.
  389. Avis N.E., Crawford S., Manuel J. Quality of life among younger women with breast cancer //J. Clin. Oncol. 2005. Vol. 23, N 15. P. 3322-3330.
  390. Katz A. The sounds of silence: sexuality information for cancer patients // J. Clin. Oncol. 2005. Vol. 23, N 1. P. 238-241.
  391. Flynn K.E., Reese J.B., Jeffery D.D., Abernethy A.P., Lin L., Shelby R.A. et al. Patient experiences with communication about sex during and after treatment for cancer // Psychooncology. 2012. Vol. 21, N 6. P. 594-601.
  392. Bober S.L., Varela V.S. Sexuality in adult cancer survivors: challenges and intervention //J. Clin. Oncol. 2012. Vol. 30, N 30. P. 3712-3719.
  393. Dunn J., Steginga S.K. Young women’s experience of breast cancer: defining young and identifying concerns // Psychooncology. 2000. Vol. 9, N 2. P. 137-146.
  394. Erikson E.H. Identity: youth and crisis. Oxford : Norton and Co, 1968.
  395. Levinson D.J. The seasons of a man’s life. New York, NY : Random House Digital, 1978.
  396. Arnett J.J. Emerging adulthood: a theory of development from the late teens through the twenties // Am. Psychol. 2000. Vol. 55, N 5. P. 469-480.
  397. Schover L.R. Sexuality and body image in younger women with breast cancer // J. Natl Cancer Inst. Monogr. 1994. Vol. 16. P. 177-182.
  398. Waskul D.D., van der Riet P. The abject embodiment of cancer patients: dignity, selfhood, and the grotesque body // Symb. Interact. 2002. Vol. 25. P. 487-513.
  399. Kasper A.S. A feminist, qualitative methodology: a study of women with breast cancer// Qual. Sociol. 1994. Vol. 17. P. 263-281.
  400. Han J., Grothuesmann D., Neises M., Hille U., Hillemanns P. Quality of life and satisfaction after breast cancer operation //Arch. Gynecol. Obstet. 2010. Vol. 282, NLP 75-82.
  401. White C.A. Body image dimensions and cancer: a heuristic cognitive behavioural model // Psychooncology. 2000. Vol. 9, N 3. P. 183-192.
  402. Liu J., Peh C.X., Mahendran R. Body image and emotional distress in newly diagnosed cancer patients: the mediating role of dysfunctional attitudes and rumination // Body Image. 2016. Vol. 20. P. 58-64.
  403. Przezdziecki A., Sherman K.A., Baillie A., Taylor A., Foley E., Stalgis-Bilin-ski K. My changed body: breast cancer, body image, distress and self-compassion // Psychooncology. 2013. Vol. 22, N 8. P. 1872-1879.
  404. Bakht S., Najafi S. Body image and sexual dysfunctions: comparison between breast cancer patients and healthy women // Procedia Soc. Behav. Sci. 2010. Vol. 5. P. 1493-1497.
  405. Tiggemann M. Body image across the adult life span: stability and change // Body Image. 2004. Vol. 1, N 1. P. 29-41.
  406. Miller C.T., Downey K.T A meta-analysis of heavyweight and self-esteem // Pers. Soc. Psychol. Rev. 1999. Vol. 3, N 1. P. 68-84.
  407. Paterson C.L., Lengacher C.A., Donovan K.A., Kip K.E., Tofthagen C.S. Body image in younger breast cancer survivors: a systematic review // Cancer Nurs. 2016. Vol. 39, N 1. P. E39-E58.
  408. Miller S.J., Schnur J.B., Weinberger-Litman S.L., Montgomery G.H. The relationship between body image, age, and distress in women facing breast cancer surgery // Palliat. Support. Care. 2014. Vol. 12, N 5. P. 363-367.
  409. Fisher B., Anderson S., Bryant J., Margolese R.G., Deutsch M., Fisher E.R. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer //N. Engl. J. Med. 2002. Vol. 347, N 16. P. 1233-1241.
  410. Veronesi U., Cascinelli N., Mariani L., Greco M., Saccozzi R., Luini A. et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer // N. Engl. J. Med. 2002. Vol. 347, N 16. P. 1227-1232.
  411. Morrow M., Jagsi R., Aiderman A.K., Griggs JJ., Hawley S.T., Hamilton A.S. et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer //JAMA. 2009. Vol. 302, N 14. P. 1551-1556.
  412. Gomez S.L., Lichtensztajn D., Kurian A.W., Telli M.L., Chang E.T., Keegan Т.Н. et al. Increasing mastectomy rates for early-stage breast cancer? Population-based trends from California //J. Clin. Oncol. 2010. Vol. 28, N 10. P. el55-el57.
  413. Mahmood U., Hanlon A.L., Koshy M., Buras R., Chumsri S., Tkaczuk K.H. et al. Increasing national mastectomy rates for the treatment of early stage breast cancer // Ann. Surg. Oncol. 2013. Vol. 20, N 5. P. 1436-1443.
  414. Katipamula R., Degnim A.C., Hoskin T, Boughey J.C., Loprinzi C., Grant C.S. et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging //J. Clin. Oncol. 2009. Vol. 27, N 25. P. 4082-4088.
  415. Tuttle T.M., Habermann E.B., Grund E.H., Morris T.J., Virnig B.A. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment //J. Clin. Oncol. 2007. Vol. 25, N 33. P. 5203-5209.
  416. Herrinton L.J., Barlow W.E., Yu O., Geiger A.M., Elmore J.G., Barton M.B. et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project //J. Clin. Oncol. 2005. Vol. 23, N 19. P. 4275-4286.
  417. Anderson C., Islam J.Y., Elizabeth Hodgson M., Sabatino S.A., Rodriguez J.L., Lee C.N. et al. Long-term satisfaction and body image after contralateral prophylactic mastectomy // Ann. Surg. Oncol. 2017. Vol. 29. P. el8-e20.
  418. Yurek D., Farrar W., Andersen B.L. Breast cancer surgery: comparing surgical groups and determining individual differences in postoperative sexuality and body change stress // J. Consult. Clin. Psychol. 2000. Vol. 68, N 4. P. 697-709.
  419. Engel J., Kerr J., Schlesinger-Raab A., Sauer H., Holzel D. Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study // Breast J. 2004. Vol. 10, N 3. P. 223-231.
  420. Frost M.H., Schaid D.J., Sellers T.A., Slezak J.M., Arnold P.G., Woods J.E. et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy //JAMA. 2000. Vol. 284, N 3. P. 319-324.
  421. Pinto A.C. Sexuality and breast cancer: prime time for young patients //J. Thorac. Dis. 2013. Vol. 5, suppl. 1. P. S81-S86.
  422. Kedde H., van de Wiel H.B., Weijmar Schultz W.C., Wijsen C. Sexual dysfunction in young women with breast cancer // Support. Care Cancer. 2013. Vol. 21, N 1. P. 271-280.
  423. Rumsey N„ Harcourt D. Body image and disfigurement: issues and interventions // Body Image. 2004. Vol. 1, N 1. P. 83-97.
  424. Lansdown R., Rumsey N., Bradbury E., Carr T, Partridge J. Visibly different: coping with disfigurement. London : Hodder Arnold, 1997.
  425. Langellier K.M., Sullivan C.F. Breast talk in breast cancer narratives // Qual. Health Res. 1998. Vol. 8, N 1. P. 76-94.
  426. Kwait R.M., Pesek S., Onstad M., Edmonson D., Clark M.A., Raker C. et al. Influential forces in breast cancer surgical decision making and the impact on body image and sexual function // Ann. Surg. Oncol. 2016. Vol. 23, N 10. P. 3403—3411.
  427. Fobair P, Stewart S.L., Chang S„ D’Onofrio C., Banks PJ., Bloom J.R. Body image and sexual problems in young women with breast cancer // Psychooncology. 2006. Vol. 15, N 7. P. 579-594.
  428. Helgeson VS., Cohen S. Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research // Health Psychol. 1996. Vol. 15, N2. P. 135-148.
  429. Manne S. Couples coping with cancer: research issues and recent findings // J. Clin. Psychol. Med. Settings. 1994. Vol. 1, N 4. P. 317-330.
  430. Peters-Golden H. Breast cancer: varied perceptions of social support in the illness experience // Soc. Sci. Med. 1982. Vol. 16, N 4. P. 483-491.
  431. Sadovsky R., Basson R., Krychman M„ Morales A.M., Schover L., Wang R. et al. Cancer and sexual problems // J. Sex. Med. 2010. Vol. 7, N 1. Pt 2. P. 349-373.
  432. Katz A. Breast cancer and women’s sexuality // Am. J. Nurs. 2011. Vol. Ill, N 4. P. 63-67.
  433. Bredart A., Dolbeault S., Savignoni A., Besancenet C., This P, Giami A. et al. Prevalence and associated factors of sexual problems after early-stage breast cancer treatment: results of a French exploratory survey // Psychooncology. 2011. Vol. 20, N8. P. 841-850.
  434. Jain S., Santa-Maria C.A., Gradishar WJ. The role of ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast cancer // Oncology. 2015. Vol. 29, N 7. P. 473-478.
  435. Baumgart J., Nilsson K., Stavreus-Evers A., Kask K., Villman K., Lindman H. et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer // Am. J. Obstet. Gynecol. 2011. Vol. 204, N 1. P. 26.el-e7.
  436. Rosenberg S.M., Partridge A.H. Premature menopause in young breast cancer: effects on quality of life and treatment interventions // J. Thorac. Dis. 2013. Vol. 5, suppl. 1. P S55-S61.
  437. Anchan R.M., Ginsburg E.S. Fertility concerns and preservation in younger women with breast cancer // Crit. Rev. Oncol. Hematol. 2010. Vol. 74, N 3. P. 175-192.
  438. Shuster L.T., Rhodes DJ., Gostout B.S., Grossardt B.R., Rocca W.A. Premature menopause or early menopause: long-term health consequences // Maturitas. 2010. Vol. 65, N2. P. 161-166.
  439. Burstein H.J., Lacchetti C., Anderson H., Buchholz T.A., Davidson N.E., Gelmon K.E. et al. Adjuvant endocrine therapy for women with hormone receptorpositive breast Cancer: American Society of Clinical Oncology clinical practice guideline update //J. Oncol. Pract. 2015. Vol. 12. P. 390-393.
  440. Paluch-Shimon S., Pagani O., Partridge A.H., Abulkhair O., Cardoso M.J., Dent R.A. et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) // Breast. 2017. Vol. 35. P. 203-217.
  441. Ribi K., Luo W., Bernhard J., Francis P.A., Burstein H.J., Ciruelos E. et al. Adjuvant Tamoxifen plus ovarian function suppression versus Tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial //J. Clin. Oncol. 2016. Vol. 34. P. 1601-1610.
  442. Lewis R.W., Fugl-Meyer K.S., Corona G., Hayes R.D., Laumann E.O., Moreira E.D. Jr et al. Definitions/epidemiology/ risk factors for sexual dysfunction // J. Sex. Med. 2010. Vol. 7, N 4. Pt 2. P. 1598-1607.
  443. Laumann E.O., Paik A., Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors // JAMA. 1999. Vol. 281, N 6. P. 537-544.
  444. Goldfarb S. Endocrine therapy and its effect on sexual function // Am. Soc. Clin. Oncol. Educ. Book. 2015. Vol. 35. P. e575-e581.
  445. Layeequr Rahman R., Baker T, Crawford S., Kauffman R. SOFT trial can be very hard on young women // Breast. 2015. Vol. 24, N 6. P. 767-768.
  446. Francis P.A., Pagani O., Fleming G.F., Walley B.A., Colleoni M., Lang I. et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer // N. Engl. J. Med. 2018. Vol. 379, N 2. P. 122-137.
  447. Francis P.A., Regan M.M., Fleming G.F., Lang L, Ciruelos E., Bellet M. et al. Adjuvant ovarian suppression in premenopausal breast cancer // N. Engl. J. Med. 2015.Vol. 372, N 5. P. 436-446.
  448. Frechette D., Paquet L., Verma S., Clemons M., Wheatley-Price P, Gertler S.Z. et al. The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study // Breast Cancer Res. Treat. 2013. Vol. 141, N 1. P. 111-117.
  449. Finch A., Metcalfe K.A., Chiang J.K., Elit L., McLaughlin J., Springate C. et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation // Gynecol. Oncol. 2011. Vol. 121, N 1. P. 163-168.
  450. Tucker P.E., Bulsara M.K., Salfinger S.G., Tan J.J.-S., Green H., Cohen P.A. Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy // Gynecol. Oncol. 2015. Vol. 140, N 1. P. 95-100.
  451. Pezaro C., James P, McKinley J., Shanahan M., Young M.A., Mitchell G. The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause // Fam. Cancer. 2012. Vol. 11,N3. P. 403-410.
  452. Dizon D.S. Quality of life after breast cancer: survivorship and sexuality // Breast J. 2009. Vol. 15, N 5. P. 500-504.
  453. Emilee G., Ussher J.M., Perz J. Sexuality after breast cancer: a review // Maturitas. 2010. Vol. 66, N 4. P. 397-407.
  454. Elmir R., Jackson D„ Beale B., Schmied V. Against all odds: Australian women’s experiences of recovery from breast cancer //J. Clin. Nurs. 2010. Vol. 19, N 17-18. P. 2531-2538.
  455. ReeseJ.B., Shelby R.A., Keefe FJ., Porter L.S., Abernethy A.P. Sexual concerns in cancer patients: a comparison of GI and breast cancer patients // Support. Care Cancer. 2010. Vol. 18, N9. P. 1179-1189.
  456. Fobair P, Spiegel D. Concerns about sexuality after breast cancer // Cancer J. 2009. Vol. 15, N 1. P. 19-26.
  457. Fang S.Y., Lin Y.C., Chen T.C., Lin C.Y. Impact of marital coping on the relationship between body image and sexuality among breast cancer survivors // Support. Care Cancer. 2015. Vol. 23, N 9. P. 2551-2559.
  458. Shaw L.K., Sherman K.A., Fitness J., Elder E. Factors associated with romantic relationship formation difficulties in women with breast cancer // Psychooncology. 2018. Vol. 27, N 4. P. 1270-1276.
  459. Kurowecki D., Fergus K.D. Wearing my heart on my chest: dating, new relationships, and the reconfiguration of self-esteem after breast cancer // Psychooncology. 2014. Vol. 23, N 1. P. 52-64.
  460. Christie K.M., Meyerowitz B.E., Maly R.C. Depression and sexual adjustment following breast cancer in low-income Hispanic and non-Hispanic White women // Psychooncology. 2010. Vol. 19, N 10. P. 1069-1077.
  461. Giedzinska A.S., Meyerowitz B.E., Ganz P.A., Rowland J.H. Health-related quality of life in a multiethnic sample of breast cancer survivors // Ann. Behav. Med. 2004. Vol. 28, N 1. P. 39-51.
  462. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016 // CA Cancer J. Clin. 2016.Vol. 66, N 1. P. 7-30.
  463. Ashing-Giwa K.T., Padilla G., Tejero J., Kraemer J., Wright K., Coscarelli A. et al. Understanding the breast cancer experience of women: a qualitative study of African American, Asian American, Latina and Caucasian cancer survivors // Psychooncology. 2004. Vol. 13, N 6. P. 408-428.
  464. Taylor K.L., Lamdan R.M., Siegel J.E., Shelby R., Hrywna M., Moran-Klimi K. Treatment regimen, sexual attractiveness concerns and psychological adjustment among African American breast cancer patients // Psychooncology. 2002. Vol. 11, N 6. P. 505-517.
  465. Wilmoth M.C., Sanders L.D. Accept me for myself: African American women’s issues after breast cancer // Oncol. Nurs. Forum. 2001. Vol. 28, N 5. P. 875-879.
  466. Lewis P.E., Sheng M., Rhodes M.M., Jackson K.E., Schover L.R. Psychosocial concerns of young African American breast cancer survivors // J. Psychosoc. Oncol. 2012. Vol. 30, N 2. P. 168-184.
  467. Hoffman-Goetz L. Cancer experiences of African-American women as portrayed in popular mass magazines // Psychooncology. 1999. Vol. 8, N 1. P 36-45.
  468. Masi C.M., Gehlert S. Perceptions of breast cancer treatment among African-American women and men: implications for interventions //J. Gen. Intern. Med. 2009. Vol. 24, N 3. P. 408-414.
  469. Germino B.B., Mishel M.H., Alexander G.R., Jenerette C., Blyler D., Baker C. et al. Engaging African American breast cancer survivors in an intervention trial: culture, responsiveness and community //J. Cancer Surviv. 2011. Vol. 5, N 1. P. 82-91.
  470. Schover L.R., Rhodes M.M., Baum G., Adams J.H., Jenkins R., Lewis P. et al. Sisters peer counseling in reproductive issues after treatment (SPIRIT): a peer counseling program to improve reproductive health among African American breast cancer survivors // Cancer. 2011. Vol. 117, N 21. P. 4983-4992.
  471. Viladrich A., Yeh M.C., Bruning N., Weiss R. «Do real women have curves»? paradoxical body images among Latinas in New York City // J. Immigr. Minor. Health. 2009. Vol. 11, N 1. P. 20-28.
  472. Gil R.M., Vazquez C.I. The Maria paradox: how Latinas can merge old world traditions with new world self-esteem. New York : Open Road Media, 2014.
  473. Pompper D., Koenig J. Cross-cultural-generational perceptions of ideal body image: Hispanic women and magazine standards // J. Mass Commun. Q. 2004. Vol. 81, N l.P. 89-107.
  474. Buki L.P., Reich М., Lehardy E.N. «Our organs have a purpose»: body image acceptance in Latina breast cancer survivors // Psychooncology. 2016. Vol. 25, N 11. P 1337-1342.
  475. Ashing-Giwa K.T., Padilla G.V., Bohorquez D.E., Tejero J.S., Garcia M. Understanding the breast cancer experience of Latina women // J. Psychosoc. Oncol. 2006. Vol. 24, N 3. P. 19-52.
  476. Martinez-Ramos G.P., Biggs M.J.G., Lozano Y. Quality of life of Latina breast cancer survivors: from silence to empowerment // Adv. Soc. Work. 2013. Vol. 14. P. 82-101.
  477. Lopez-Class M., Perret-Gentil M., Kreling B., Caicedo L„ Mandelblatt J., Graves K.D. Quality of life among immigrant Latina breast cancer survivors: realities of culture and enhancing cancer care //J. Cancer Educ. 2011. Vol. 26, N 4. P. 724-733.
  478. Boehmer U., Glickman M., Winter M., Clark M.A. Breast cancer survivors of different sexual orientations: which factors explain survivors’ quality of life and adjustment? // Ann. Oncol. 2013. Vol. 24, N 6. P. 1622-1630.
  479. Brown M.T., McElroy J.A. Unmet support needs of sexual and gender minority breast cancer survivors // Support. Care Cancer. 2018. Vol. 26, N 4. P. 1189-1196.
  480. Fobair P, O’Hanlan K., Koopman C., Classen C., Dimiceli S., Drooker N. et al. Comparison of lesbian and heterosexual women’s response to newly diagnosed breast cancer // Psychooncology. 2001. Vol. 10, N 1. P. 40-51.
  481. Rubin L.R., Tanenbaum M. «Does that make me a woman»? breast cancer, mastectomy, and breast reconstruction decisions among sexual minority women // Psychol. Women Q. 2011. Vol. 35, N 3. P. 401-414.
  482. Park E.R., Norris R.L., Bober S.L. Sexual health communication during cancer care: barriers and recommendations // Cancer J. 2009. Vol. 15, N 1. P. 74-77.
  483. Goldfarb S.B., Abramsohn E., Andersen B.L., Baron S.R., Carter J., Dickler M. et al. A national network to advance the field of cancer and female sexuality // J. Sex. Med. 2013. Vol. 10, N 2. P. 319-325.
  484. Bober S., Reese J.B., Barbera L., Bradford A., Carpenter K.M., Goldfarb S. et al. How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer // Curr. Opin. Support. Palliat. Care. 2016. Vol. 10. P. 44-54.
  485. Carter J., Goldfrank D., Schover L.R. Simple strategies for vaginal health promotion in cancer survivors //J. Sex. Med. 2011. Vol. 8, N 2. P. 549-559.
  486. Coady D., Kennedy V. Sexual health in women affected by cancer: focus on sexual pain // Obstet. Gynecol. 2016. Vol. 128, N 4. P. 775-791.
  487. Pavlidis N.A. Coexistence of pregnancy and malignancy // Oncologist. 2002. Vol. 7, N 4. P. 279-287.
  488. Stensheim H., Moller B., van Dijk T. et al. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study //J. Clin. Oncol. 2009. Vol. 27, N 1. P. 45-51.
  489. Lee Y.Y., Robets C.L., Dobbins T. et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994-2008: a population-based linkage study // BJOG. 2012. Vol. 119, N13. P. 1572-1582.
  490. Haas J.F. Pregnancy in association with newly diagnosed cancer: a populationbased epidemiologic assessment // Int. J. Cancer. 1984. Vol. 34, N 2. P. 229-235.
  491. Abenhaim H.A., Azoulay L., Holcroft C.A. et al. Incidence, risk factors, and obstetrical outcomes of women with breast cancer in pregnancy // Breast J. 2012. Vol. 18, N 6. P. 564-568.
  492. Sobotka T. United Nations Department of economic and social affairs. Pathways to low fertility: European perspectives // Expert Paper No. 2013/08. New York, 2013.
  493. Andersson T.M., Johansson A.L., Hsieh C.C. et al. Increasing incidence of pregnancy-associated breast cancer in Sweden // Obstet. Gynecol. 2009. Vol. 114, N 3. P. 568-572.
  494. Koch-Institut R. (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Krebs in Deutschland 2011/2012. 10. Ausgabe. Berlin, 2015.
  495. Amant E, Loibl S., Neven P. et al. Breast cancer in pregnancy // Lancet. 2012. Vol. 379, N 9815. P. 570-579.
  496. Loibl S., Han S.N., von Minckwitz G., Bontenbal M. et al. Treatment of breast cancer during pregnancy: an observational study // Lancet Oncol. 2012. Vol. 13, N 9. P 887-896.
  497. Amant E, von Minckwitz G., Han S.N. et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study // J. Clin. Oncol. 2013. Vol. 31, N 20. P. 2532-2539.
  498. Azim H.A. Jr, Santoro L., Russell-Edu W. et al. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies // Cancer Treat. Rev. 2012. Vol. 38. P. 834-842.
  499. Callihan E.B., Gao D., Jindal S. et al. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer // Breast Cancer Res. Treat. 2013. Vol. 138, N 2. P. 549-559.
  500. Woo J.C., Yu T, Hurd TC. Breast cancer in pregnancy: a literature review // Arch. Surg. 2003. Vol. 138, NLP. 91-98.
  501. Nettleton J., Long J., Kuban D. et al. Breast cancer during pregnancy: quantifying the risk of treatment delay // Obstet. Gynecol. 1996. Vol. 87. P. 414-418.
  502. Amant E, Deckers S., Van Calsteren K. et al. Breast cancer in pregnancy: recommendations of an international consensus meeting // Eur. J. Cancer. 2010. Vol. 46, N 18. P. 3158-3168.
  503. American College of Radiology. ACR-SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation // Resolution. Vol. 39. Reston, VA : ACR, 2014. URL: https://www.acr.org/Search-Results#q=pregnant%20patients (date of access March 12, 2018)
  504. Robbins J., Jeffries D., Roubidoux M., Helvie M. Accuracy of diagnostic mammography and breast ultrasound during pregnancy and lactation // AJR Am. J. Roentgenol. 2011. Vol. 196, N 3. P. 716-722.
  505. Vashi R., Hooley R., Butler R. et al. Breast imaging of the pregnant and lactating patient: imaging modalities and pregnancy associated breast cancer // AJR Am. J. Roentgenol. 2013. Vol. 200, N 2. P. 321-328.
  506. Nguyen C.P., Goodman L.H. Fetal risk in diagnostic radiology // Semin. Ultrasound CT MR. 2012. Vol. 33, N 1. P. 4-10.
  507. Ray J.G., Vermeulen M.J., Bharatha A. et al. Association between MRI exposure during pregnancy and fetal and childhood outcomes // JAMA. 2016. Vol. 316, N9. P. 952-961.'
  508. Patenaude Y, Pugash D., Lim K. et al. Diagnostic imaging committee; Society of Obstetricians and Gynaecologists of Canada. The use of magnetic resonance imaging in the obstetric patient // J. Obstet. Gynaecol. Can. 2014. Vol. 36, N 4. P. 349-363.
  509. Pavlidis N., Pentheroudakis G. Metastatic involvement of placenta and foetus in pregnant women with cancer // Recent Results Cancer Res. 2008. Vol. 178. P. 183-194.
  510. Berry D.L., Theriault R.L., Holmes F.A. et al. Management of breast cancer during pregnancy using a standardized protocol //J. Clin. Oncol. 1999. Vol. 17, N 3. P. 855-861.
  511. Toesca A., Gentilini O., Peccatori F. et al. Locoregional treatment of breast cancer during pregnancy // Gynecol. Surg. 2014. Vol. 11, N 4. P. 279-284.
  512. Huang J., Barbera L., Brouwers M. et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review //J. Clin. Oncol. 2003. Vol. 21, N3. P. 555-563.
  513. Lohsiriwat V, Peccatori F.A., Martella S. et al. Immediate breast reconstruction with expander in pregnant breast cancer patients // Breast. 2013. Vol. 22, N 5. P. 657-660.
  514. Gentilini O„ Cremonesi M., Toesca A. et al. Sentinel lymph node biopsy in pregnant patients with breast cancer // Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37, N 1. P. 78-83.
  515. Khera S.Y., Kiluk J.V, Hasson D.M. et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping // Breast J. 2008. Vol. 14. P. 250-254.
  516. Gropper A.B., Calvillo K.Z., Dominici L. et al. Sentinel lymph node biopsy in pregnant women with breast cancer // Ann. Surg. Oncol. 2014. Vol. 21. P 2506-2511.
  517. Pandit-Taskar N., Dauer L.T., Montgomery L., St Germain J., Zanzonico P.B., Divgi C.R. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients // J. Nucl. Med. 2006. Vol. 47. P. 1202-1208.
  518. Otake M., Schrdl W.J., Lee S. Threshold for radiation-related severe mental retardation in prenatally exposed A-bomb survivors: a re-analysis // Int. J. Radiat. Biol. 1996. Vol. 70, N 6. P. 755-763.
  519. Kai H.B., Struikmans H. Radiotherapy during pregnancy: fact and fiction // Lancet Oncol. 2005. Vol. 6, N 5. P. 328-333.
  520. National Toxicology Program. NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy // NTP Monogr. 2013. Vol. 2. P. 1-214.
  521. de Haan J., Verheecke M., Van Calsteren K. et al.; International Network on Cancer and Infertility Pregnancy (INCIP). Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients // Lancet Oncol. 2018. Vol. 19, N 3. P. 337-346.
  522. Queisser-Luft A., Stolz G., Wiesel A. et al. Malformations in newborn: results based on 30,940 infants and fetuses from the Mainz congenital birth defect monitoring system (1990-1998) // Arch. Gynecol. Obstet. 2002. Vol. 266. P. 163-167.
  523. Loibl S., Schmidt A., Gentilini O. et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients // JAMA Oncol. 2015. Vol. 1,N8. P. 1145-1153.
  524. Bines J., Earl H., Buzaid A.C., Saad E.D. Anthracyclines and taxanes in the neo/ adjuvant treatment of breast cancer: does the sequence matter? // Ann. Oncol. 2014. Vol. 25, N 6. P. 1079-1085.
  525. von Minckwitz G., Schneeweiss A., Loibl S. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial // Lancet Oncol. 2014. Vol. 15, N 7. P. 747-756.
  526. Loibl S., O’Shaughnessy J., Untch M. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial // Lancet Oncol. 2018. Vol. 19, N 4. P. 497-509. DOI: https://doi. org/10.1016/S1470-2045(18)30111-6
  527. Sikov W.M., Berry D.A., Perou C.M. et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) // J. Clin. Oncol. 2015. Vol. 33, N 1. P. 13-21.
  528. Kohler C., Oppelt P, Favero G. et al. How much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancy // Am. J. Obstet. Gynecol. 2015. Vol. 213, N 2. P. 2O6.el-e5.
  529. Gray R., Bradley R., Braybrooke J. et al. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials. San Antonio Breast Cancer Symposium 2017 // Cancer Res. 2018. Vol. 78, N 4. Suppl. Abstr. GS1-01.
  530. Moebus V, Jackisch C., Lueck H.J. et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study //J. Clin. Oncol. 2010. Vol. 28, N 17. P. 2874-2880.
  531. Cardonick E., Gilmandyar D., Somer R.A. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy // Obstet. Gynecol. 2012. Vol. 120, N 6. P. 1267-1272.
  532. van Hasselt J.G., van Calsteren K., Heyns L. et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel // Ann. Oncol. 2014. Vol. 25, N 10. P. 2059-2065.
  533. Gottschalk I., Berg C., Harbeck N. et al. Fetal renal insufficiency following trastuzumab treatment for breast cancer in pregnancy: case report and review of the current literature // Breast Care (Basel). 2011. Vol. 6. P. 475-478.
  534. Zagouri E, Sergentanis T.N., Chrysikos D. et al. Trastuzumab administration during pregnancy: a systematic review and meta-analysis // Breast Cancer Res. Treat. 2013. Vol. 137, N 2. P. 349-357.
  535. Barthelmes L., Davidson L.A., Gaffney C., Gateley C.A. Tamoxifen and pregnancy // Breast. 2004. Vol. 13, N 6. P. 446-451.
  536. Isaacs RJ„ Hunter W., Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy - case report and literature review // Gynecol. Oncol. 2001. Vol. 80. P. 405-408.
  537. Tewari K., Bonebrake R.G., Asrat T. et al. Ambiguous genitalia in infant exposed to tamoxifen in utero // Lancet. 1997. Vol. 350. P. 183.
  538. Wang M.L., Dorer DJ., Fleming M.P., Catlin E.A. Clinical outcomes of near-term infants // Pediatrics. 2004. Vol. 114, N 2. P. 372-376.
  539. Aviles A., Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero // Clin. Lymphoma. 2001. Vol. 2, N3. P. 173-177.
  540. Nulman L, Laslo D., Fried S. et al. Neurodevelopment of children exposed in utero to treatment of maternal malignancy // Br. J. Cancer. 2001. Vol. 85, N 11. P. 1611-1618.
  541. Amant E, Vandenbroucke T, Verheecke M. et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. International Network on Cancer, Infertility, and Pregnancy (INCIP) //N. Engl. J. Med. 2015. Vol. 373, N 19. P. 1824-1834.
  542. Cardonick E., Dougherty R., Grana G. et al. Breast cancer during pregnancy: maternal and fetal outcomes // Cancer J. 2010. Vol. 16. P. 76-82.
  543. Pistilli B., Bellettini G., Giovannetti E. et al. Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: how should we counsel cancer patients about breastfeeding? // Cancer Treat. Rev. 2013. Vol. 39, N 3. P. 207-211.
  544. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018 // CA Cancer J. Clin. 2018. Vol. 68, N 1. P. 7-30. URL: https://doi.org/10.3322/caac.21442
  545. Falkson G., Holcroft C., Gelman R.S., Tormey D.C., Wolter J.M., Cummings F.J. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group Study // J. Clin. Oncol. 1995. Vol. 13, N 6. P. 1453-1458.
  546. Howlader N„ Noone A., Krapcho M., Miller D., Bishop K., Kosary C. et al. SEER cancer statistics review, 1975-2014. Bethesda, MD : Natl Cancer Institute, 2017.
  547. Cardoso E, Beishon M., Cardoso M.J., Corneliussen-James D., Gralow J., Mertz S. et al. Global status of advanced/metastatic breast cancer (ABC/mBC): a decade report 2005-2015 // Eur. J. Cancer. 2016. Vol. 57. P. S5-S6.
  548. Li H.C., Wen X.F., Hou' Y.E, Shen K.W, Wu J., Lu J.S. et al. Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer // Asian J. Surg. 2003. Vol. 26, N 3. P. 163-168.
  549. NCCN. NCCN Clinical Guidelines Version 1.2018: Genetic/familial high-risk assessment: breast and ovarian. 2018.
  550. Cardoso E, Senkus E., Costa A., Papadopoulos E., Aapro M., Andre F. et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) // Ann. Oncol. 2018. Vol. 29, N 8. P. 1634-1657.
  551. NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast cancer. Version 1.2018 [[Electronic resource]]. 2018. URL: https://www. nccn.org/professionals/physician_gls/pdf/breast.pdf
  552. Klijn J.G.M., De Jong F.H. Treatment with a luteinising-hormone- releasing analogue (Buserelin) in premenopausal patients with metastatic breast cancer // Lancet. 1982. Vol. 319, N 8283. P. 1213-1216.
  553. Williams M.R., Walker KJ., Turkes A., Blarney R.W, Nicholson R.I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer // Br. J. Cancer. 1986. Vol. 53, N 5. P. 629-636.
  554. Taylor C.W, Green S., Dalton W.S., Martino S., Rector D., Ingle J.N. et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study // J. Clin. Oncol. 1998. Vol. 16, N 3. P. 994-999.
  555. Horton S., Gauvreau C.L. Cancer in low- and middle-income countries: an economic overview // Disease Control Priorities. Cancer. Vol. 3. 3rd ed. Bethesda, MD:NCBI, 2015.
  556. Prinja S., Nandi A., Horton S., Levin C., Laxminarayan R. Costs, effectiveness, and cost-effectiveness of selected surgical procedures and platforms // Disease Control Priorities. Essential Surgery. Vol. 1.3rd ed. Washington, DC : The World Bank, 2015.
  557. Robertson J.F., Blarney R.W. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women // Eur. J. Cancer. 2003. Vol. 39, N 7. P. 861-869.
  558. Blarney R.W., Jonat W„ Kaufmann M., Raffaele Bianco A., Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer // Eur. J. Cancer. 1992. Vol. 28, N 4-5. P. 810-814.
  559. Blarney R.W., Jonat W., Kaufmann M., Bianco A.R.N.M. Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer // Eur. J. Cancer. 1993. Vol. 29A, N 10. P. 1498.
  560. Al Asiri M., Tunio M.A., Abdulmoniem R. Is radiation-induced ovarian ablation in breast cancer an obsolete procedure? Results of a meta-analysis // Breast Cancer Targets Ther. 2016. Vol. 8. P. 109-116.
  561. Paluch-Shimon S., Pagani O., Partridge A.H., Abulkhair O., Cardoso M.-J., Dent R.A. et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) // Breast. 2017. Vol. 35. P. 203-217.
  562. Freedman R.A., Partridge A.EL Management of breast cancer in very young women [Electronic resource] // Breast. 2013. Vol. 22. P. S176-S179. URL: http:// linkinghub.elsevier.com/retrieve/pii/S0960977613001690
  563. Havrilesky L.J., Moss H.A., Chino J., Myers E.R., Kauff N.D. Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers // Gynecol. Oncol. 2017. Vol. 145, N 3. P. 549-554.
  564. Buchanan R.B., Blarney R.W., Durrant K.R., Howell A., Paterson A.G., Preece PE. et al. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer // J. Clin. Oncol. 1986. Vol. 4, N9. P. 1326-1330.
  565. Ingle J.N., Krook J.E., Green S.J., Kubista T.P., Everson L.K., Ahmann D.L. et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer //J. Clin. Oncol. 1986. Vol. 4, N 2. P. 178-185. URL: http://www.ncbi.nlm.nih.gov/pubmed/3511184
  566. Sawka C.A., Pritchard K.I., Shelley W., DeBoer G., Paterson A.H.G., Meakin J.W. et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.l // Breast Cancer Res. Treat. 1997. Vol. 44, N 3. P. 211-215.
  567. Crump M., Sawka C.A., DeBoer G., Buchanan R.B., Ingle J.N., Forbes J. et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer // Breast Cancer Res. Treat. 1997. Vol. 44, N 3. P. 201-210.
  568. Michaud L.B., Jones K.L., Buzdar A.U. Combination endocrine therapy in the management of breast cancer // Oncologist. 2001. Vol. 6, N 6. P. 538-546.
  569. Rugo H.S., Rumble R.B., Macrae E., Barton D.L., Connolly H.K., Dickler M.N. et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline // J. Clin. Oncol. 2016. Vol. 34, N 25. P. 3069-3103.
  570. Thill M., Liedtke C. AGO recommendations for the diagnosis and treatment of patients with advanced and metastatic breast cancer: update 2016 // Breast Care. 2016.Vol. 11, N 3. P. 216-222.
  571. Boccardo Е, Rubagotti A., Perrotta A., Amoroso D., Balestrero M„ De Matteis A. et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study // Ann. Oncol. 1994. Vol. 5, N 4. P. 337-342.
  572. Jonat W., Kaufmann M., Blarney R.W., Howell A., Collins J.P., Coates A. et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer // Eur. J. Cancer. 1995. Vol. 31, N2. P. 137-142.
  573. Klijn J.G.M., Beex L.V.A.M., Mauriac L., Van Zijl J.A., Veyret C., Wildiers J. et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study //J. Natl Cancer Inst. 2000. Vol. 92, N 11. P. 903-911. URL: http://www.scopus.com/inward/record.url?eid=2-s2.0-0034616656&partnerID=40&md5=ffdbe2e42fl0044cl4cd0dafabaed9bb
  574. Klijn J.G., Blarney R.W., Boccardo E, Tominaga T, Duchateau L., Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a metaanalysis of four randomized trials //J. Clin. Oncol. 2001. Vol. 19. P. 343-353. URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubM ed&dopt=Citation&list_uids= 11208825
  575. Kaufmann M., Jonat W., Kleeberg U„ Eiermann W., Janicke E, Hilfrich J. et al. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group //J. Clin. Oncol. 1989. Vol. 7, N 8. P. 1113-1119. URL: http://www.ncbi. nlm.nih.gov/pubmed/2526863
  576. Masuda N., Iwata H., Rai Y, Anan K., Takeuchi T, Kohno N. et al. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer // Breast Cancer Res. Treat. 2011. Vol. 126, N 2. P. 443-451.
  577. Bellet M., Gray K.P., Francis P.A., Lang L, Ciruelos E., Lluch A. et al. Twelvemonth estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy // J. Clin. Oncol. 2016. Vol. 34, N 14. P. 1584-1593.
  578. Nishimura R., Anan K., Yamamoto Y, Higaki K., Tanaka M., Shibuta K. et al. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial // Oncol. Rep. 2013. Vol. 29, N 5. P. 1707-1713.
  579. Carlson R.W., Theriault R., Schurman C.M., Rivera E., Chung C.T, Phan S.C. et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women // J. Clin. Oncol. 2010. Vol. 28, N 25. P. 3917-3921.
  580. Cheung K.L., Agrawal A., Folkerd EJ., Dowsett M., Winterbottom L. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women // Eur. J. Cancer. 2010. Vol. 46, N 16. P. 2936-2942.
  581. Kurebayashi J., Toyama Т, Sumino S., Miyajima E., Fujimoto T. Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptorpositive breast cancer: a phase III, randomized, open-label, parallel-group comparative // Breast Cancer. 2017. Vol. 24, N 1. P. 161-170.
  582. Young O.E., Renshaw L., Macaskill E.J., White S., Faratian D., Thomas J.SJ. et al. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptorpositive primary breast cancer // Eur. J. Cancer. 2008. Vol. 44, N 3. P. 391-399. URL: http://www.ncbi.nlm.nih.gov/pubmed/18083023
  583. Bartsch R., Bago-Horvath Z., Berghoff A., Devries C., Pluschnig U., Dubsky P. et al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer // Eur. J. Cancer. 2012. Vol. 48, N 13. P. 1932-1938.
  584. Robertson J.F.R., Bondarenko I.M., Trishkina E., Dvorkin M., Panasci L., Manikhas A. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial [Electronic resource] // Lancet. 2016. Vol. 388, N 10 063. P. 2997-3005. URL: http://linkinghub.elsevier.com/retrieve/pii/ S0140673616323893
  585. Buzdar A., Jonat W., Howell A., Jones S.E., Blomqvist C., Vogel C.L. et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials //J. Clin. Oncol. 1996. Vol. 14, N 7. P. 2000-2011.
  586. Willemse P.H., van der Ploeg E., Sleijfer D.T., Tjabbes T, van Veelen H. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer // Eur. J. Cancer. 1990. Vol. 26, N 3. P. 337-343.
  587. Bines J., Dienstmann R., Obadia R.M., Branco L.G.P., Quintella D.C., Castro TM. et al. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial // Ann. Oncol. 2014. Vol. 25, N 4. P. 831-836. URL: http://www.ncbi.nlm.nih.gov/pubmed/24615412
  588. Koboldt D.C., Fulton R.S., McLellan M.D., Schmidt H., Kalicki-Veizer J., McMichael J.F. et al. Comprehensive molecular portraits of human breast tumours // Nature. 2012. Vol. 490, N 7418. P. 61-70.
  589. Dhillon S. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer // Drugs. 2013. Vol. 73, N 5. P. 475-485.
  590. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer // N. Engl. J. Med. 2012. Vol. 366, N 6. P. 520-529. DOI: https://doi.org/10.1056/ NEJMoal 109653
  591. Barnes D.M., Gillett C.E. Cyclin DI in breast cancer // Breast Cancer Res. Treat. 1998. Vol. 52, N 1-3. P. 1-15. URL: http://www.ncbi.nlm.nih.gov/htbin-post/ Entrez/query?db=m&form=6&dopt=r&uid= 10066068
  592. Tripathy D., Im S.A., Colleoni M., Franke E, Bardia A., Harbeck N. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial // Lancet Oncol. 2018. Vol. 19, N 7. P. 904-915.
  593. Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.-S., Sonke G.S., Paluch-Shimon S. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer // N. Engl. J. Med. 2016. Vol. 375, N 18. P. 1738-1748. DOI: https://doi. org/10.1056/NEJMoa 1609709
  594. Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., Paluch-Shimon S. et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptorpositive, HER2-negative advanced breast cancer // Ann. Oncol. 2018. Vol. 29. P. 1541-1547.
  595. Goetz M.P., Toi M., Campone M., Sohn J., Paluch- Shimon S., Huober J. et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer // J. Clin. Oncol. 2017. Vol. 35, N 32. P. 3638-3646. DOI: https://doi.org/10.1200/ JCO.2017.75.6155 URL: http://www.ncbi.nlm.nih.gov/pubmed/28968163
  596. Cristofanilli M., Turner N.C., Bondarenko L, Ro J., Im S.A., Masuda N. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor- positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase // Lancet Oncol. 2016. Vol. 17, N 4. P. 425-439.
  597. Turner N.C., Slamon D.J., Ro J., Bondarenko L, Im S.-A., Masuda N. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer // N. Engl. J. Med. 2018. Vol. 379, N 20. P. 1926-1936.
  598. Sledge G.W., Toi M., Neven P, Sohn J., Inoue K., Pivot X. et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/ HER2-advanced breast cancer who had progressed while receiving endocrine therapy // J. Clin. Oncol. 2017. Vol. 35, N 25. P. 2875-2884.
  599. Neven P, Rugo H.S., Tolaney S.M., Iwata H., Toi M., Goetz M.P. et al. Abstract 1002: Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer // J. Clin. Oncol. 2018. Vol. 36. Abstr. 1002.
  600. Krop I.E., Mayer LA., Ganju V, Dickler M., Johnston S., Morales S. et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial // Lancet Oncol. 2016. Vol. 17, N 6. P. 811-821.
  601. Baselga J., Im S.A., Iwata H., Cortes J., De Laurentiis M., Jiang Z. et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial // Lancet Oncol. 2017.Vol. 18, N7. P. 904-916.
  602. Di Leo A., Johnston S., Lee K.S., Ciruelos E., Lonning P.E., Janni W. et al. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptorpositive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial // Lancet Oncol. 2018. Vol. 19, N 1. P. 87-100.
  603. Dickler M.N., Barry W.T., Cirrincione C.T, Ellis MJ., Moynahan M.E., Innocenti F. et al. Phase HI trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance) // J. Clin. Oncol. 2016. Vol. 34, N 22. P. 2602-2609.
  604. Martin M., Loibl S., von Minckwitz G., Morales S., Martinez N„ Guerrero A. et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study //J. Clin. Oncol. 2015. Vol. 33, N 9. P. 1045-1052. URL: http://www.ncbi.nlm.nih.gov/pubmed/25691671
  605. Gray R., Bhattacharya S., Bowden C., Miller K., Comis R.L. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer //J. Clin. Oncol. 2009. Vol. 27, N 30. P. 4966-4972. URL: http://jco.ascopubs.org/content/27/30/4966.long
  606. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer // N. Engl. J. Med. 2007. Vol. 357, N 26. P. 2666-2676. URL: http://www.pubmedcentral.nih. gov/articlerender.fcgi?artid=3684040&tool=pmcentrez&rendertype=abstract
  607. Miles D.W., Chan A., Dirix L.Y., Cortes J., Pivot X., Tomczak P. et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer //J. Clin. Oncol. 2010. Vol. 28, N 20. P. 3239-3247. URL: http://www.ncbi.nlm.nih.gov/pubmed/20498403
  608. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marconi P.K., Fehrenbacher L. et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer // J. Clin. Oncol. 2005. Vol. 23, N 4. P. 792-799.
  609. Wilcken N., Hornbuckle J., Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer // Cochrane Database Syst. Rev. 2003. Vol. 2. CD002747.
  610. Kim H., Choi D.H., Park W., Huh S.J., Nam S.J., Lee J.E. et al. Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients // Radiat. Oncol. J. 2013. Vol. 31, N 4. P. 222-227.
  611. Tutt A., Tovey H., Cheang M.C.U., Kernaghan S„ Kilburn L., Gazinska P. et al. Carboplatin in BRCAl/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial //Nat. Med. 2018. Vol. 24, N 5. P. 628-637.
  612. Tutt A., Ellis P, Kilburn L., Gilett C., Pinder S., Abraham J. et al. Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) // Cancer Res. 2015. Vol. 75, N9. Abstr. S3-01.
  613. Schmid P, Adams S., Rugo H.S., Schneeweiss A., Barrios C.H., Iwata H. et al. Abstract LBA1 PR: IMpassionl30: Results from a global, randomised, doubleblind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) // Ann. Oncol. 2018. Vol. 29, suppl. 8. Abstr. LBA1PR.
  614. Gucalp A., Tolaney S., Isakoff S.J., Ingle J.N., Liu M.C., Carey L.A. et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer // Clin. Cancer Res. 2013. Vol. 19, N 19 p. 5505-5512.
  615. Bonnefoi H., Grellety T, Tredan O., Saghatchian M., Dalenc E, Mailliez A. et al. A phase II trial of abiraterone acetate plus prednisone in patients with triplenegative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1) // Ann. Oncol. 2016. Vol. 27, N 5. P. 812-818.
  616. Lyons T, Gucalp A., Arumov A., Patil S., Edelweiss M., Gorsky M. et al. Abstract 531: Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer // J. Clin. Oncol. 2018.Vol. 38. Abstr. 531.
  617. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy // Nat. Rev. Cancer. 2004. Vol. 4, N 6. P. 423-436. URL: http://www.nature.com/ doifinder/10.1038/nrc 1369
  618. Andre N., Carre M., Pasquier E. Metronomics: towards personalized chemotherapy? // Nat. Rev. Clin. Oncol. 2014. Vol. 11, N 7. P. 413-431.
  619. Cazzaniga M.E., Dionisio M.R., Riva F. Metronomic chemotherapy for advanced breast cancer patients // Cancer Lett. 2017. Vol. 400. P. 252-258.
  620. Lien K., Georgsdottir S., Sivanathan L., Chan K., Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis // Eur. J. Cancer. 2013. Vol. 49, N 16. P. 3387-3395.
  621. Colleoni M., Gray K.P., Gelber S., Lang L, Thiirlimann B., Gianni L. et al. Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptornegative early breast cancer: International Breast Cancer Study Group Trial 22-00 // J. Clin. Oncol. 2016. Vol. 34, N 28. P. 3400-3408.
  622. Robson M., Im S.-A., Senkus E., Xu B., Domchek S.M., Masuda N. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation // N. Engl. J. Med. 2017. Vol. 377, N 6. P. 523-533. DOI: https://doi.org/10.1056/ NEJMoal706450
  623. Tung N.M., Im S.-A., Senkus-Konefka E., Xu B., Domchek S.M., Masuda N. et al. Abstract 1052: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): efficacy in patients with visceral metastases //J. Clin. Oncol. 2018. Vol. 36, N 15. Abstr. 1052.
  624. Litton J.K., Rugo H.S., Ettl J., Hurvitz S.A., Gon.alves A., Lee K.-H. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation // N. Engl. J. Med. 2018. Vol. 379, N 8. P. 753-763.
  625. Cardonick E., Dougherty R., Grana G., Gilmandyar D., Ghaffar S., Usmani A. Breast cancer during pregnancy: maternal and fetal outcomes // Cancer J. 2010. Vol. 16, N 1. P. 76-82. DOI: https://doi.org/10.1097/PPO.0b013e3181ce46f9
  626. Azim H.A. Jr, Peccatori F.A. Treatment of metastatic breast cancer during pregnancy: we need to talk! // Breast. 2008. Vol. 17. P. 426-428.
  627. Loibl S., Schmidt A., Gentilini O., Kaufman B., Kuhl C„ Denkert C. et al. Breast cancer diagnosed during pregnancy adapting recent advances in breast cancer care for pregnant patients //JAMA Oncol. 2015. Vol. 1, N 8. P. 1145-1153.
  628. Peccatori F.A., Azim H.A., Orecchia R., Hoekstra H.J., Pavlidis N., Kesic VG. Pentheroudakis on behalf of the EGWG. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2013. Vol. 24, N 6. P. 160-170. DOI: https://doi.org/10.1093/annonc/indtl99
  629. Azim H.A., Peccatori F.A., Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors // Cancer Treat. Rev. 2010. Vol. 36, N2. P. 101-109.
  630. Cuvier C., Espie M., Extra J.M., Marty M. Vinorelbine in pregnancy // Eur. J. Cancer Part A. 1997. Vol. 33, N 1. P. 168-169.
  631. Braems G., Denys H., De Wever O., Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy // Oncologist. 2011. Vol. 16, N 11. P. 1574-1551.
  632. Azim H.A., Azim H., Peccatori .FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge // Expert Rev. Clin. Immunol. 2010. Vol. 6, N6. P. 821-826.
  633. Toy W., Shen Y, Won H., Green B., Sakr R.A., Will M. et al. ESRI ligand-binding domain mutations in hormone-resistant breast cancer //Nat. Genet. 2013. Vol. 45, N 12. P. 1439-1445.
  634. Jeselsohn R., Buchwalter G., De Angelis C„ Brown M., Schiff R. ESRI mutations-a mechanism for acquired endocrine resistance in breast cancer // Nat. Rev. Clin. Oncol. 2015. Vol. 12, N 10. P. 573-583.
  635. Toy W, Weir H., Razavi P, Lawson M., Goeppert A.U., Mazzola A.M. et al. Activating ESRI mutations differentially affect the efficacy of ER antagonists // Cancer Discov. 2017. Vol. 7, N 3. P. 277-287.
  636. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018 // CA Cancer J. Clin. 2018. Vol. 68, N 1. P. 7-30.
  637. Litton J.K., Eralp Y, Gonzalez-Angulo A.M., Broglio K., Uyei A., Hortobagyi G.N. et al. Multifocal breast cancer in women < or =35 years old // Cancer. 2007. Vol. 110, N7. P. 1445-1450.
  638. Clamp A., Danson S., Clemons M. Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies // Lancet Oncol. 2002. Vol. 3, N 10. P. 611-619.
  639. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche m, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies // Lancet Oncol. 2012. Vol. 13, N 11. P. 1141-1151.
  640. Cadeau C., Fournier A., Mesrine S. et al. Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: evidence from the E3N cohort // Int. J. Cancer. 2016. Vol. 139, N 10. P. 2193-2200.
  641. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial //JAMA. 2002. Vol. 288, N 3. P. 321-333.
  642. Travis R., Key T. Oestrogen exposure and breast cancer risk // Breast Cancer Res. 2003.Vol. 5, N 5. P. 239-247.
  643. Hilakivi-Clarke L., de Assis S., Warri A. Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk //J. Mammary Gland Biol. Neoplasia. 2013. Vol. 18. P. 25-42.
  644. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC : AICR, 2007. URL: http://www.wcrf.org/int/research-we-fund/continuous-update-proj ect-cup/second-expert-report
  645. Travis R.C., Key T.J. Oestrogen exposure and breast cancer risk // Breast Cancer Res. 2003. Vol. 5, N 5. P. 239-247.
  646. Henderson TO., Amsterdam A., Bhatia S., Hudson M.M., Meadows A.T., NegliaJ.P. et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer // Ann. Intern. Med. 2010. Vol. 152, N 7. P. 444-455, W144-W154.
  647. Guibout C., Adjadj E., Rubino C., Shamsaldin A., Grimaud E., Hawkins M. et al. Malignant breast tumors after radiotherapy for a first cancer during childhood // J. Clin. Oncol. 2005. Vol. 23, N 1. P. 197-204.
  648. Preston D.L., Cullings H., Suyama A. et al. Solid cancer incidence in atomic bomb survivors exposed in utero or as young children // J. Natl Cancer Inst. 2008. Vol. 100. P. 428-436.
  649. Pukkala E., Kesminiene A., Poliakov S. et al. Breast cancer in Belarus and Ukraine after the Chernobyl accident // Int. J. Cancer. 2006. Vol. 119. P. 651-658.
  650. Barlow W.E., White E., Ballard-Barbash R., Vacek P.M., Titus-Ernstoff L., Carney P.A. et al. Prospective breast cancer risk prediction model for women undergoing screening mammography // J. Natl Cancer Inst. 2006. Vol. 98, N 17. P. 1204-1214.
  651. Boyd N.F., Guo H., Martin L.J., Sun L., Stone J., Fishell E. et al. Mammographic density and the risk and detection of breast cancer // N. Engl. J. Med. 2007. Vol. 356, N 3. P. 227-236.
  652. McCormack V.A., dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis // Cancer Epidemiol. Biomarkers Prev. 2006. Vol. 15. P. 1159-1169.
  653. Pettersson A., Hankinson S.E., Willett W.C., Lagiou P., Trichopoulos D., Tamimi R.M. Nondense mammographic area and risk of breast cancer // Breast Cancer Res. 2011. Vol. 13, N5. P. R100. [20. Rauh C., Hack C.C., Haberle L., Hein A., Engel A., Schrauder M.G. et al. Percent mammographic density and dense area as risk factors for breast cancer // Geburtshilfe Frauenheilkd. 2012. Vol. 72. P. 727-733.
  654. Cote M.L., Ruterbusch J.J., Alosh B., Bandyopadhyay S., Kim E., Albashiti B. et al. Benign breast disease and the risk of subsequent breast cancer in African American women // Cancer Prev. Res. (Phila.). 2012. Vol. 5, N 12. P. 1375-1380.
  655. Hartmann L.C., Sellers Т.А., Frost М.Н., Lingle W.L., Degnim A.C., Ghosh K. et al. Benign breast disease and the risk of breast cancer // N. Engl. J. Med. 2005. Vol. 353, N 3. P. 229-237.
  656. Dupont W.D., Pari F.F., Hartmann W.H., Brinton L.A., Winfield A.C., Worrell J. A. et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia // Cancer. 1993. Vol. 71, N 4. P. 1258-1265.
  657. .Ward E.M., De Santis C.E., Lin C.C., Kramer J.L., Jemal A., Kohler B. et al. Cancer statistics: breast cancer in situ // CA Cancer J. Clin. 2015. Vol. 65, N 6. P. 481-495.
  658. Kerlikowske K. Epidemiology of ductal carcinoma in situ //J. Natl Cancer Inst. Monogr. 2010. Vol. 2010, N 41. P. 139-141.
  659. Welch H.G., Black W.C. Using autopsy series to estimate the disease «reservoir» for ductal carcinoma in situ of the breast: how much more breast cancer can we find? // Ann. Intern. Med. 1997. Vol. 127. P. 1023-1028.
  660. Collins L.C., Tamimi R.M., Baer H.J., Connolly J.L., Colditz G.A., Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study // Cancer. 2005. Vol. 103, N 9. P 1778-1784.
  661. Erbas B., Provenzano E., Armes J., Gertig D. The natural history of ductal carcinoma in situ of the breast: a review // Breast Cancer Res. Treat. 2006. Vol. 97, N 2. P. 135-144.
  662. Sanders M.E., Schuyler Р.А., Simpson J.F., Page D.L., Dupont WD. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up // Mod. Pathol. 2015. Vol. 28, N 5. P. 662-669.
  663. Stuart K.E., Houssami N., Taylor R., Hayen A., Boyages J. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis // BMC Cancer. 2015. Vol. 15. P. 890.
  664. Inskip P.D., Curtis R.E. New malignancies following childhood cancer in the United States, 1973-2002 // Int. J. Cancer. 2007. Vol. 121, N 10. P. 2233-2240.
  665. Buist D.S., Abraham L.A., Barlow W.E., Krishnaraj A., Holdridge R.C., Sickles E.A. et al. Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer // Breast Cancer Res. Treat. 2010. Vol. 124, N 3. P. 863-873.
  666. Colditz G.A., Kaphingst K.A., Hankinson S.E., Rosner B. Family history and risk of breast cancer: nurses’ health study // Breast Cancer Res. Treat. 2012. Vol. 133, N3. P. 1097-1104.
  667. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease // Lancet. 2001. Vol. 358, N 9291. P. 1389-1399.
  668. Lynch H.T., Lynch J.F. Breast cancer genetics in an oncology clinic: 328 consecutive patients // Cancer Genet. Cytogenet. 1986. Vol. 22, N 4. P. 369-371.
  669. Margolin S., Johansson H., Rutqvist L.E., Lindblom A., Fornander T. Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County // Fam. Cancer. 2006. Vol. 5, N 4. P. 309-321.
  670. Lalloo Е, Evans D.G. Familial breast cancer // Clin. Genet. 2012. Vol. 82, N 2. P. 105-114.
  671. Sharif S., Moran A., Huson S.M., Iddenden R., Shenton A., Howard E. et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening //J. Med. Genet. 2007. Vol. 44, N8. P. 481-484.
  672. Mavaddat N., Barrowdale D., Andrulis I.L. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) // Cancer Epidemiol. Biomarkers Prev. 2012. Vol. 21. P. 134-147.
  673. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium // Am. J. Hum. Genet. 1998. Vol. 62, N 3. P. 676-689.
  674. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies // Am. J. Hum. Genet. 2003. Vol. 72, N 5. P. 1117-1130.
  675. King M.C., Marks J.H„ Mandell J.B.; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 // Science. 2003. Vol. 302. P. 643-646.
  676. Ziegler R.G., Hoover R.N., Pike M.C., Hildesheim A., Nomura A.M., West D.W. et al. Migration patterns and breast cancer risk in Asian-American women // J. Natl Cancer Inst. 1993. Vol. 85, N 22. P. 1819-1827.
  677. Thompson D., Easton D. The genetic epidemiology of breast cancer genes // J. Mammary Gland Biol. Neoplasia. 2004. Vol. 9, N 3. P. 221-236.
  678. Diez O., Osorio A., Duran M., Martinez-Ferrandis J.I., de la Hoya M., Salazar R. et al. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects // Hum. Mutat. 2003. Vol. 22, N 4. P. 301-312.
  679. Mersch J., Jackson M.A., Park M., Nebgen D., Peterson S.K., Singletary C. et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian // Cancer. 2015. Vol. 121, N 2. P. 269-275.
  680. Thompson D., Duedal S., Kirner J., McGuffog L., Last J., Reiman A. et al. Cancer risks and mortality in heterozygous ATM mutation carriers // J. Natl Cancer Inst. 2005. Vol. 97, N 11. P. 813-822.
  681. Seal S., Thompson D., Renwick A., Elliott A., Kelly P, Barfoot R. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles // Nat. Genet. 2006. Vol. 38, N 11. P. 1239-1241.
  682. Wong M.W, Nordfors C., Mossman D., Pecenpetelovska G., Avery-Kiejda K.A., Talseth-Palmer B. et al. BRIPL PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer // Breast Cancer Res. Treat. 2011. Vol. 127, N 3. P. 853-859.
  683. Melhem-Bertrandt A., Bojadzieva J., Ready KJ., Obeid E., Liu D.D., Gutierrez-Barrera A.M. et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations // Cancer. 2012. Vol. 118, N 4. P. 908-913.
  684. Honrado Е., Benitez J., Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications // Mod. Pathol. 2005. Vol. 18, N 10. P. 1305-1320.
  685. NCCN Guidelines version 1.2018. BRCA-related breast and/or ovarian cancer syndrome. URL: http://www.nccn.org/professionals/physician_gls/pdf/
  686. Tyrer J., Duffy S.W., Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors // Stat. Med. 2004. Vol. 23, N 7. P. 1111-1130.
  687. Antoniou A.C., Cunningham A.P., Peto J., Evans D.G., Lalloo E, Narod S.A. et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions // Br. J. Cancer. 2008. Vol. 98, N 8. P. 1457-1466.
  688. Powell M., Jamshidian E, Cheyne K., Nititham J., Prebil L.A., Ereman R. Assessing breast cancer risk models in Marin County, a population with high rates of delayed childbirth // Clin. Breast Cancer. 2014. Vol. 14, N 3. P. 212-220.el.
  689. Armstrong J., Toscano M., Kotchko N., Friedman S., Schwartz M.D., Virgo K.S. et al. Utilization and outcomes of BRCA genetic testing and counseling in a National Commercially Insured Population: The ABOUT Study // JAMA Oncol. 2015. Vol. 1,N9. P. 1251-1260.
  690. Domagala P, Hybiak J., Rys J., Byrski T, Cybulski C., Lubinski J. Pathological complete response after cisplatin neoadjuvant therapy is associated with the down-regulation of DNA repair genes in BRCAl-associated triple-negative breast cancers // Oncotarget. 2016. Vol. 7, N 42. P. 68 662-68 673.
  691. Byrski T, Huzarski T, Dent R., Gronwald J., Zuziak D., Cybulski C. et al. Response to neoadjuvant therapy with cisplatin in BRCA 1-positive breast cancer patients // Breast Cancer Res. Treat. 2009. Vol. 115, N 2. P 359-363.
  692. Arun B., Bayraktar S., Liu D.D., Gutierrez Barrera A.M., Atchley D., Pusztai L. et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience //J. Clin. Oncol. 2011. Vol. 29, N 28. P. 3739-3746.
  693. Tutt A., Paul E., Kilburn L., Gilett C., Pinder S., Abraham J. et al. The TNT trial: a randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA 1/2 breast cancer // Cancer Res. 2014. Vol. 75. Abstr. S3-01.
  694. Robson M., Goessl C., Domchek S. Olaparib for metastatic germline BRCA-mutated breast cancer //N. Engl. J. Med. 2017. Vol. 377, N 18. P. 1792-1793.
  695. Ame J.C., Spenlehauer C., de Murcia G. The PARP superfamily // BioEssays. 2004.Vol. 26, N 8. P. 882-893.
  696. Gronwald J., Robidoux A., Kim-Sing C., Tung N., Lynch H.T., Foulkes W.D. et al. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers // Breast Cancer Res. Treat. 2014. Vol. 146, N 2. P. 421-427.
  697. Narod S.A., Brunet J.S., Ghadirian P, Robson M., Heimdal K., Neuhausen S.L. et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group // Lancet. 2000. Vol. 356, N 9245. P. 1876-1881.
  698. Metcalfe K., Lynch H.T, Ghadirian P, Tung N., Kim-Sing C., Olopade O.I. et al. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers // Breast Cancer Res Treat. 2011. Vol. 127, NLP. 287-296.
  699. Metcalfe К., Lynch Н.Т., Ghadirian Р., Tung N., Olivotto I., Warner E. et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers // J. Clin. Oncol. 2004. Vol. 22, N 12. P. 2328-2335.
  700. Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality //JAMA. 2010. Vol. 304, N 9. P. 967-975.
  701. Le-Petross H.T., Whitman G.J., Atchley D.P., Yuan Y, Gutierrez-Barrera A., Hortobagyi G.N. et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer // Cancer. 2011. Vol. 117, N 17. P. 3900-3907.
  702. Tung N., Domchek S.M., Stadler Z., Nathanson K.L., Couch E, Garber J.E. et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations // Nat. Rev. Clin. Oncol. 2016. Vol. 13, N 9. P. 581-588.
  703. Ramus S.J., Antoniou A.C., Kuchenbaecker K.B., Soucy P, Beesley J., Chen X. et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers // Hum. Mutat. 2012. Vol. 33, N 4. P. 690-702.
  704. Brentnail T. A. Cancer surveillance of patients from familial pancreatic cancer kindreds // Med. Clin. North Am. 2000. Vol. 84, N 3. P 707-718.
  705. Canto M.L, Goggins M., Hruban R.H., Petersen G.M., Giardiello F.M., Yeo C. et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study // Clin. Gastroenterol. Hepatol. 2006. Vol. 4, N6. P. 766-781.
  706. Kuerer H. Establishing a cancer genetics service // Kuerer’s Breast Surgical Oncology. New York : McGraw-Hill Professional, 2010.
  707. MacDonald DJ., Blazer K.R., Weitzel J.N. Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership // J. Natl Compr. Cancer Netw. 2010. Vol. 8, N 5. P. 615-624.
  708. Febbraro T, Robison K., Wilbur J.S., Laprise J., Bregar A., Lopes V et al. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals // Gynecol. Oncol. 2015. Vol. 138, N 1. P. 109-114.
  709. Levy D.E., Garber J.E., Shields A.E. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization // J. Gen. Intern. Med. 2009. Vol. 24, N 7. P. 822-828.
  710. American College of Radiology. Breast imaging reporting and data system (BI-RADS™). 5th ed. Reston, VA : American College of Radiology, 2013.
  711. Kim J.Y., Lee S.H., Lee J.W. et al. Magnetic resonance imaging characteristics of invasive breast cancer in women aged less than 35 years // Acta Radiol. 2015. Vol. 56, N 8. P. 924-932.
  712. Veltman J., Mann R., Kok T. Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI // Eur. Radiol. 2008. Vol. 18. P. 931-938.
  713. Giess C., Yeh E., Raza S. et al. Background parenchymal enhancement at breast MR imaging: normal patterns, diagnostic challenges, and potential for falsepositive and false-negative interpretation // Radiographics. 2014. Vol. 34, N 1. P. 234-247.
  714. Checka C.M. et al. The relationship of mammographic density and age: implications for breast cancer screening // AJR Am. J. Roentgenol. 2012. Vol. 198, N 3. P. W292-W295.
  715. Boyd N.F., Guo H., Martin LJ. Mammographic density and the risk and detection of breast cancer // N. Engl. J. Med. 2007. Vol. 356, N 3. P. 227-236.
  716. Stavros A.T., Thickman D., Rapp C.L. et al. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions // Radiology. 1995. Vol. 196, N 1. P. 123-134.
  717. Holley R.J., Scoutt L.M., Philpotts L.E. Breast ultrasonography: state of the art // Radiology. 2013. Vol. 268, N 3. P. 642-659.
  718. Brem R.F., Tabar L., Duffy S. et al. Assessing improvement in detection of breast cancer with three-dimensional automated breast ultrasound in women with dense breast tissue: the Somolnsight study // Radiology. 2015. Vol. 274, N 3. P. 663-673.
  719. Wilczek B., Wilczek H., Rasouliyan L., Leifland K. Adding 3D automated breast ultrasound to mammography screening in women with heterogeneously and extremely dense breasts: report from a hospital-based, high-volume, single-center breast cancer screening program // Eur. J. Radiol. 2016. Vol. 85, N 9. P. 1554-1563.
  720. Houssami N., Simpson I.L. et al. Sydney breast imaging study accuracy study: comparative sensitivity and specificity of mammography and sonography in young women with symptoms // AJR Am. J. Roentgenol. 2003. Vol. 180, N 4. P. 935-940.
  721. Kemp Jacobsen K., O’Meara E.S., Key D. et al. Comparing sensitivity and specificity of screening mammography in the United States and Denmark // Int. J. Cancer. 2015. Vol. 137, N 9. P. 2198-2207.
  722. Warner E., Plewes D.B., Hill K.A. et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography and clinical breast examination // JAMA. 2004. Vol. 292, N 11. P. 1317-1325.
  723. The Royal College of Radiologists. Guidance on screening and symptomatic breast imaging. 3rd ed. 2013.
  724. Houssami N., Turner R.M. Rapid review: estimates of incremental breast cancer detection from tomosynthesis (3D-mammography) screening in women with dense breasts // Breast. 2016. Vol. 30. P. 141-145.
  725. Kim W.H., Chang J. M., Lee J. Diagnostic performance of tomosynthesis and breast ultrasonography in women with dense breasts: a prospective comparison study // Breast Cancer Res. Treat. 2017. Vol. 162, N 1. P. 85-94.
  726. Berg W.A., Gutierrez L., Ness Aiver M.S. Diagnostic accuracy of mammography, clinical examination, US and MR imaging in preoperative assessment of breast cancer // Radiology. 2004. Vol. 233, N 3. P. 830-849.
  727. Warner E., Hill K., Causer P. et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging //J. Clin. Oncol. 2011. Vol. 29, N 13. P 1664-1669.
  728. Kriege M., Brekelmanns C.T., Boetes C. et al. Efficacy of MRI and mammography for breast cancer screening in women with a familial and genetic predisposition // N. Engl. J. Med. 2004. Vol. 351, N 5. P. 427-437.
  729. Sardanelli E, Boetes C., Borisch B. et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group // Eur. J. Cancer. 2010. Vol. 46. P. 1296-1316.
  730. Obdeijn I.M., Winter-Warnars G.A., Mann R.M. et al. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study // Breast Cancer Res. Treat. 2014. Vol. 144, N 3. P. 577-582.
  731. Phi X., Saadatmand S., De Bock G. et al. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis // Br. J. Cancer. 2016. Vol. 114, N 6. P. 631-637.
  732. Houssami N., Turner R., Macaskill P. et al. An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence // J. Clin. Oncol. 2014. Vol. 32, N 5. P. 392-401.
  733. Houssami N., Turner R., Morrow M. Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes // Ann. Surg. 2013. Vol. 257, N 2. P. 249-255.
  734. Paluch-Shimon S., Pagani O., Partridge A. et al. Second International Consensus guidelines for breast cancer in young women (BCY2) // Breast. 2016. Vol. 26. P. 87-99.
  735. Russo J., Moral R., Balogh G.A. et al. The protective role of pregnancy in breast cancer // Breast Cancer Res. 2005. Vol. 7, N 3. P. 131-142.
  736. Faguy K. Breast disorders in pregnant and lactating women // Radiol. Technol. 2015. Vol. 86, N 4. P. 419-438.
  737. Schackmuth E.M., Harlow C.L., Norton L.W Milk fistula: a complication after breast core biopsy // AJR Am. J. Roentgenol. 1993. Vol. 161. P. 961-962.
  738. Robbins J., Jeffries D., Roubidoux M. et al. Accuracy of diagnostic mammography and breast ultrasound during pregnancy and lactation // AJR Am. J. Roentgenol. 2011. Vol. 196,N3.P. 716-722.
  739. Magno S., Terribile D., Franceschini G. et al. Early onset lactating adenoma and the role of breast MRI: a case report // J. Med. Case Rep. 2009. Vol. 3. P. 43.
  740. Talele А.С., SLanetz PJ., Edmister W.B. et al. The lactating breast: MR1 findings an literature review // Breast J. 2003. Vol. 9. P. 237-240.
  741. Joshi S., Dialani V, Marotti J. et al. Breast disease in the pregnant and lactating patient: radiological-pathological correlation // Insights Imaging. 2013. Vol. 4. P. 527-538.Azim Н.А. Jr, Partrdige А.Н. Biology of breast cancer in young women // Breast Cancer Res. 2014. Vol. 16, N 4. P. 427.
  742. Gnerlich J.L., Deshpande A.D., Jeffe D.B., Sweet A., White N., Margenthaler J. A. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease //J. Am. Coll. Surg. 2009. Vol. 208, N 3. P. 341-347.
  743. Han W., Kang S.Y.; Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer // Breast Cancer Res. Treat. 2010. Vol. 119, N 1. P. 193-200.
  744. Azim Н.А. Jr, Michiels S., Bedard P.L., Singhal S.K., Criscitiello C., Ignatiadis M. et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling // Clin. Cancer Res. 2012. Vol. 18, N 5. P. 1341-1351.
  745. Fredholm H„ Eaker S., Frisell J., Holmberg L., Fredriksson I., Lindman H. Breast cancer in young women: poor survival despite intensive treatment // PLoS One. 2009.Vol. 4.N11.P. 1-9.
  746. Cancello G., Maisonneuve P, Rotmensz N., Viale G., Mastropasqua M.G., Pruneri G. et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer // Ann. Oncol. 2010.Vol. 21, N 10. P. 1974-1981.
  747. Partridge A.H., Hughes M.E., Warner E.T., Ottesen R.A., Wong Y.N., Edge S.B. et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival //J. Clin. Oncol. 2016. Vol. 34, N 27. P. 3308-3314.
  748. Anders C.K., Hsu D.S., Broadwater G., Acharya C.R., Foekens J.A., Zhang Y. et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression //J. Clin. Oncol. 2008. Vol. 26, N 20. P. 3324-3330.
  749. Walker R.A., Lees E., Webb M.B., Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different // Br. J. Cancer. 1996. Vol. 74, N 11. P. 1796-1800.
  750. Colleoni M., Rotmensz N., Robertson C., Orlando L., Viale G., Renne G. et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation // Ann. Oncol. 2002. Vol. 13, N 2. P. 273-279.
  751. 11. Azim H.A. Jr, Nguyen B., Brohec S., Zoppoli G., Sotiriou C. Genomic aberrations in young and elderly breast cancer patients // BMC Med. 2015. Vol. 13, N 1. P. 266.
  752. Azim H.A. Jr, Azim H. Breast cancer arising at a young age: do we need to define a cut-off? // Breast. 2013. Vol. 22, N 6. P. 1007-1008.
  753. Jenkins E.O., Deal A.M., Anders C.K., Prat A., Perou C.M., Carey L.A. et al. Agespecific changes in intrinsic breast cancer subtypes: a focus on older women // Oncologist. 2014. Vol. 19, N 10. P. 1076-1083.
  754. Lim E., Vaillant E, Wu D., Forrest N.C., Pal B., Hart A.H. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers // Nat. Med. 2009. Vol. 15, N 8. P. 907-913.
  755. Huzarski T, Byrski T, Gronwald J., Gorski B., Domagala P, Cybulski C. et al. Ten-year survival in patients with BRCAl-negative and ВRCA1-positive breast cancer//J. Clin. Oncol. 2013. Vol. 31, N 26. P. 3191-3196.
  756. Young S., Pilarski R.T., Donenberg T, Shapiro C., Hammond L.S., Miller J. et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer // BMC Cancer. 2009. Vol. 9, N 1. P. 86.
  757. Kim J.B., Stein R., O’Hare MJ. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis // Tumour Biol. 2005. Vol. 26, N 4. P. 173-185.
  758. Bhowmick N.A., Moses H.L. Tumor-stroma interactions // Curr. Opin. Genet. Dev. 2005. Vol. 15, N 1. P. 97-101.
  759. McDaniel S.M., Rumer K.K., Biroc S.L., Metz R.P., Singh M., Porter W. et al. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis // Am. J. Pathol. 2006. Vol. 168, N 2. P. 608-620.
  760. Easton D.F. How many more breast cancer predisposition genes are there? // Breast Cancer Res. 1999. Vol. 1, N 1. P. 14-17.
  761. Moynahan M.E., Chiu J.W., Koller B.H., Jasin M. Brcal controls homology-directed DNA repair // Mol. Cell. 1999. Vol. 4, N 4. P. 511-518.
  762. Burke W., Daly M., Garber J., Botkin J., Kahn MJ., Lynch P. et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium // JAMA. 1997. Vol. 277, N 12. P. 997-1003.
  763. Kuchenbaecker K.B., Hopper J.L., Barnes D.R., Phillips K.-A., Mooij T.M., Roos-Blom M.-J. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2mutation carriers //JAMA. 2017. Vol. 317, N 23. P. 2402.
  764. NCCN Guidelines Version 2.2017 Hereditary Breast and/or Ovarian Cancer Syndrome. URL: http://www.nccn.org/professionals/physician_gls/pdf/genetics_ screening.pdf (date of access November 8, 2017)
  765. Rosenberg S.M., Ruddy K.J., Tamimi R.M., Gelber S., Schapira L., Come S. et al. BRCA1 and BRCA2mutation testing in young women with breast cancer // JAMA Oncol. 2016. Vol. 2, N 6. P. 730.
  766. Bai E, Chan H.L., Scott A., Smith M.D., Fan C., Herschkowitz J.I. et al. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development // Cancer Res. 2014. Vol. 74, N 21. P. 6161-6172.
  767. Ma Y, Katiyar P, Jones L.P., Fan S., Zhang Y, Furth PA. et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells // Mol. Endocrinol. 2006. Vol. 20, N 1. P. 14-34.
  768. Metcalfe K., Lynch H.T., Foulkes W.D., Tung N., Kim-Sing C., Olopade O.I. et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2mutation carriers //JAMA Oncol. 2015. Vol. 1, N 3. P. 306.
  769. Azim H., Azim H.A. Jr. Targeting RANKL in breast cancer: bone metastasis and beyond // Expert Rev. Anticancer Ther. 2013. Vol. 13, N 2. P. 195-201.
  770. Gonzalez-Suarez E., Jacob A.P., Jones J., Miller R., Roudier-Meyer M.P., Erwert R. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis // Nature. 2010. Vol. 468, N 7320. P. 103-107.
  771. Schramek D., Leibbrandt A., Sigi V, Kenner L., Pospisilik J.A., Lee HJ. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer // Nature. 2010. Vol. 468, N 7320. P. 98-102.
  772. Asselin-Labat M.L., Vaillant E, Sheridan J.M., Pal B., Wu D., Simpson E.R. et al. Control of mammary stem cell function by steroid hormone signalling // Nature. 2010. Vol. 465, N 7299. P. 798-802.
  773. Azim H.A. Jr, Peccatori F.A., Brohee S., Branstetter D., Loi S., Viale G. et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy // Breast Cancer Res. 2015. Vol. 17, N 1. P. 24.
  774. Sigi V, Owusu-Boaitey K., Joshi P.A., Kavirayani A., Wirnsberger G., Novatchkova M. et al. RANKL/ RANK control Brcal mutation-driven mammary tumors // Cell Res. 2016. Vol. 26, N 7. P. 761-774.
  775. Nolan E., Vaillant E, Branstetter D., Pal B., Giner G., Whitehead L. et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers // Nat. Med. 2016. Vol. 22, N 8. P. 933-939.
  776. Widschwendter М., Burnell М., Fraser L., Rosenthal A.N., Philpott S., Reisel D. et al. Osteoprotegerin (OPG), the endogenous inhibitor of receptor activator of NF-кВ ligand (RANKL), is dysregulated in BRCA mutation carriers // EBioMedicine. 2015.Vol. 2, N 10. P. 1331-1339.
  777. Oden L., Akbari M., Zaman T, Singer C.F., Sun P, Narod S.A. et al. Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers // Oncotarget. 2016. Vol. 7, N 52. P. 86 687-86 694.
  778. Gnant M., Pfeiler G., Dubsky P.C., Hubalek M., Greil R., Jakesz R. et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, doubleblind, placebo-controlled trial // Lancet. 2015. Vol. 386, N 9992. P. 433-443.
  779. Curtis C., Shah S.P., Chin S.-Е, Turashvili G., Rueda O.M., Dunning MJ. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups // Nature. 2012. Vol. 486, N 7403. P. 346-352.
  780. Yau C., Fedele V, Roydasgupta R., Fridlyand J., Hubbard A., Gray J.W. et al. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers // Breast Cancer Res. 2007. Vol. 9, N 5. P. R59.
  781. TCGA. Comprehensive molecular portraits of human breast tumours // Nature. 2012. Vol. 487, N 7407. P. 61-70.
  782. Noviello C., Courjal E, Theillet C. Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion // Clin. Cancer Res. 1996. Vol. 2, N 9. P. 1601-1606.
  783. Pereira B., Chin S.-Е, Rueda O.M., Vollan H.-K.M., Provenzano E., Bardwell H.A. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes // Nat. Commun. 2016. Vol. 7. Article ID 11479.
  784. Nik-Zainal S., Davies H., Staaf J., Ramakrishna M., Glodzik D., Zou X. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences // Nature. 2016. Vol. 534, N 7605. P. 1-20.
  785. Tindemans L, Serafini N., Di Santo J.P, Hendriks R.W. GATA-3 function in innate and adaptive immunity // Immunity. 2014. Vol. 41, N 2. P. 191-206.
  786. Asselin-Labat M.-L., Sutherland K.D., Barker H., Thomas R., Shackleton M., Forrest N.C. et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation //Nat. Cell Biol. 2007. Vol. 9, N 2. P. 201-209.
  787. Kouros-Mehr H., Kim J., Bechis S.K., Werb Z. GATA-3 and the regulation of the mammary luminal cell fate // Curr. Opin. Cell Biol. 2008. Vol. 20, N 2. P. 164-170.
  788. Kouros-Mehr IL, Slorach E.M., Sternlicht M.D., Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland // Cell. 2006. Vol. 127, N5. P. 1041-1055.
  789. Mair B., Konopka T, Kerzendorfer C., Sleiman K., Salic S., Serra V. et al. Gain- and loss-of-function mutations in the breast cancer gene GATA3 result in differential drug sensitivity // PLoS Genet. 2016. Vol. 12, N 9. P. 1-26.
  790. Chou J., Provot S., Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! //J. Cell. Physiol. 2010. Vol. 222, N 1. P. 42-49.
  791. Yu-Rice Y, Jin Y, Han B., Qu Y, Johnson J., Watanabe T. et al. FOXCI is involved in ERa silencing by counteracting GATA3 binding and is implicated in endocrine resistance // Oncogene. 2016. Vol. 35, N 41. P. 5400-5411.
  792. Azim Н.А. Jr, Santoro L., Russell-Edu W., Pentheroudakis G., Pavlidis N., Peccatori F.A. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies // Cancer Treat. Rev. 2012. Vol. 38, N 7. P. 834 842.
  793. Hartman E.K., Eslick G.D. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis // Breast Cancer Res. Treat. 2016.Vol. 160, N 2. P. 347-360.
  794. Lambertini M., Santoro L., Del Mastro L., Nguyen B., Livraghi L., Ugolini D. et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies // Cancer Treat. Rev. 2016. Vol. 49. P. 65-76.
  795. Lyons T.R., O’Brien J., Borges V.F., Conklin M.W., Keely P.J., Eliceiri K.W. et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2 // Nat. Med. 2011. Vol. 17, N 9. P. 1109-115.
  796. O’Brien J., Lyons T, Monks J., Lucia M.S., Wilson R.S., Hines L. et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species // Am. J. Pathol. 2010. Vol. 176, N 3. P. 1241-1255.
  797. Azim H.A. Jr, Brohee S., Peccatori F.A., Desmedt C., Loi S., Lambrechts D. et al. Biology of breast cancer during pregnancy using genomic profiling // Endocr. Relat. Cancer. 2014. Vol. 21, N 4. P. 545-554.
  798. Nguyen B., Venet D., Azim H.A. Jr, Brown D., Desmedt C., Lambertini M. et al. Breast cancer diagnosed during pregnancy is associated with enrichment of nonsilent mutations, mismatch repair deficiency signature and mucin mutations // NPJ Breast Cancer. 2018. Vol. 4. P. 23.
  799. Paluch-Shimon S., Pagani O., Partridge A.H., Abulkhair O„ Cardoso MJ., Dent R.A. et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) // Breast. 2017. Vol. 35. P. 203-217.
  800. Rosenberg S.M., Partridge A.H. Management of breast cancer in very young women // Breast. 2015. Vol. 24. P. S154-S158.
  801. Partridge A.H. Chemotherapy in premenopausal breast cancer patients // Breast Care. 2015. Vol. 10, N 5. P 307-310.
  802. Balmana J., Domchek S.M., Tutt A., Garber J.E. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for ВRCA1/2-associated cancers // Cancer Discov. 2011. Vol. 1, N 1. P. 29-34.
  803. Robson M., Im S.A., Senkus E., Xu B., Domchek S.M., Masuda M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation // N. Engl. J. Med. 2017. Vol. 377, N 6. P. 523-533.
  804. Ferlay J., Shin H.-R., Bray E, Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 // Int. J. Cancer. 2010. Vol. 127, N 12. P. 2893-2917.
  805. DeSantis C.E., Fedewa S.A., Goding Sauer A., Kramer J.L., Smith R.A., Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women // CA Cancer J. Clin. 2016. Vol. 66, N 1. P. 31-42.
  806. Anders C.K., Johnson R., Litton J., Phillips M., Bleyer A. Breast cancer before age 40 years // Semin. Oncol. 2009. Vol. 36, N 3. P. 237-249.
  807. Narod S.A. Breast cancer in young women // Nat. Rev. Clin. Oncol. 2012. Vol. 9, N 8. P 460-470.
  808. GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012.International Agency for Research on Cancer. 2012. URL: http://globocan. iarc.fr/Pages/age-specific_table_sel.aspx (date of access August 10, 2017).
  809. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016 // CA Cancer J. Clin. 2016. Vol. 66, N 1. P. 7-30.
  810. Toriola A.T., Colditz G.A. Trends in breast cancer incidence and mortality in the United States: implications for prevention // Breast Cancer Res. Treat. 2013. Vol. 138, N 3. P. 665-673.
  811. Johnson R.H., Chien F.L., Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976-2009 //JAMA. 2013. Vol. 309, N 8. P. 800-805.
  812. Clavel-Chapelon E, Gerber M. Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? // Breast Cancer Res. Treat. 2002. Vol. 72, N2. P. 107-115.
  813. Warner E.T., Colditz G.A., Palmer J.R., Partridge A.H., Rosner B.A., Tamimi R.M. Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? // Breast Cancer Res. Treat. 2013. Vol. 142, N 1. P. 165-175.
  814. Talamini R., Franceschi S., La Vecchia C., Negri E., Borsa L., Montella M. et al. The role of reproductive and menstrual factors in cancer of the breast before and after menopause // Eur. J. Cancer. 1996. Vol. 32, N 2. P. 303-310.
  815. Lambe M., Hsieh C.-С., Trichopoulos D., Ekbom A., Pavia M., Adami H.-O. Transient increase in the risk of breast cancer after giving birth // N. Engl. J. Med. 1994. Vol. 331, N 1. P. 5-9.
  816. Liu Q., Wuu J., Lambe M., Hsieh S.-Е, Ekbom A., Hsieh C.-C. Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden) // Cancer Causes Control. 2002. Vol. 13, N 4. P. 299-305.
  817. Shakhar K., Valdimarsdottir H.B., Bovbjerg D.H. Heightened risk of breast cancer following pregnancy: could lasting systemic immune alterations contribute? // Cancer Epidemiol. Biomarkers Prev. 2007. Vol. 16, N 6. P. 1082-1086.
  818. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiologic studies//Lancet. 1999. Vol. 347, N 9017. P. 1713-1727.
  819. Gierisch J.M., Coeytaux R.R., Urrutia R.P., Havrilesky L.J., Moorman P.G., Lowery WJ. et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review // Cancer Epidemiol. Biomarkers Prev. 2013. Vol. 22, N 11. P. 1931-1943.
  820. van den Belt-Dusebout A.W., Spaan M., Lambalk C.B., Kortman M., Laven J.S., van Santbrink E.J. et al. Ovarian stimulation for in vitro fertilization and longterm risk of breast cancer //JAMA. 2016. Vol. 316, N 3. P. 300-312.
  821. Venn A., Watson L., Lumley J., Giles G., King C., Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilization // Lancet. 1995. Vol. 346, N 8981. P. 995-1000.
  822. Brinton L.A., Trabert B., Shalev V, Lunenfeld E., Sella T, Chodick G. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services // Fertil. Steril. 2013. Vol. 99, N5. P. 1189-1196.
  823. Sergentanis T.N., Diamantaras A., Perlepe С., Kanavidis Р., Skalkidou A., Petridou E.Т. IVF and breast cancer: a systematic review and meta-analysis // Hum. Reprod. Update. 2014. Vol. 20, N 1. P. 106-123.
  824. Eliassen A.H., Missmer S.A., Tworoger S.S., Spiegelman D., Barbieri R.L., Dowsett M. et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women // J. Natl Cancer Inst. 2006. Vol. 98, N 19. P. 1406-1415.
  825. Kaaks R., Berrino E, Key T„ Rinaldi S., Dossus L., Biessy C. et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC) //J. Natl Cancer Inst. 2005. Vol. 97, N 10. P. 755-765.
  826. 23. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D. et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women //J. Natl Cancer Inst. 1998. Vol. 90, N 17. P. 1292-1299.
  827. Ahlgren M., Melbye M„ Wohlfahrt J., S.rensen T.I.A. Growth patterns and the risk of breast cancer in women //N. Engl. J. Med. 2004. Vol. 351, N 16. P. 1619-1626.
  828. Gunnell D., Okasha M., Davey Smith G., Oliver S.E., Sandhu J., Jolly J.M.P. Height, leg length, and cancer risk: a systematic review // Epidemiol. Rev. 2001. Vol. 23, N 2. P. 313-342.
  829. Friedenreich C.M. Review of anthropometric factors and breast cancer risk // Eur. J. Cancer Prev. 2001. Vol. 10, N 1. P. 15-32.
  830. Carmichael A.R., Bates T. Obesity and breast cancer: a review of the literature // Breast. 2004. Vol. 13, N 2. P. 85-92.
  831. Steindorf K., Ritte R., Eomois P.-P, Lukanova A., Tjonneland A., Johnsen N.F. et al. Physical activity and risk of breast cancer overall and by hormone receptor status: the European prospective investigation into cancer and nutrition // Int. J. Cancer. 2013. Vol. 132, N 7. P. 1667-1678.
  832. Maruti S.S., Willett W.C., Feskanich D., Rosner B., Colditz G.A. A prospective study of age-specific physical activity and premenopausal breast cancer //J. Natl Cancer Inst. 2008. Vol. 100, N 10. P. 728-737.
  833. Rockhill B., Willett W.C., Hunter D.J., Manson J.E., Hankinson S.E., Coldtiz G.A. A prospective study of recreational physical activity and breast cancer risk // Arch. Intern. Med. 1999. Vol. 159, N 19. P 2290-2296.
  834. Baer H.J., Tworoger S.S., Hankinson S.E., Willett W.C. Body fatness at young ages and risk of breast cancer throughout life // Am. J. Epidemiol. 2010. Vol. 171, N 11. P. 1183-1194.
  835. Liu Y, Colditz G.A., Rosner B., Berkey C.S., Collins L.C., Schnitt SJ. et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk //J. Natl Cancer Inst. 2013. Vol. 105, N 20. P. 1571-1578.
  836. Willett W.C., Stampfer M.J., Colditz G.A., Rosner B.A., Hennekens C.H., Speizer F.E. Moderate alcohol consumption and the risk of breast cancer // N. Engl. J. Med. 1987. Vol. 316, N 19. P. 1174-1180.
  837. Chen W.Y., Rosner B., Hankinson S.E., Colditz G.A., Willett W.C. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk // JAMA. 2011. Vol. 206, N 17. P. 1884-1890.
  838. Bowlin S.J., Leske М.С., Varma A., Nasca P., Weinstein A., Caplan L. Breast cancer risk and alcohol consumption: results from a large case-control study // Int. J. Epidemiol. 1997. Vol. 26, N 5. P. 915-923.
  839. Harris H.R., Willett W.C., Vaidya R.L., Michels K.B. An adolescent and early adulthood dietary pattern with inflammation and the incidence of breast cancer // Cancer Res. 2017. Vol. 77, N 5. P. 1179-1187.
  840. Frazier A.L., Ryan C.T., Rockett H., Willett W.C., Colditz G.A. Adolescent diet and risk of breast cancer // Breast Cancer Res. 2003. Vol. 5, N 3. P. R59-R64.
  841. Shin M„ Holmes M.D., Hankinson S.E., Wu K., Colditz G.A., Willett W.C. Intake of dietary products, calcium, and vitamin D and risk of breast cancer // J. Natl Cancer Inst. 2002. Vol. 94, N 17. P. 1301-1311.
  842. Castello A., Pollan M., Buijsse B., Ruiz A., Casas A.M., Baena-Canada J.M. et al. Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case-control EpiGEICAM study // Br. J. Cancer. 2014. Vol. Ill, N 7. P. 1454-1462.
  843. Hirko K.A., Willett W.C., Hankinson S.E., Rosner B.A., Beck A.H., Tamimi R.M. et al. Healthy dietary patterns and risk of breast cancer by molecular subtype // Breast Cancer Res. Treat. 2016. Vol. 155, N 3. P. 579-588.
  844. Schwingshackl L., Hoffmann G. Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis of observational studies // Cancer Med. 2015. Vol. 4, N 12. P. 1933-1947.
  845. Moskowitz C.S., Chou J.F., Wolden S.L., Bernstein J.L., Malhotra J., Novetsky Friedman D. et al. Breast cancer after chest radiation therapy for childhood cancer // J. Clin. Oncol. 2014. Vol. 32, N 21. P. 2217-2223.
  846. Gnerlich J.L., Deshpande A.D., Jeffe D.B., Sweet A., White N., Margenthaler J. A. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease //J. Am. Coll. Surg. 2009. Vol. 208, N 3. P. 341-347.
  847. Morris GJ., Naidu S., Topham A.K., Guiles E, Xu Y„ McCue P. et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database // Cancer. 2007. Vol. 110, N 4. P. 876-884.
  848. Amirikia K.C., Mills P, Bush J., Newman L.A. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations // Cancer. 2011. Vol. 117, N 12. P. 2747-2753.
  849. Carey L.A., Perou C.M., Livasy C.A., Dressier L.G., Cowan D., Conway K. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study // JAMA. 2006. Vol. 295, N 21. P. 2492-2502.
  850. Copson E., Maishman T, Gerty S., Eccles B., Stanton L., Cutress R.I. et al. Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study// Br.J. Cancer. 2014. Vol. 110, N 1. P. 230-241.
  851. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours // Nature. 2012. Vol. 490, N 7418. P. 61-70.
  852. Tung N., Lin N.U., Kidd J., Allen B.A., Singh N., Wenstrup RJ. et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer //J. Clin. Oncol. 2016. Vol. 34, N 13. P. 1460-1468.
  853. Gabai-Kapara E., Lahad A., Kaufman B., Friedman E., Segev S., Renbaum P. et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2 // Proc. Natl Acad. Sci. USA. 2014. Vol. Ill, N 39. P. 14 205-14 210.
  854. Roa B.B., Boyd A.A., Volcik K., Richards C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 // Nat. Genet. 1996. Vol. 14, N2. P. 185-187.
  855. Warner E., Foulkes W, Goodwin P., Meschino W, Blondal J., Paterson C. et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer //J. Natl Cancer Inst. 1999. Vol. 91, N 14. P. 1241-1247.
  856. Pal T, Bonner D„ Cragun D., Monteiro A.N.A., Phelan C., Servais L. et al. A high frequency of BRCA mutations in young black women with breast cancer from Florida// Cancer. 2015. Vol. 121, N 23. P. 4173-4180.
  857. Villarreal-Garza C., Weitzel J.N., Llacuachaqui M., Sifuentes E., Magallanes-Hoyos M.C., Gallardo L. et al. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer // Breast Cancer Res. Treat. 2015. Vol. 150, N 2. P. 389-394.
  858. Ruddy K.J., Gelber S., Tamimi R.M., Schapira L., Come S.E., Meyer M.E. et al. Breast cancer presentation and diagnostic delays in young women // Cancer. 2014.Vol. 120, N 1. P. 20-25.
  859. Fredholm H„ Eaker S., Frisell J., Holmberg L., Fredriksson I., Lindman H. Breast cancer in young women: poor survival despite intensive treatment // PLoS One. 2009. Vol. 4, N 11. Article ID e7695.
  860. Keegan TH., DeRouen M.C., Press D.J., Kurian A.W, Clarke C.A. Occurrence of breast cancer subtypes in adolescent and young women // Breast Cancer Res. 2012.Vol. 14. P. R55.
  861. Collins L.C., Marotti J.D., Gelber S., Cole K., Ruddy K., Kereakoglow S. et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer // Breast Cancer Res. Treat. 2012. Vol. 131, N 3. P. 1061-1066.
  862. Copson E., Eccles B., Maishman T, Gerty S., Stanton L., Cutress R.I. et al. Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study //J. Natl Cancer Inst. 2013.Vol. 105, N 13. P. 978-988.
  863. Swain S.M., Nunes R., Yoshizawa C., Rothney M., Sing A.P. Quantitative gene expression by recurrence score in ER-positive breast cancer, by age // Adv. Ther. 2015.Vol. 32, N 12. P. 1222-1236.
  864. Azim H.A. Jr, Nguyen B., Brohee S., Zoppoli G., Sotiriou C. Genomic aberrations in young and elderly breast cancer patients // BMC Med. 2015. Vol. 13. P. 266.
  865. Han W, Kim S.W, Park I.A., Kang D., Kim S.W, Youn Y.K. et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer // BMC Cancer. 2004. Vol. 4. P. 82.
  866. Partridge А.Н., Hughes М.Е., Warner E.T., Ottesen R.A., Wong Y.N., Edge S.B. et al. Subtypedependent relationship between young age at diagnosis and breast cancer survival //J. Clin. Oncol. 2016. Vol. 34, N 27. P. 3308-3314.
  867. Swain S.M., Jeong J., Geyer C.E. Jr, Costantino J.P, Pajon E.R., Fehrenbacher L. et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer // N. Engl. J. Med. 2010. Vol. 362, N 22. P. 2053-2065.
  868. Bellet M., Gray K.P., Francis P.A., Lang L, Ciruelos E., Lluch A. et al. Twelvemonth estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the Suppression of Ovarian Function Trial (SOFT): the SOFT-EST substudy // J.Clin. Oncol. 2016. Vol. 34, N 14. P. 1584-1593.
  869. Francis P.A., Regan M.M., Fleming G.F., Lang L, Ciruelos E., Bellet M. et al. Adjuvant ovarian suppression in premenopausal breast cancer // N. Engl. J. Med. 2015. Vol. 372, N 5. P. 436-446.
  870. Saha P, Regan M.M., Pagani O., Francis P.A., Walley B.A., Ribi K. et al. Treatment efficacy, adherence and quality-of life among very young women (age <35 years) in the 1BCSG TEXT and SOFT Adjuvant Endocrine Therapy Trials //J. Clin. Oncol. 2017. Vol. 35. P. 3113-3122. '
  871. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials // Lancet. 2005. Vol. 365, N 9472. P. 1687-1717.
  872. Ademuyiwa F.O., Gao E, Hao L., Morgensztern D., Aft R.L., Ma C.X. et al. US breast cancer mortality trends in young women according to race // Cancer. 2015. Vol. 121, N 9. P. 1469-1476.
  873. Wheeler S.B., Reeder-Hayes K.E., Carey L.A. Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research // Oncologist. 2013. Vol. 18, N 9. P. 986-993.
  874. Roberts M.C., Wheeler S.B., Reeder-Hayes K. Racial/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review // Am. J. Public Health. 2015. Vol. 105, N S3. P. e4-el5.
  875. Paluch-Shimon S., Pagani O., Partridge A.H., Bar-Meir E., Fallowfield L., Fenlon D. et al. Second international consensus guidelines for breast cancer in young women (BCY2) // Breast. 2016. Vol. 26. P. 87-99.
  876. Kroman N„ Holtveg H., Wohlfahrt J., Jensen M.B., Mouridsen H.T, Blichert-Toft M. et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma // Cancer. 2004. Vol. 100, N 4. P. 688-693.
  877. Mahmood U., Morris C., Neuner G., Koshy M., Kesmodel S., Buras R. et al. Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer // Int. J. Radiat. Oncol. Biol. Phys. 2012. Vol. 83, N 5. P. 1387-1393.
  878. Kurian A.W., Lichtensztajn D.Y, Keegan TH., Nelson D.O., Clarke C.A., Gomez S.L. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011 //JAMA. 2014. Vol. 312, N 9. P. 902-914.
  879. Braunstein L.Z., Taghian A.G., Niemierko A., Salama L., Capuco A., Bellon J.R. et al. Breastcancer subtype, age, and lymph node status as predictors of local recurrence following breastconserving therapy // Breast Cancer Res. Treat. 2017. Vol. 161, N 1. P. 173-179.
  880. Arvold N.D., Taghian A.G., Niemierko A., Abi Raad R.F., Sreedhara M., Nguyen P.L. et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy // J. Clin. Oncol. 2011. Vol. 29, N 29. P 3885-3891.
  881. Aalders K.C., Postma E.L., Strobbe L.J., van der Heiden-van der Loo M., Sonke G.S., Boersma L.J. et al. Contemporary locoregional recurrence rates in young patients with early-stage breast cancer // J. Clin. Oncol. 2016. Vol. 34, N 18. P. 2107-2114.
  882. Radosa J.C., Eaton A., Stempel M., Khander A., Liedtke C., Solomayer E.F. et al. Evaluation of local and distant recurrence patterns in patients with triplenegative breast cancer according to age // Ann. Surg. Oncol. 2017. Vol. 24, N 3. P . 698-704.
  883. Kuijer A., King TA. Age, molecular subtypes and local therapy decision-making // Breast. 2017. Vol. 34. P. S70-S77.
  884. King T.A., Sakr R., Patil S., Gurevich L, Stempel M., Sampson M. et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy //J. Clin. Oncol. 2011. Vol. 29, N 16. P. 2158-2164.
  885. Rosenberg S.M., Sepucha K., Ruddy KJ., Tamimi R.M., Gelber S., Meyer M.E. et al. Local therapy decision-making and contralateral prophylactic mastectomy in young women with early-stage breast cancer // Ann. Surg. Oncol. 2015. Vol. 22, N 12. P. 3809-3815.
  886. Rosenberg S.M., Partridge A.H. Management of breast cancer in very young women // Breast. 2015. Vol. 24, suppl. 2. P. S154-S158.
  887. Han W., Kang S.Y.; Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer // Breast Cancer Res. Treat. 2010. Vol. 119, N 1. P. 193-200.
  888. Elkum N., Dermime S., Ajarim D., Al-Zahrani A., Alsayed A., Tulbah A. et al. Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience // BMC Cancer. 2007. Vol. 7, N 1. P. 222.
  889. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer // N. Engl. J. Med. 2004. Vol. 351. P. 2817-2826.
  890. Paik S., Tang G„ Shak S., Kim C., Baker J., Kim W. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer //J. Clin. Oncol. 2006. Vol. 24, N 23. P. 3726-3734.
  891. Sparano J.A., Gray R.J., Makower D.F., Pritchard K.I., Albain K.S., Hayes D.E et al. Prospective validation of a 21-gene expression assay in breast cancer // N. Engl. J. Med. 2015. Vol. 373, N 21. P. 2005-2014.
  892. Petkov VI., Miller D.P., Howlader N., Gliner N„ Howe W., Schussler N. et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study //NPJ Breast Cancer. 2016. Vol. 2. Article ID 16017.
  893. Makubate В., Donnan Р.Т., Dewar J. A., Thompson A.M., McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality// Br.J. Cancer. 2013. Vol. 108, N 7. P. 1515-1524.
  894. Partridge A.H., Wang P.S., Winer E.P., Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer // J. Clin. Oncol. 2003. Vol. 21, N4. P. 602-606.
  895. Hershman D.L., Kushi L.H., Shao T, Buono D., Kershenbaum A., Tsai WY. et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients //J. Clin. Oncol. 2010. Vol. 28, N 27. P. 4120-4128.
  896. Llarena N.C., Estevez S.L., Tucker S.L., Jeruss J.S. Impact of fertility concerns on tamoxifen initiation and persistence //J. Natl Cancer Inst. 2015. Vol. 107, N 10. Article ID djv202.
  897. Rosenberg S.M., Partridge A.H. New insights into nonadherence with adjuvant endocrine therapy among young women with breast cancer //J. Natl Cancer Inst. 2015. Vol. 107, N 10. Article ID djv245.
  898. Land S.R., Walcott F.L., Liu Q., Wickerham D.L., Costantino J.P, Ganz P.A. Symptoms and QOL as predictors of chemoprevention adherence in NRG Oncology/NSABP Trial P-1 //J. Natl Cancer Inst. 2016. Vol. 108, N 4. Article ID djv365.
  899. Murphy C.C., Bartholomew L.K., Carpentier M.Y., Bluethmann S.M., Vernon S.W Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review // Breast Cancer Res. Treat. 2012. Vol. 134, N 2. P. 459-478.
  900. Goodwin P.J., Ennis M„ Pritchard K.L., Trudeau M„ Hood N. Risk of menopause during the first year after breast cancer diagnosis //J. Clin. Oncol. 1999. Vol. 17, N 8. P. 2365-2370.
  901. Petrek J.A., Naughton M.J., Case L.D., Paskett E.D., Naftalis E.Z., Singletary S.E. et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study // J. Clin. Oncol. 2006. Vol. 24, N 7. P. 1045-1051.
  902. Sukumvanich P, Case L.D., Van Zee K„ Singletary S.E., Paskett E.D., Petrek J.A. et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study // Cancer. 2010. Vol. 116, N 13. P. 3102-3111.
  903. Ruddy KJ., Gelber S.I., Tamimi R.M., Ginsburg E.S., Schapira L., Come S.E. et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer// J. Clin. Oncol. 2014. Vol. 32, N 11. P. 1151-1156.
  904. Davies M.C., Hall M.L., Jacobs H.S. Bone mineral loss in young women with amenorrhea// BMJ. 1990. Vol. 301. P. 790-793.
  905. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H. Menopause and the risk of coronary artery disease in women // N. Engl. J. Med. 1987. Vol. 316, N 18. P. 1105-1110.
  906. Rocca W.A., Shuster L.T, Grossardt B.R., Maraganore D.M., Gostout B.S., Geda YE. et al. Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of oophorectomy and aging// Womens Health (Loud.). 2009. Vol. 5, N 1. P. 39-48.
  907. Ganz Р.А., Greendale G.A., Petersen L., Kahn B., Bower J.E. Breast cancer in younger women: reproductive and late health effects of treatment // J. Clin. Oncol. 2003. Vol. 21, N 22. P. 4184-4193.
  908. Leining M.G., Gelber S., Rosenberg R., Przypyszny M., Winer E.P., Partridge A.H. Menopausal-type symptoms in young breast cancer survivors // Ann. Oncol. 2006. Vol. 17, N 12. P. 1777-1782.
  909. Crandall C., Petersen L., Ganz P.A., Greendale G.A. Association of breast cancer and its therapy with menopause-related symptoms // Menopause. 2004. Vol. 11, N5. P. 519-530.
  910. Webber К., Mok K., Bennett B., Lloyd A.R., Friedlander M., Juraskova I. et al. If I am in the mood, I enjoy it: an exploration of cancer-related fatigue and sexual functioning in women with breast cancer // Oncologist. 2011. Vol. 16, N 9. P. 1333-1344.
  911. Kroenke C.H., Chen W.Y., Rosner B., Holmes M.D. Weight, weight gain, and survival after breast cancer diagnosis // J. Clin. Oncol. 2005. Vol. 23, N 7. P. 1370-1378.
  912. Avis N.E., Crawford S., Manuel J. Quality of life among younger women with breast cancer //J. Clin. Oncol. 2005. Vol. 23, N 15. P. 3322-3330.
  913. Irwin M.L., McTiernan A., Baumgartner R.N., Baumgartner K.B., Bernstein L., Gilliland F.D. et al. Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors //J. Clin. Oncol. 2005. Vol. 23, N 4. P. 774-782.
  914. Avis N.E., Crawford S., Manuel J. Psychosocial problems among younger women with breast cancer // Psychooncology. 2004. Vol. 13, N 5. P. 295-308.
  915. Chan D.S., Vieira A.R., Aune D., Bandera E.V, Greenwood D.C., McTiernan A. et al. Body mass index and survival in women with breast cancer-systematic literature review and metaanalysis of 82 follow-up studies // Ann. Oncol. 2014. Vol. 25, N 10. P. 1901-1914.
  916. Demark-Wahnefried W, Petersen B.L., Winer E.P., Marks L., Aziz N., Marcom K.et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy //J. Clin. Oncol. 2001. Vol. 19, N 9. P. 2381-2389.
  917. Holmes M.D., Chen W.Y., Feskanich D., Kroenke C.H., Colditz G.A. Physical activity and survival after breast cancer diagnosis //JAMA. 2005. Vol. 293, N 20. P. 2479-2486.
  918. Kroenke C.H., Rosner B., Chen W.Y., Kawachi I., Colditz G.A., Holmes M.D. Functional impact of breast cancer by age at diagnosis // J. Clin. Oncol. 2004. Vol. 22, N 10. P. 1849-1856.
  919. Howard-Anderson J., Ganz P.A., Bower J.E., Stanton A.L. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review //J. Natl Cancer Inst. 2012. Vol. 104, N 5. P. 386-405.
  920. Wong-Kim E.C., Bloom J.R. Depression experienced by young women newly diagnosed with breast cancer // Psychooncology. 2005. Vol. 14, N 7. P. 564-573.
  921. Kendall A.R., Mahue-Giangreco M., Carpenter C.L., Ganz P.A., Bernstein L.Influence of exercise activity on quality of life in long-term breast cancer survivors // Qual. Life Res. 2005. Vol. 14, N 2. P. 361-371.
  922. Harrison S.A., Hayes S.C., Newman В. Age-related differences in exercise and quality of life among breast cancer survivors // Med. Sci. Sports Exerc. 2010. Vol. 42, N 1. P. 67-74.
  923. Partridge A.H., Pagani O„ Abulkhair O„ Aebi S„ Amant E, Azim H.A. et al. First international consensus guidelines for breast cancer in young women (BCY1) // Breast. 2014. Vol. 23, N 3. P. 209-220.
  924. Ford D., Easton D.F., Stratton М. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium // Am. J. Hum. Genet. 1998. Vol. 62. P. 676-689.
  925. Roa B.B., Boyd A.A., Volcik K., Richards C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 // Nat. Genet. 1996. Vol. 14. P. 185-187.
  926. Paul A., Paul S. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers // Front. Biosci. (Landmark Ed.). 2014. Vol. 19. P. 605-618.
  927. King M.C., Marks J.H., Mandell J.B.; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 // Science. 2003. Vol. 302. P. 643-646.
  928. Walsh Т, Casadei S., Lee M.K. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing// Proc. Natl Acad. Sci. USA. 2011. Vol. 108. P. 18 032-18 037.
  929. Kuchenbaecker K.B., Hopper J.L., Barnes D.R. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers //JAMA. 2017. Vol. 317. P. 2402-2416.
  930. Mersch J., Jackson M.A., Park M. et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian // Cancer. 2015. Vol. 121. P. 269-275.
  931. Easton D.F., Pharoah P.D., Antoniou A.C. et al. Gene-panel sequencing and the prediction of breast-cancer risk //N. Engl. J. Med. 2015. Vol. 372. P. 2243-2257.
  932. Rosenberg S.M., Ruddy K.J., Tamimi R.M. et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer // JAMA Oncol. 2016. Vol. 2. P. 730-736.
  933. Xu X., Weaver Z., Linke S.P. et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells // Mol. Cell. 1999. Vol. 3. P. 389-395.
  934. Yu V.P., Koehler M., Steinlein C. et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation // Genes Dev. 2000. Vol. 14. P. 1400-1406.
  935. Foulkes W.D., Shuen A.Y. In brief: BRCA1 and BRCA2 // J. Pathol. 2013. Vol. 230. P. 347-349.
  936. Pardo B., Gomez-Gonzalez B., Aguilera A. DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship // Cell. Mol. Life Sci. 2009. Vol. 66. P. 1039-1056.
  937. Venkitaraman A.R. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment // Annu. Rev. Pathol. 2009. Vol. 4. P. 461-487.
  938. Roy R., Chun J., Powell S.N. BRCA1 and BRCA2: different roles in a common pathway of genome protection // Nat. Rev. Cancer. 2012. Vol. 12. P. 68-78.
  939. Yang H., Jeffrey P.D., Miller J. et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSSl-ssDNA structure // Science. 2002. Vol. 297. P. 1837-1848.
  940. Jensen R.B., Carreira A., Kowalczykowski S.C. Purified human BRCA2 stimulates RAD51-mediated recombination //Nature. 2010. Vol. 467. P. 678-683.
  941. Wang B., Matsuoka S., Ballif B.A. et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response // Science. 2007. Vol. 316. P. 1194-1198.
  942. Chen L., Nievera C.J., Lee A.Y., Wu X. Cell cycle-dependent complex formation of BRCA1. CtIP. MRN is important for DNA double-strand break repair // J. Biol. Chem. 2008. Vol. 283. P. 7713-7720. DOI: https://doi.org/10.1074/jbc. M710245200 Epub 2008 Jan 2.
  943. Zhang E, Maj., Wu J. et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response // Cure. Biol. 2009. Vol. 19. P. 524-529.
  944. Tutt A., Bertwistle D., Valentine J. et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences // EMBO J. 2001. Vol. 20. P. 4704-4716.
  945. Turner N., Tutt A., Ashworth A. Hallmarks of‘ «BRCAness» in sporadic cancers // Nat. Rev. Cancer. 2004. Vol. 4. P. 814-819.
  946. Caestecker K.W., Van de Walle G.R. The role of BRCA1 in DNA double-strand repair: past and present // Exp. Cell Res. 2013. Vol. 319. P. 575-587.
  947. Таня Гальярди (Tanja Gagliardi), University of Aberdeen, Aberdeen, UK, e-mail: t.gagliardi@nhs.net
  948. Карен А. Гелмон (Karen A. Gelmon), BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada, e-mail: kgelmon@bccancer.bc.ca
  949. Оресте Джентилини (Oreste Gentilini), Breast Unit, San Raffaele University and Research Hospital, Milan, Italy, e-mail: gentilini.oreste@hsr.it
  950. Клара Хангр (Clara Hungr), Cambridge Health Alliance, Cambridge, MA, USA, e-mail: chung@challiance.org
  951. Белла Кауфман (Bella Kaufman), Breast Oncology Institute, Sheba Medical Centre, Ramat Gan, Israel
  952. Асся Консулова (Assia Konsoulova), Medical Oncology Clinic, University Hospital Sveta Marina, Varna, Bulgaria
  953. Филип Д. Порву (Philip D. Poorvu), Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
  954. Джоана Мурато Рибейро (Joana Mourato Ribeiro), Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal, e-mail: joana.ribeiro@fundacaochampalimaud.pt
  955. Osorio A., de la Hoya M., Rodriguez-Lopez R. et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer // Int. J. Cancer. 2002. Vol. 99. P. 305-309.
  956. Cavalli L.R., Singh B., Isaacs C. et al. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer // Cancer Genet. Cytogenet. 2004. Vol. 149. P. 38-43.
  957. Konishi H, Mohseni M, Tamaki A et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells // Proc. Natl Acad. Sci. USA. 2011. Vol. 108. P. 17 773-17 778.
  958. Ludwig T, Chapman D.L., Papaioannou VE., Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brcal, Brca2, Brcal/Brca2, Brcal/p53, and Brca2/p53 nullizygous embryos // Genes Dev. 1997. Vol. 11. P. 1226-1241.
  959. Evers B., Jonkers J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects // Oncogene. 2006. Vol. 25. P. 5885-5897.
  960. Leegte B., van der Hout A.H., Deffenbaugh A.M. et al. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations // J. Med. Genet. 2005. Vol. 42. P. e20.
  961. Spannuth W.A., Thaker Р.Н., Sood A.K. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer // Am. J. Obstet. Gynecol. 2007. Vol. 196. P. e6-e9.
  962. Greenblatt M.S., Chappuis P.O., Bond J.P. et al. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution // Cancer Res. 2001. Vol. 61. P. 4092-4097.
  963. Holstege H., Joosse S.A., van Oostrom C.T. et al. High incidence of proteintruncating TP53 mutations in BRCAl-related breast cancer // Cancer Res. 2009. Vol. 69. P. 3625-3633.
  964. Sedic M., Kuperwasser C. BRCAl-hapoinsufficiency: unraveling the molecular and cellular basis for tissue-specific cancer // Cell Cycle. 2017. Vol. 15. P. 621-627.
  965. Monteiro A.N. BRCAl: the enigma of tissue-specific tumor development // Trends Genet. 2003. Vol. 19. P. 312-315.
  966. Elledge SJ., Amon A. The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients // Cancer Cell. 2002. Vol. 1. P. 129-132.
  967. Sedic M., Skibinski A., Brown N. et al. Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence // Nat. Commun. 2015.Vol. 6. Article ID 7505.
  968. Palacios J., Robles-Frias M.J., Castilla M.A. et al. The molecular pathology of hereditary breast cancer // Pathobiology. 2008. Vol. 75. P. 85-94.
  969. Mavaddat N., Barrowdale D., Andrulis I.L. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) // Cancer Epidemiol. Biomarkers Prev. 2012. Vol. 21. P. 134-147.
  970. Lakhani S.R., Van De Vijver M.J., Jacquemier J. et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 //J. Clin. Oncol. 2002. Vol. 20. P. 2310-2318.
  971. Honrado E., Benitez J., Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer // Crit. Rev. Oncol. Hematol. 2006. Vol. 59. P. 27-39.
  972. Atchley D.P., Albarracin C.T., Lopez A. et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer // J. Clin. Oncol. 2008. Vol. 26. P. 4282-4288.
  973. Molyneux G., Smalley M.J. The cell of origin of BRCA1 mutation-associated breast cancer: a cautionary tale of gene expression profiling //J. Mammary Gland Biol. Neoplasia. 201 1. Vol' 16. P. 51-55.
  974. Molyneux G., Geyer F.C., Magnay F.A. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells // Cell Stem Cell. 2010. Vol. 7. P. 403-417.
  975. Lim E., Vaillant E, Wu D. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers // Nat. Med. 2009. Vol. 15. P. 907-913.
  976. Saal L.H., Gruvberger-Saal S.K., Persson C. et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair // Nat. Genet. 2008. Vol. 40. P. 102-107.
  977. Eerola H., Heikkila P, Tamminen A. et al. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families // Breast Cancer Res. 2005. Vol. 7. P. R93-R100.
  978. Lewin R., Sulkes A., Shochat T. et a], Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations // Breast Cancer Res. Treat. 2016.Vol. 157. P. 511-516.
  979. Halpern N., Sonnenblick A., Uziely B. et al. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer // Int. J. Cancer. 2017. Vol. 140. P. 2145-2149.
  980. 4Goodwin P.J., Phillips K.A., West D.W. et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study //J. Clin. Oncol. 2012. Vol. 30. P 19-26.
  981. Rennert G., Bisland-Naggan S., Barnett-Griness O. et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations // N. Engl. J. Med. 2007.Vol. 357. P. 115-123.
  982. Huzarski T, Byrski T, Gronwald J. et al. Ten-year survival in patients with BRCA1-negative and BRCAl-positive breast cancer // J. Clin. Oncol. 2013. Vol. 31. P. 3191-3196.
  983. 5E1-Tamer M., Russo D., Troxel A. et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers // Ann. Surg. Oncol. 2004. Vol. 11. P. 157-164.
  984. Veronesi A., de Giacomi C., Magri M.D. et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases // BMC Cancer. 2005.Vol. 5. P. 70.
  985. Brekelmans С.Т., Seynaeve С., Menke-Pluymers М. et al. Survival and prognostic factors in BRCA 1-associated breast cancer // Ann. Oncol. 2006. Vol. 17. P. 391-400.
  986. Arun B., Bayraktar S., Liu D.D. et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience //J. Clin. Oncol. 2011. Vol. 29. P. 3739-3746.
  987. Bonadona V, Dussart-Moser S., Voirin N. et al. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review // Breast Cancer Res. Treat. 2007. Vol. 101. P. 233-245.
  988. Foulkes W.D., Chappuis P.O., Wong N. et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome // Ann. Oncol. 2000. Vol. 11. P. 307-313.
  989. Moller P, Borg A., Evans D.G. et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy // Int. J. Cancer. 2002. Vol. 101. P. 555-559.
  990. Robson M.E., Chappuis P.O., Satagopan J. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/ BRCA2 mutation status and administration of adjuvant treatment // Breast Cancer Res. 2004. Vol. 6. P. R8-R17.
  991. Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with «BRCAness»: a review // Oncologist. 2013. Vol. 18. P. 909-916.
  992. Bayraktar S., Gluck S. Systemic therapy options in BRCA mutation-associated Breast cancer // Breast Cancer Res. Treat. 2043. Vol. 135. P. 355-366.
  993. Zhong Q„ Peng H.L., Zhao X. et al. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis // Clin Cancer Res. 2015. Vol. 21. P. 211-220.
  994. van den Broek A.J., Schmidt M.K., van’t Veer L.J. et al. Worse breast cancer prognosis of BRCA1/ BRCA2 mutation carriers: what’s the evidence? A systematic review with meta-analysis//PLoS One. 2015. Vol. 10 Article ID e0120189.
  995. Lee E.H., Park S.K., Park B. et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis // Breast Cancer Res. Treat. 2010. Vol. 122. P. 11-25.
  996. Baretta Z., Mocellin S„ Goldin E. et al. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis // Medicine. 2016. Vol. 95. P. e4975.
  997. Маттео Ламбертини (Matteo Lambertini), Department of Medical Oncology, Clinica di Oncologia Medica, Policlinico San Martino-IST, University of Genova, Genoa, Italy
  998. Натали Левассер (Nathalie Levasseur), BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada, e-mail: Nathalie.Levasseur@bccancer.bc.ca
  999. Сибилле Лойбль (Sibylle Loibl), German Breast Group, Neu-Isenburg, Germany, Centrum fur Hamatologie und Onkologie Bethanien, Frankfurt am Main, Germany, e-mail: sibylle.loibl@gbg.de
  1000. Роза Ди Микко (Rosa Di Micco), Breast Unit, San Raffaele University and Research Hospital, Milan, Italy Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy, e-mail: dimicco.rosa@hsr.it
  1001. Бастиен Нгуен (Bastien Nguyen), Breast Cancer Translational Research Laboratory (BCTL), Institut Jules Bordet, UniversithLibre de Bruxelles (ULB), Brussels, Belgium
  1002. Оливия Пагани (Olivia Pagani), Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), and International Breast Cancer Study Group (IBCSG), Lugano, Viganello, Switzerland, e-mail: olivia.pagani@eoc.ch
  1003. Шани Палух-Шимон (Shani Paluch-Shimon), Breast Oncology Unit, Shaare Zedek Medical Centre, Jerusalem, Israel, e-mail: shanips@szmc.org.il
  1004. Энн Г. Партридж (Ann H. Partridge), Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA, e-mail: ann_partridge@dfci.harvard.edu
  1005. Федро А. Пеккатори (Fedro A. Peccatori), Fertility and Procreation Unit, Division of Gynecologic Oncology, European Institute of Oncology, Milan, Italy, e-mail: fedro.peccatori@ieo.it
  1006. Tassone P, Tagliaferri P, Perricelli A. et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells // Br. J. Cancer. 2003. Vol. 88. P. 1285-1291.
  1007. Quinn J.E., Kennedy R.D., Mullan P.B. et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis // Cancer Res. 2003. Vol. 63. P 6221-6228.
  1008. Kennedy R.D., Quinn J.E., Mullan P.B. et al. The role of BRCA1 in the cellular response to chemotherapy // J. Natl Cancer Inst. 2004. Vol. 96. P. 1659-1668.
  1009. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis // Fam. Cancer. 2006. Vol. 5. P. 135-142.
  1010. Kriege М., Seynaeve С., Meijers-Heijboer Н. et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers // J. Clin. Oncol. 2009. Vol. 27. P. 3764-3771.
  1011. Byrski T, Gronwahl J., Huzarski T. et al. Pathologic complete response rates in young women with BRCAl-positive breast cancers after neoadjuvant chemotherapy //J. Clin. Oncol. 2010. Vol. 28. P. 375-379.
  1012. Byrski T, Dent R., Blecharz P. et al. Results of a phase II open-label, nonrandomized trial of cisplatin chemotherapy in patients with BRCAl-positive metastatic breast cancer // Breast Cancer Res. 2014. Vol. 14. P. R110.
  1013. Wysocki P.J., Korski K., Lamperska K. et al. Primary resistance to docetaxelbased chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations // Med. Sci. Monit. 2008. Vol. 14. P. SC7-SC10.
  1014. Byrski T, Gronwald J., Huzarski T. et al. Response to neo-adjuvant chemotherapy in women with BRCAl-positive breast cancers // Breast Cancer Res. Treat. 2008. Vol. 108. P. 289-296.
  1015. Kriege M., Jager A., Hooning MJ. et aL The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers // Cancer. 2012.Vol. 118. P. 899-907.
  1016. Raphael J., Mazouni C., Caron O. et al. Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy? // Med. Oncol. 2014. Vol. 31. P. 850.
  1017. Paluch-Shimon S., Friedman E., Berger R. et al. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers // Breast Cancer Res. Treat. 2016. Vol. 157. P. 157-165.
  1018. Esteller M., Silva J.M., Dominguez G. et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors // J. Natl Cancer Inst. 2000. Vol. 92. P. 564-569.
  1019. Turner N.C., Reis-Filho J.S., Russell A.M. et al. BRCA1 dysfunction in sporadic basal-like breast cancer // Oncogene. 2007. Vol. 26. P. 2126-2132.
  1020. Carey L., Winer E., Viale G. et al. Triple-negative breast cancer: disease entity or title of convenience? // Nat. Rev. Clin. Oncol. 2010. Vol. 7. P. 683-692.
  1021. Curigliano G., Goldhirsch A. The triple-negative subtype: new ideas for the poorest prognosis breast cancer //J. Natl Cancer Inst. Monogr. 2011. Vol. 2011. P. 108-110.
  1022. Telli M.L., Jensen K.C., Vinayak S. et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105 //J. Clin. Oncol. 2015. Vol. 33. P. 1895-1901.
  1023. Telli M.L., Timms K.M., Reid J. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer // Clin. Cancer Res. 2016. Vol. 22. P. 3764-3773.
  1024. Telli M., McMillan A., Ford J.M. et al. Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): a pooled analysis // Cancer Res. 2016. Vol. 76, N 4. Suppl. Abstr. P3-07-12.70.Kriege М., Seynaeve С., Meijers-Heijboer Н. et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers // J. Clin. Oncol. 2009. Vol. 27. P. 3764-3771.
  1025. Isakoff S.J., Mayer E.L., Не L. et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triplenegative breast cancer // J. Clin. Oncol. 2015. Vol. 33. P. 1902-1909.
  1026. Silver D.P., Richardson A.L., Eklund A.C. et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer // J. Clin. Oncol. 2010. Vol. 28. P. 1145-1153.
  1027. von Minckwitz G., Schneeweiss A., Loibl S. et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial // Lancet Oncol. 2014. Vol. 15. P. 747-756.
  1028. Hahnen E., Lederer B., Hauke J. et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto Randomized Clinical Trial //JAMA Oncol. 2017.Vol. 3. P. 1378-1385.
  1029. Carey L.A. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer //J. Clin. Oncol. 2010. Vol. 28. P. 361-363.
  1030. Boudin L., Goncalves A., Sabatier R. et al. Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation // Bone Marrow Transplant. 2016. Vol. 51. P. 1082-1086.
  1031. Pristauz G., Petru E., Stacher E. et al. Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations // Histopathology. 2010. Vol. 57. P. 877-884.
  1032. Farmer H., McCabe N., Lord C.J. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy // Nature. 2005. Vol. 434. P. 917-921.
  1033. Fong P.C., Boss D.S., Yap TA. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers//N. Engl. J. Med. 2009. Vol. 361. P. 123-134.
  1034. Tutt A., Robson M„ Garber J.E. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial // Lancet. 2010. Vol. 376. P. 235-244.
  1035. Gelmon K.A., Tischkowitz M., Mackay H. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study // Lancet Oncol. 2011. Vol. 12. P. 852-861.
  1036. 96. Kaufman B., Shapira-Frommer R., Schmutzler R.K. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation //J. Clin. Oncol. 2015. Vol. 33. P. 244-250.
  1037. Dent R.A., Lindeman G.J., Clemons M. et al. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer // Breast Cancer Res. 2013.Vol. 15. P. R88.
  1038. Balmana J., Tung N.M., Isakoff S.J. et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors // Ann. Oncol. 2014. Vol. 25. P. 1656-1663.
  1039. Lee J.M., Hays J.L., Annunziata C.M. et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses //J. Natl Cancer Inst. 2014. Vol. 106. Article ID dju 089.
  1040. Matulonis U.A., Wulf G.M., Barry W.T. et al. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer // Ann. Oncol. 2017. Vol. 28. P. 512-518.
  1041. Tan A.R., Toppmeyer D., Stein M.N. et al. Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. ASCO Meeting Abstracts //J. Clin. Oncol. 2011. Vol. 29. Absrt. 3041.
  1042. Somlo G., Sparano J.A., Cigler T. et al. ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial. ASCO Meeting Abstracts // J. Clin. Oncol. 2012. Vol. 30. Abstr. 1010.
  1043. Isakoff S.J., Overmoyer B., Tung N.M. et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. ASCO Meeting Abstracts // J. Clin. Oncol. 2010. Vol. 28. Abstr. 1019.
  1044. Wolf D.M., Yau C., Sanil A. et al. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial // NPJ Breast Cancer. 2017. Vol. 3. P. 31.
  1045. Severson T.M., Wolf D.M., Yau C. et al. The BRCAlness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting // Breast Cancer Res. 2017. Vol. 19. P. 99.
  1046. Drew Y, Ledermann J., Hall G. et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer // Br. J. Cancer. 2016. Vol. 114. P. e21.
  1047. Wilson R.H., Evans T.J., Middleton M.R. et al. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours // Br. J. Cancer. 2017. Vol. 116. P. 884-892.
  1048. Sandhu S.K., Schehnan W.R., Wilding G. et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial // Lancet Oncol. 2013. Vol. 14. P. 882-892.
  1049. de Bono J., Ramanathan R.K., Mina L. et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers // Cancer Discov. 2017. Vol. 7. P. 620-629.
  1050. Edwards S.L., Brough R., Lord C.J. et al. Resistance to therapy caused by intragenic deletion in BRCA2 //Nature. 2008. Vol. 451. P. 1111-1115.
  1051. Swisher E.M., Sakai W, Karlan B.Y. et al. Secondary BRCA1 mutations in BRCAl-mutated ovarian carcinomas with platinum resistance // Cancer Res. 2008.Vol. 68. P. 2581-2586.
  1052. Bouwman P, Jonkers J. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? // Clin. Cancer Res. 2014. Vol. 20. P. 540-547.
  1053. Delaloge S., Wolp-Diniz R„ Byrski T. et al. Activity of trabectedin in germline BRCAl/2-mutated metastatic breast cancer: results of an international first-in-class phase II study // Ann. Oncol. 2014. Vol. 25. P. 1152-1158.
  1054. Ghouadni A., Delaloge S., Lardelli Р. et al. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: a subset analysis of a dedicated phase II trial // Breast. 2017. Vol. 34. P. 18-23.
  1055. Balmana J., Cruz C., Arun B. Anti-tumor activity of PM01183(lurbinectedin) in BRCA1/2 associated metastatic breast cancer patients; results of a single-agent phase II trial. ESMO paper // Ann. Oncol. 2016. Vol. 27. P. 68-99.
  1056. Cardillo T.M., Sharkey R.M., Rossi D.L. et al. Synthetic lethality exploitation by an Anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCAl/2-wild-type triple negative breast cancer // Clin. Cancer Res. 2017. Vol. 23. P. 3405-3415.
  1057. Du Y., Yamaguchi H., Wei Y. et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors // Nat. Med. 2016. Vol' 22. P. 194-201.
  1058. Zimmer J., Tacconi E.M.C., Folio C. et al. Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds // Mol. Cell. 2016. Vol. 61. P. 449-460.
  1059. Tung N., Lin N.U., Kidd J. et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer //J. Clin. Oncol. 2016. Vol. 34. P. 1460-1468.
  1060. Tung N., Battelli C., Allen B. et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel // Cancer. 2015. Vol. 121. P. 25-33.
  1061. McCuaig J.M., Armel S.R., Novokmet A. et al. Routine TP53 testing for breast cancer under age 30: ready for prime time? // Fam. Cancer. 2012. Vol. 11. P. 607-613.
  1062. Weller M. Predicting response to cancer chemotherapy: the role of p53 // Cell Tissue Res. 1998. Vol. 292. P. 435-445.
  1063. Бану Арун (Ванн Arun), Department of Breast Medical Oncology and Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, e-mail: barun@mdanderson.org
  1064. Хэмди А. Азим (Hamdy A. Azim), Department of Clinical Oncology, Cairo University Hospital, Cairo, Egypt
  1065. Хатем А. Азим младший (Hatem A. Azim Jr), Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut (AUB), Beirut, Lebanon
  1066. Солей Байрактар (Soley Bayraktar), Biruni Univeristy School of Medicine, Protokol Yolu, Istanbul, Turkey
  1067. Шэрон Бобер (Sharon Bober), Dana-Farber Cancer Institute, Boston, MA, USA, e-mail: sharon_bober@dfci. harvard.edu
  1068. Фатима Кардосо (Fatima Cardoso), Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal, e-mail: fatimacardoso@fundacaochampalimaud.pt
  1069. Мария Хоао Кардосо (Maria Joro Cardoso), Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal, e-mail: maria.joao.cardoso@fundacaochampalimaud.pt
  1070. Джузеппе Курильяно (Giuseppe Curigliano), IEO, European Institute of Oncology IRCCS, Milano, Italy, Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy, e-mail: giuseppe.curigliano@ieo.it
  1071. Ринат Ерушалми (Rinat Yerushalmi), Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel, e-mail: rinaty@clait.org.il
  1072. Элла Эврон (Ella Evrou), Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
  1073. Kappel S., Janschek E., Wolf B. et al. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family // Breast Cancer Res. Treat. 2015. Vol. 151. P. 671-678.
  1074. Bridges K.A., Chen X., Liu H. et al. MK-8776, a novel chkl kinase inhibitor, radiosensitizes p53-defective human tumor cells // Oncotarget. 2016. Vol. 7. P.71 660-771 662.
  1075. Hirai H., Iwasawa Y, Okada M et al. Small-molecule inhibition of Weel kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents // Mol. Cancer Ther. 2009. Vol. 8. P. 2992-3000.
  1076. Markman B., Tabernero J., Krop I. et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors // Ann. Oncol. 2012. Vol. 23. P. 2399-2408.
  1077. Tischkowitz M., Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia // Cancer Res. 2010. Vol. 70. P. 7353-7359.
  1078. Tung N., Domchek S.M., Stadler Z. et al. Counselling framework for moderatepenetrance cancer-susceptibility mutations // Nat. Rev. Clin. Oncol. 2016. Vol. 13. P. 581-588.
  1079. Ferreira А.С., Suriano G., Mendes N. et al. E-cadherin impairment increases cell survival through Notch-dependent upregulation of Bcl-2 // Hum. Mol. Genet. 2012. Vol. 21. P. 334-343.
  1080. Mateus A.R., Seruca R., Machado J.C. et al. EGFR regulates RhoA-GTP dependent cell motility in E-cadherin mutant cells // Hum. Mol. Genet. 2007. Vol. 16. P. 1639-1647."
  1081. Mateus A.R., Simoes-Correia J., Figueiredo J. et al. E-cadherin mutations and cell motility: a genotype-phenotype correlation // Exp. Cell Res. 2009. Vol. 315. P. 1393-1402.
  1082. Hearle N., Schumacher V, Menko F.H. et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome // Clin. Cancer Res. 2006. Vol. 12. P. 3209-3215.
  1083. Valencia О.М., Samuel S.E., Viscusi R.K., Riall T.S., Neumayer L.A., Aziz H. The role of genetic testing in patients with breast cancer: a review // JAMA Surg. 2017. Vol. 152, N 6. P. 589-594.
  1084. Gentilini O.D., Cardoso M.J., Poortmans P. Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients // Breast. 2017. Vol. 35. P. 32-33.
  1085. Valachis A., Nearchou A.D., Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis // Breast Cancer Res. Treat. 2014. Vol. 144, N 3. P. 443-455.
  1086. Evans D.G., Harkness E.E, Plaskocinska L, Wallace A.J., Clancy T, Woodward E.R. et al. Pathology update to the Manchester Scoring System based on testing in over 4000 families //J. Med. Genet. 2017. Vol. 54, N 10. P. 674-681.
  1087. Wevers M.R., Ausems M.G., Verhoef S., Bleiker E.M., Hahn D.E., Brouwer T. et al. Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? Results from a randomized clinical trial // Genet. Med. 2016. Vol. 18, N 2. P. 137-144.
  1088. Kurian A.W, Griffith K.A., Hamilton A.S., Ward K.C., Morrow M., Katz SJ. et al. Genetic testing and counseling among patients with newly diagnosed breast cancer //JAMA. 2017. Vol. 317, N 5. P. 531-534.
  1089. Yadav S., Reeves A., Campian S., Sufka A., Zakalik D. Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis // Hered. Cancer Clin. Pract. 2017. Vol. 15. P. 11.
  1090. Wevers M.R., Aaronson N.K., Bleiker E.M.A., Hahn D.E.E., Brouwer T, van Dalen T. et al. Rapid genetic counseling and testing in newly diagnosed breast cancer: patients’ and health professionals’ attitudes, experiences, and evaluation of effects on treatment decision making //J. Surg. Oncol. 2017. Vol. 116, N 8. P. 1029-1039.
  1091. Shah P.D., Patil S., Dickler M.N., Offit K., Hudis C.A., Robson M.E. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status // Cancer. 2016. Vol. 122, N 8. P. 1178-1184.
  1092. Pierce L.J., Phillips K.A., Griffith K.A., Buys S., Gaffney D.K., Moran M.S. et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy // Breast Cancer Res. Treat. 2010. Vol. 121, N 2. P. 389-398.
  1093. Metcalfe K., Gershman S., Ghadirian P, Lynch H.T, Snyder C., Tung N. et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis // BMJ. 2014. Vol. 348. P g226.
  1094. Metcalfe K., Gershman S., Lynch H.T, Ghadirian P, Tung N., Kim-Sing C. et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers // Br. J. Cancer. 2011. Vol. 104, N 9. P. 1384-1392.
  1095. Peled A.W, Irwin C.S., Hwang E.S., Ewing C.A., Alvarado M., Esserman L.J. Total skin-sparing mastectomy in BRCA mutation carriers // Ann. Surg. Oncol. 2014. Vol. 21, N 1. P. 37-41.
  1096. Lyman G.H., Temin S., Edge S.B., Newman L.A., Turner R.R., Weaver D.L. et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update //J. Clin. Oncol. 2014. Vol. 32, N 13. P. 1365-1383.
  1097. Burger A., Thurtle D., Owen S., Mannu G., Pilgrim S., Vinayagam R. et al. Sentinel lymph node biopsy for risk-reducing mastectomy // Breast J. 2013. Vol. 19, N 5. P. 529-532.
  1098. Джулия X. Роуленд (Julia H. Rowland), Smith Center for Healing and the Arts, Washington, DC, USA Department of Psychiatry, Georgetown University School of Medicine, Washington, DC, USA
  1099. Забине Зайлер (Sabine Seiler), German Breast Group, Neu-Isenburg, Germany
  1100. Эльжбета Сенкус (Elzbieta Senkus), Department of Oncology & Radiotherapy, Medical University of Gdansk, Gdansk, Poland, e-mail: elsenkus@gumed.edu.pl
  1101. Дарио Трапани (Dario Trapani), IEO, European Institute of Oncology IRCCS, Milano, Italy, Department of Oncology and Hemato-Oncology, University of Milano, Milan, Italy, e-mail: dario.trapani@ieo.it
  1102. Люция Травадо (Luzia Travado), Psycho-Oncology, Neuropsychiatry Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal
  1103. Симона Воловат (Simona Volovat), Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal

В ходе подготовки статей по дерматологии для пользователей сайта МедУнивер - отечественная литература не использовалась.

Редактор: Искандер Милевски. Дата обновления публикации: 1.11.2026
Медунивер Поиск по сайту и его разделы Мы в Telegram Мы в MAX Мы в YouTube Мы в Вконтакте Контакты, реклама
Информация на сайте подлежит консультации лечащим врачом и не заменяет очной консультации с ним.
См. подробнее в пользовательском соглашении.